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Abstract 
 
Diabetes and insulin resistance are prominent cardiovascular risk factors 
and are projected to affect more than 500 million individuals worldwide in the 
next few decades. Managing hyperglycaemia is not sufficient to reduce the 
cardiovascular risk that these diseases confer, and there is increasing 
awareness of insulin resistance as an independent predictor of morbidity and 
mortality. Animal models partially recapitulate this profile: mice with insulin 
receptor knockout (IRKO) show elements of human metabolic syndrome, 
such as hypertension and endothelial dysfunction. These mice also exhibit 
impaired vascular repair after arterial injury and associated defects in the 
number and function of endothelial progenitor cells and mature endothelial 
cells. These impairments appear to relate to reduced nitric oxide 
bioavailability and oxidative stress. Loss of intact endothelial insulin 
signalling seems to play a key pathogenetic role.  
 
In this work, we describe a murine model with global insulin receptor 
knockout and concomitant rescue of endothelial insulin receptor expression 
(HIRECOxIRKO). In order to achieve this, we have targeted expression of a 
human insulin receptor transgene to vascular endothelial cells using a Tie-2 
promoter. This manipulation results in a viable mouse with preserved 
glucoregulation. We have confirmed endothelium-specific expression of the 
human insulin receptor transgene in HIRECOxIRKO mice. These animals 
display restoration of normal blood pressure, endothelial function and 
vascular repair after arterial injury, as compared with IRKO littermates, often 
with recovery to wild-type levels. We have observed augmented endothelial 
cell migration and, perhaps, proliferation, which may mediate increased 
vascular repair. We also present evidence of increased nitric oxide 
bioavailability, which may underpin the rescue of vasomotor function. Much 
work remains, but this project supports the pursuit of endothelial insulin 
sensitisation as a potential therapeutic target in insulin resistance.   
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Chapter 1 Introduction 
1.1 Diabetes Mellitus, Insulin Resistance and Cardiovascular 
Risk 
 Background Epidemiology 1.1.1
Diabetes mellitus (DM) is a multi-system metabolic disorder which is rising in 
prevalence within an ageing and increasingly overweight global population 
[1]. It is implicated in 28-38% of mortality in North America and Europe, with 
a higher proportion seen in developing countries, and is responsible for 
healthcare expenditure of US$ 548 billion worldwide [2]. Moreover, the 
prevalence of DM is forecast to rise to over 500 million people worldwide by 
2035 [2]. Type I DM, which accounts for 10% of all diabetes, is characterised 
by autoimmune destruction and failure of pancreatic beta-cells, resulting in 
absolute insulin deficiency, often from a young age [2]. Most of the 
remainder is type II DM, in which beta-cells become progressively less 
responsive to the presence of glucose but retain a degree of capacity to 
produce insulin. However, co-existing insulin resistance in peripheral target 
tissues results in progressive hyperinsulinaemia despite hyperglycaemia [3].  
 
Patients with T2DM have demonstrably higher rates of all-cause mortality 
than individuals with normal glucose metabolism, resulting in an additional 
mortality risk equivalent to that of 15 years of ageing [4]. The Framingham 
study was the first large epidemiological paper to report a link with 
cardiovascular disease (CVD): it showed a two-fold increase in 
cardiovascular complications in diabetic compared with non-diabetic men, 
and the increase was three-fold in women [5]. This association with 
cardiovascular risk has been demonstrated recurrently since, and this 
includes patients with established cardiovascular disease [6].  
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 Impact of Insulin Resistance in Humans 1.1.2
Hyperglycaemia per se is closely linked to microvascular complications of 
diabetes, such as retinopathy, neuropathy and nephropathy [7]. It is also 
associated with CVD, as demonstrated by a 2004 meta-analysis that 
showed an increase of 1.18 in relative risk for every 1% increment in 
glycosylated haemoglobin (HbA1c) [8]. Indeed, pooled evidence from large 
prospective studies of non-diabetic subjects has implicated glycaemia as an 
independent risk factor for mortality [9].  
 
However, sustained hyperglycaemia alone is not sufficient to explain the 
excess of CVD seen in individuals with disturbed glucose homoeostasis, and 
is in fact likely to account for only a minority of cardiovascular events [10]. 
This has been surmised in theory since the early 1990s [11], with an 
accumulating portfolio of supporting data subsequently. The Helsinki 
Policemen Study, one of the contributors to the above pooled analysis [9], 
showed that in 970 healthy middle-aged men, hyperinsulinaemia was an 
independent risk factor for heart disease after 22 years of follow-up [12]. 
Similarly, Hu et al performed a prospective twenty-year follow-up study on 
117,000 nurses, and noted that in those who eventually became diabetic, 
there was a higher CVD risk than in healthy subjects even in the period 
before diagnosis [13]. Finally, the AusDiab study showed that impaired 
fasting glucose (IFG) was an independent cardiovascular risk factor [14]. 
These findings have raised the possibility of a “ticking clock” phenomenon in 
which the beginnings of CVD risk pre-date biochemically detectable 
glycaemic derangements [10].  
 
Pathophysiologically, this “pre-diabetes” period is characterised by a chronic 
reduction in end-organ insulin sensitivity, resulting in a requirement for 
increased pancreatic insulin secretion: compensatory hyperinsulinaemia 
[11]. Whilst early metabolic testing may unmask IFG or impaired glucose 
tolerance (IGT) after oral glucose challenge, the rising insulin concentration 
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can help maintain broadly normal plasma glucose levels for decades, such 
that the condition evades formal diagnosis [3]. This phase of insulin 
resistance is associated with elevation in plasma free fatty acid 
concentration and hypertension, resulting in many pre-diabetic individuals 
suffering from a constellation of cardiovascular risk factors, as first described 
in Reaven’s 1988 Banting lecture [15]. Importantly, this risk occurs in the 
absence of total beta-cell failure and hyperglycaemia [10]. Our 
understanding of this disturbance has subsequently been refined and it has 
been named “metabolic syndrome” or “syndrome X”, a combination of three 
or more of the following insults: abdominal obesity, hypertension, raised 
plasma glucose concentration, raised triglycerides and low high density 
lipoprotein (HDL) cholesterol [11] (Figure 1-1). Thus, by the time frank 
diabetes has developed, many patients have already been exposed to a 
high risk of cardiovascular illness, the exact pathogenetic mechanisms of 
which are incompletely understood. This may, in part, explain the modest 
reduction in macrovascular events noted in clinical trials of strict glycaemic 
control [7]. Clearly, insulin resistance merits attention as a window of 
opportunity for early intervention and cardiovascular risk reduction.  
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Figure 1-1 The Metabolic Syndrome  
Adapted from Cubbon et al, 2012 [16] 
 
 Treatment of Insulin Resistance  1.1.3
One of the cornerstones of diabetes therapy in general is strict glycaemic 
control, mainly driven by the observation that this yields significant 
reductions in microvascular disease; this was demonstrated convincingly in 
the United Kingdom Prospective Diabetes Study, in which patients were 
randomised either to intensive or conventional glucose lowering strategies 
[7]. This seminal study failed to show a significant risk reduction for 
macrovascular outcomes, although a modest benefit was seen in these end-
points in a ten-year follow up study published in 2008 [17]. Similarly, the 
large Action to Control Cardiovascular Risk in Diabetes (ACCORD) study 
was terminated prematurely when an interim analysis revealed a higher 
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mortality rate in the intensive treatment arm, without any beneficial effects on 
cardiovascular end-points [18]. This suggestion has been borne out in a 
meta-analysis of several large randomised controlled trials, which failed to 
show a significant reduction in short- to medium-term mortality [19]. One 
must balance these data with the results of the Diabetes Control and 
Complications Trial (DCCT), which showed reduced microvascular and 
macrovascular end points with intensive glycaemic control in type I diabetes 
[20]. It appears that longer follow-up does reveal some benefits in 
macrovascular outcomes with tight glycaemic control [17], but clearly other 
aspects of the insulin resistant phenotype could be targeted therapeutically.  
 
It is tempting to surmise that the slightly disappointing findings in some of the 
above studies could be explained by the propensity for intensive glycaemic 
control to cause problematic hypoglycaemia; alternatively, it may lend 
support to the suggestion that glycaemia is not as potent a risk factor for 
macrovascular disease as one may initially suspect. If so, a potential 
explanation for the paradoxical finding of greater mortality in the ACCORD 
study is that strategies that increase circulating insulin levels may 
exacerbate the portion of biological damage that is attributable to insulin 
resistance and thus augment overall cardiovascular risk.  
 
Drug agents that improve insulin sensitivity in target organs appear 
attractive, but the evidence for improvements in cardiovascular end points to 
date has been relatively unconvincing. Metformin is a key agent used to help 
maintain glucose levels within a healthy range, and there are some data to 
show reduced rates of myocardial infarction in obese patients with T2DM 
taking metformin [21]. Another class that has so far yielded largely 
disappointing results is the thiazolidinediones [22]. In fact, there has been a 
link with an increase in symptoms compatible with heart failure in patients 
treated with rosiglitazone, one such agent [22]. Meta-analysis of safety data 
for rosiglitazone showed a paradoxical increase in non-fatal myocardial 
infarction as well [23], resulting in the temporary withdrawal of the drug from 
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the market. These findings were not recaptured in a more recent study, 
suggesting that this class of agents may not be as harmful as once thought 
[24]. Equally, adverse events may reflect the pleiotropic effects of agonism 
of the thiazolidinedione target, the peroxisome profilerator activated 
receptor-gamma (PPAR-ɣ), and the phenomenon may not be a class effect 
[25]. Indeed, the ProACTIVE study highlighted a possible CVD risk reduction 
with pioglitazone, a different member of this drug class [26]. This must be 
interpreted with caution as the quoted benefits here were based on a non-
prespecified secondary end point. However, both metformin and the 
thiazolidinediones carry some promise and therefore insulin sensitisation 
may still be a valid therapeutic strategy. Overall, ongoing drug development 
in this class has implications for patient safety and may prompt wider 
financial concerns, leaving us with a pharmacopeia that does not include 
adequate provision for cardiovascular risk reduction in insulin resistance.  
 
This caveat notwithstanding, it is not necessarily wise to exclude insulin 
sensitisation as a way of reducing macrovascular risk in diabetes and pre-
diabetes. Instead, the thiazolidinedione experience provides a case for 
developing alternative and more refined methods of achieving greater tissue 
insulin sensitivity. The insulin receptor may present a more precise target for 
rational drug design, and in order to investigate this possibility, this project 
will focus on the interplay between insulin receptor physiology, its 
manipulation and the effects this has on cardiovascular risk.  
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1.2  Physiology and Pathophysiology of Insulin Signalling  
 Physiological Action of Insulin 1.2.1
Human insulin is a 5.8 kiloDalton (kDa) polypeptide comprising 51 amino 
acids, and is synthesised in pancreatic beta-cells. It is encoded on 
chromosome 11p15 in a precursor form known as preproinsulin, which 
undergoes post-translational modification by way of cleavage of a signal 
peptide sequence [27, 28]. The resulting molecule, proinsulin, consists of an 
A-chain and a B-chain, joined by a third connecting subunit known as C-
peptide. Within the Golgi apparatus, C-peptide is cleaved, allowing the 
remaining A- and B-chain subunits of the resulting dimer to link by forming 
disulphide bonds; this is the form in which insulin is released systemically in 
response to glucose ingestion [27] (Figure 1-2).  
Figure 1-2  Schema demonstrating structure of proinsulin (A) and 
insulin (B) 
SS = disulphide bond. 
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Cellular glucose uptake is mediated by a group of glucose transporters 
(GLUT); most are basally expressed on target-cell membranes, and allow 
transport of glucose from the blood to the intracellular environment for use in 
metabolism [29]. GLUT-4 channels are the predominant isoform in cells that 
store energy in the form of glycogen or lipids, such as skeletal myocytes and 
adipocytes. GLUT-4 is stored in intracellular vesicles under basal conditions, 
and re-localisation of the transporter to the plasma membrane is an inducible 
process triggered by the binding of insulin to its cell surface receptor [30]. In 
storage tissues, glucose is converted to glycogen or lipids, following which it 
can be broken down again when blood glucose levels drop. As the 
translocation of GLUT-4 to the plasma membrane relies on intact insulin 
receptor binding and intracellular signalling, defects in this process can 
result in glucoregulatory derangements in the insulin-resistant state [30].  
 
 Structure of the Insulin Receptor 1.2.2
The insulin receptor belongs to the receptor tyrosine kinase family and is a 
320 kDa heterodimeric protein encoded, in humans, on chromosome 19p13 
[31, 32]. The tetramer comprises two alpha and two beta subunits, linked 
with disulphide bonds [33, 34]. The alpha subunits, which are predominantly 
extracellular, appear to form the majority of the hormone-binding domain 
[35]. However, the beta subunits also comprise a small extracellular portion, 
thus presenting an additional ligand binding site; these act synergistically 
and encourage cross-linking, which has the overall effect of allowing high-
affinity binding of insulin to the receptor structure [36]. The beta subunit on 
either side then spans the plasma membrane and contains a tyrosine kinase 
(TK) domain in its intracellular portion [35] (Figure 1-3).  
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Figure 1-3 Structure of the Insulin Receptor 
INS = Insulin; α = Alpha subunit; ẞ= Beta subunit; SS = disulphide bond; TK 
= tyrosine kinase domain. 
 
 Insulin Signalling in Health 1.2.3
In the resting state, the alpha subunit of the insulin receptor inhibits the beta 
subunit’s tyrosine kinase activity. Following the binding of insulin (or an 
alternative ligand such as the insulin-like growth factor-1) to the alpha 
subunit, de-repression of the beta subunit’s kinase activity occurs, triggering 
a cascade of autophosphorylation of tyrosine residues in the TK domain [37]. 
This induces a conformational change in the beta subunit and results in 
increasingly potent kinase activity, the first of many steps in a complex 
intracellular cascade of phosphorylation [38]. After activation, the whole 
receptor is internalised and degraded by receptor-mediated endocytosis [35] 
but only after the above process of autophosphorylation has triggered 
intracellular signalling. Initially, a variety of multi-site “docking” proteins such 
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as insulin receptor substrates (IRS) and Shc are phosphorylated and 
activated. These substrates help to propagate the insulin signal to target 
effectors deeper within the intracellular pool [39]. These result in the 
formation of complex, divergent and tissue-specific intracellular signalling 
pathways, summarised in Figure 1-4 [40]. The downstream effects of insulin 
receptor activation are tightly regulated in order to optimise metabolic 
function: for example, tyrosine phosphatase activity and inhibitory serine 
phosphorylation can downregulate signalling [37]. Similarly, the 
internalisation of the insulin receptor after ligand binding can act as a 
negative regulator of signalling and limit excessive activation of downstream 
nodes.  
 
These tyrosine-phosphorylated substrates interact with intracellular proteins: 
in the case of Shc, the first interaction is with growth factor receptor bound 
protein 2 (Grb-2) and son-of-sevenless (SOS), the latter of which is an 
exchange factor for guanosine triphosphate (GTP). By inducing further 
activity in proteins such as Ras and Raf, this pathway results in the 
activation of mitogen-activated protein kinases (MAPK), which mediate 
insulin’s effects as a growth factor and promoter of mitosis and cellular 
differentiation in some target cell types [40]. In vascular endothelial cells, 
however, a further downstream result of the MAPK pathway is the 
production of endothelin-1 (ET-1), a vasoconstrictor which helps maintain 
blood pressure homoeostasis by augmenting vascular tone [40].  
 
Parallel with the MAPK pathway is a cascade triggered by tyrosine 
phosphorylation of insulin receptor substrates [41]. The IRS proteins are 
expressed as various isoforms, of which IRS-1 and IRS-2 are the most 
commonly encountered; IRS-3 is mainly found in adipocytes and neural 
tissue and the expression of IRS-4 is largely limited to embryonic cells [37]. 
IRS proteins contain phosphotyrosine-binding domains at their N-termini, 
which allow close interaction with the intracellular portion of the insulin 
receptor. The central portion and C-terminus of IRS contain tyrosine 
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residues that can be phosphorylated in response to insulin receptor 
activation and thus bind downstream “adaptor” molecules [37]. In the case of 
IRS-1, one key adaptor is phosphatidylinositol-3-kinase (PI3K), an enzyme 
with a regulatory (p85) and a catalytic (p110) portion. The latter portion is 
highly unstable in isolation and is thus usually found bound to p85 to prevent 
premature degradation [37]. When IRS-1 binds the regulatory p85 subunit, 
this frees and activates the catalytic p110 portion of PI3K [40], allowing the 
phosphorylation and conversion of the lipid second messenger 
phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5- 
trisphosphate (PIP3) and propagation of the insulin signalling cascade. PI3K 
may also exert an inherent negative feedback effect on insulin signalling by 
promoting inhibitory serine phosphorylation of IRS-1 by downstream 
effectors, such as Akt [42].  
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Figure 1-4 Parallel and Tissue-Specific Pathways of Insulin Signalling 
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INS = insulin; TK = tyrosine kinase; IRS-1 = insulin receptor substrate-1; PI3K = phosphatidylinositol-3-kinase; PDK-1 = 
phosphoinositide-dependent kinase-1; eNOS = endothelial nitric oxide synthase; NO = nitric oxide; GLUT4 = glucose transporter 4; 
Grb2 = growth factor receptor bound protein 2; Sos = son of sevenless; MAPK = mitogen activated protein kinase; ET-1 = endothelin-
1. Adapted from Kim et al [40]. 
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PIP3 binds to the pleckstrin homology domain of cytosolic protein kinase B 
(otherwise known as Akt), triggering an alteration in the latter’s morphology 
[43]. Akt is then able to translocate from the cytoplasm to the plasma 
membrane, a process shown to rely on PI3K and its interaction with the 
pleckstrin homology domain of Akt [44]. This brings Akt into closer proximity 
with phosphoinositide-dependent kinase-1 (PDK-1), which phosphorylates 
the Threonine-308 site on Akt [37]. Together with serine phosphorylation 
(serine 473) by mammalian target of rapamycin complex 2 (mTORC2), this 
results in full activation of Akt and thus propagates the insulin signalling 
cascade. The downstream effects of Akt phosphorylation in this pathway are 
dependent on the nature of the target cell. In vascular endothelium, one 
effect is to phosphorylate and activate endothelial nitric oxide synthase 
(eNOS) [45], thus generating nitric oxide (NO) and promoting a variety of 
anti-atherogenic effects that will be discussed in more depth below. A 
second pathway distal to Akt involves phosphorylation and inactivation of the 
transcription factor Forkhead box class O (FoxO), resulting in it moving out 
of the nucleus [46]. Thus, by repressing the expression of vascular cell 
adhesion molecule 1 (VCAM-1), Akt-mediated actions on FoxO protect 
against atherosclerosis, as demonstrated in LDL receptor knockout mice 
with endothelium-specific deletion of FoxO [46, 47]. For a diagrammatic 
summary of the PI3K/Akt signalling pathway in endothelial cells, see  
Figure 1-5. Conversely, in skeletal muscle cells and adipocytes, both PI3K 
[48] and Akt [43] have been demonstrated to cause translocation of GLUT-4 
to the plasma membrane by inducing cytoskeletal reconfigurations via action 
on Rab small GTPases. This facilitates  cellular glucose uptake in these 
tissues [37]. In keeping with the paradigm of pathway-specific effectors, it 
has been demonstrated that blocking the MAPK pathway has no effect on 
GLUT-4 translocation [48, 49]. Insulin-induced Akt activation also leads to 
phosphorylation of glycogen synthase kinase 3-beta, and therefore loss of its 
inhibition of glycogen synthetase, allowing skeletal muscle cells and 
hepatocytes to synthesise glycogen for storage.  
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Figure 1-5  Cell Membrane Changes Resulting from Activation of the PI3K/Akt Pathway of Endothelial Insulin Signalling 
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P (in orange circle) represents phosphorylation; IRS-1 = insulin receptor substrate 1; PI3K = phosphatidylinositol-3-kinase; PIP = 
phosphatidylinositol bis/trisphosphate; PDK-1 = phosphoinositide dependent kinase 1; T308 = threonine-308; S473 = serine-473; 
mTORC2 = mammalian target of rapamycin complex 2; eNOS = endothelial nitric oxide synthase; FOXO = Forkhead box class O. 
Adapted from Gatenby et al [50]. 
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 Molecular Mechanisms of Insulin Resistance 1.2.4
The concept of insulin resistance is complex and its development and 
progression are multifactorial. Many putative mechanisms exist, including 
diminished quantity of insulin receptors and intracellular signalling proteins, 
structural aberrations of key mediators such as IRS or PI3K, and inhibitory 
post-translational modification of these proteins, leading to reduced 
propagation of insulin signalling [3].  
 
Structural anomalies in the receptor itself are rare in man, and are not 
postulated to be important in the majority of human insulin resistance [51]. In 
fact, case series describing patients who lack functioning insulin receptors 
reveal a variable, but often markedly abnormal, phenotype with severe 
growth failure and predominant hypoglycaemia [52]. However, missense 
mutations of crucial tyrosine residues within the insulin receptor, such as 
tyrosine 960, have been reported: these are associated with complete 
absence of downstream signalling and biological effects of insulin [53]. A 
specific point mutation in the human insulin receptor gene has also been 
reported to result in insulin resistance due to ineffective maturation of the 
receptor’s precursor into mature alpha and beta subunits, markedly 
interfering with the receptor’s ability to bind insulin [54]. Diminished receptor 
abundance has also been noted in skeletal muscle and adipocytes from 
obese humans, as well as muscle and liver from type 2 diabetics, although 
genetic variants were not implicated in this work [32]. Indeed, it appears that 
the majority of human insulin resistance is a multifactorial phenomenon, with 
a significant contribution from modifiable environmental factors such as diet 
and exercise [55]. Whilst weight loss can thus improve insulin sensitivity in 
people with diabetes, some data suggest this is not the case in obese, 
insulin-resistant subjects without frank diabetes, suggesting that other 
mechanisms are involved in the pathophysiology of pre-diabetes [56].  
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Murine models of insulin receptor knockout are similarly complex. 
Homozygous insufficiency of the insulin receptor (IR) leads to a consistent 
lethal phenotype comprising normal in utero development but rapid neonatal 
deterioration. In two sets of reports, IR-/- mice have been shown not to differ 
morphologically from healthy littermates but quickly develop profound 
hyperglycaemia, hyperinsulinaemia and eventual death from diabetic 
ketoacidosis within 72 hours [57, 58]. However, mice with whole-body 
haploinsufficiency of the insulin receptor (IRKO) show a much milder 
phenotype that survives to adulthood [59]. The IRKO model will be 
discussed in greater depth in subsequent sections, although in summary, 
these mice are glucocompetent but display post-prandial hyperinsulinaemia 
and hypertension, akin to human metabolic syndrome [59, 60].  
 
Aberrances downstream from the insulin receptor are also well-described: 
for example, several naturally-occurring genetic polymorphisms of IRS-1 
have been documented [32]. The most commonly seen in Caucasians, 
G972R, involves the substitution of glycine 972 for arginine and is seen 
almost twice as commonly in diabetics as it is in healthy individuals. Obese 
Caucasian carriers are relatively insulin resistant after oral glucose challenge 
[32]. Transfection studies were used to show that this variant results in 
reduced binding of PI3K to IRS-1, with concomitantly reduced PI3K activity 
[61]. Similarly, Goodyear et al observed diminished insulin-induced 
phosphorylation of the insulin receptor and IRS-1, along with blunted PI3K 
activity, in rectus abdominis muscle biopsy specimens from lean and obese 
human subjects with this polymorphism [62]. Knockout models of IRS 
proteins also aid understanding of their role in insulin sensitivity. For 
example, murine models of IRS-1 knockout show a phenotype of insulin 
resistance with growth retardation, but do not develop frank diabetes due to 
compensatory hyperinsulinaemia [63], while those with IRS-2 knockout 
display localised perturbations in insulin signalling (hepatic and beta-cell) 
and growth disturbance (neuronal) with frank type II diabetes due to the 
negative impact on pancreatic beta-cell function [64]. Combined insulin 
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receptor and IRS-1 and/or IRS-2 insufficiency result in varying degrees of 
insulin resistance, ranging from mild tissue-specific insulin resistance to 
frank diabetes [65, 66]. Furthermore, inhibitory serine phosphorylation of 
IRS-1 is also more commonly seen in insulin resistance, suggesting an 
additional pathophysiological mechanism of interference with IRS-1 function 
[37]. This notion is controversial: a knock-in study replacing the implicated 
serine 307 residue on IRS-1 with alanine showed more marked insulin 
resistance in the knock-in mice than in controls, questioning the inhibitory 
impact of phosphorylation at this residue in vivo [67]. Similarly, the entire role 
of IRS protein post-translational modification is called into question by a 
study showing that platelet derived growth factor (PDGF) signalling, which 
acts independently of IRS, is also impaired in the setting of insulin resistance 
[68].  
 
Similar principles apply to dysfunction of nodes further down the signalling 
cascade. For example, deletion of the Akt-2 isoform, in particular, results in 
insulin resistance and diabetes in mice [69]. This has a correlate in humans, 
as evidenced by the reporting of severe insulin resistance and diabetes in a 
family with an autosomal dominant mutation in the kinase portion of Akt-2 
[70]. These data imply that aberrant function at a node distal to the insulin 
receptor and its immediate substrates can also contribute to the 
pathogenesis of the insulin resistant state.  
 
Factors external to the insulin signalling axis can also modulate insulin 
signalling: for example, tumour necrosis factor-alpha (TNF-α) is an 
inflammatory cytokine that is produced in multiple body sites, including 
adipose tissue [32]. Local TNF-α concentrations correlate with body mass 
index and rise in hyperinsulinaemic states, and raised levels can impair 
insulin signalling by increasing serine phosphorylation of IRS-1, which is 
deleterious to downstream signal transduction [71]. Leptin, a fat-derived 
hormone with central nervous system effects on feeding, has also been 
implicated in insulin resistance: its circulating concentrations mirror those of 
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insulin. However, no definitive consensus exists as to its relevance in the 
pathophysiology of insulin resistance [32].  
 
 Tissue-specific Insulin Resistance 1.2.5
Various models of tissue-specific insulin receptor manipulation have begun 
to shed light on a multi-system mechanism for the pathological effects of 
whole body insulin resistance and its interplay with the metabolic syndrome. 
For example, insulin-receptor knockout targeted to murine pancreatic beta-
cells (betaIRKO) is associated with lower levels of DNA and protein 
synthesis, which prevents the augmentation of beta-cell mass required to 
mount compensatory hyperinsulinaemia in response to insulin resistance 
[72]. This contributes to hyperglycaemia and can hasten progression from 
insulin resistance to frank diabetes [46]. Hyperglycaemia may be potentiated 
by hypothalamic insulin resistance: in health, insulin acts on the arcuate 
nucleus to suppress appetite, so impairments in central nervous insulin 
signalling may result in increased food intake, hyperglycaemia and obesity 
[46].  
 
Similarly, insulin receptor dysfunction in hepatocytes, as seen in the liver 
insulin receptor knockout (LIRKO) mouse, can have wide-ranging metabolic 
effects [73]. As well as reducing global insulin sensitivity, the loss of insulin-
mediated suppression of hepatic gluconeogenesis release worsens 
hyperglycaemia. Meanwhile, disruption of the liver’s critical role in insulin 
clearance further augments hyperinsulinaemia, thus resulting in profound 
insulin resistance in this model. The hepatic insulin receptor also appears to 
have a role in lipid metabolism, and its knockout results in diminished low 
density lipoprotein (LDL) receptor abundance, a consequent reduction in 
LDL clearance from blood, and also increased secretion of apolipoprotein B, 
a key component of LDL and very low density lipoprotein (VLDL) [74]. These 
abnormalities may have implications in terms of cardiovascular risk. 
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Lipid-related consequences can result from insulin receptor dysfunction in 
other organs too. Adipose tissue-specific insulin receptor knockout (FIRKO) 
mice exhibit normal glucoregulation but impaired suppression of lipolysis, 
resulting in increased concentrations of free fatty acids (FFA) [75]. A similar 
phenotype is seen in murine models of Cre-Lox-driven muscle-specific 
knockout (MIRKO), which display normal glucocompetence but high body fat 
stores and raised triglycerides, reminiscent of human metabolic syndrome 
[76]. Mice with dual-site insulin receptor knockout, affecting both skeletal 
muscle and adipocytes, show a more severe insulin-resistant phenotype, 
suggesting that normal IR function in one tissue can partially compensate for 
a mutation in the other unless both are disrupted together [59, 77]. These 
findings suggest that perturbations of the insulin receptor in traditional target 
tissues can encourage elements of the metabolic syndrome without 
necessarily disrupting glucoregulation. Despite normal glycaemic 
parameters, raised circulating FFA can interfere with insulin signalling, 
potentially instigating a “vicious cycle” of impaired glucoregulation and 
disturbed lipid homoeostasis. Additionally, FIRKO mice show increased 
expression of monocyte chemoattractant protein-1 (MCP-1), which results in 
an influx of macrophages into adipose tissue and consequent induction of a 
chronic pro-inflammatory state [46]. These effects are compounded in 
obesity, where body fat expansion occurs due to adipocyte hypertrophy; 
enlarged adipocytes lack full functional capacity and further promote an 
inflammatory cell infiltrate into areas of white fat [46]. Thus, insulin receptor 
dysfunction at multiple organ sites can act synergistically to create both 
systemic insulin resistance and a wider constellation of increased vascular 
risk with or without dysglycaemia [59].  
 
Clearly, insulin receptors are widespread and disturbance in their number, 
function and downstream mediators can have wide-ranging effects on 
glucose metabolism, lipid clearance and inflammation. These derangements 
are closely tied in with cardiovascular risk and are worthy of attention. Of 
particular relevance to vascular health is the endothelium, which is insulin-
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responsive and thus subject to dysfunction in insulin resistance. This will be 
the focus of this research, and a discussion of the interplay between 
endothelial health and the insulin signalling axis follows.   
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1.3 The Vascular Endothelium 
 Physiological Role of the Endothelium 1.3.1
The endothelium is a cellular monolayer that lines the arteries, capillaries 
and veins that make up the mammalian circulatory system. Vascular 
endothelial cells provide an essential physical barrier between blood and 
tissue, controlling the diffusion of oxygen and nutrients to the extravascular 
environment. An intact endothelium also acts as an interface between blood 
constituents and deeper tissue, reducing the risk of inappropriate 
coagulation [78]. However, the traditional view that the endothelium is simply 
a mechanical barrier has been challenged in recent years, with increasing 
recognition that it is a complex and dynamic organ involved in mediating 
vascular tone and integrity [3, 79]. Complex cytoskeletal arrangements and 
signal transduction mechanisms involving actin fibres, intermediate filaments 
and caveolae (plasma membrane invaginations) allow endothelial cells to 
sense subtle alterations in vessel tension, thus rendering them sensitive and 
responsive to shear stress and cyclic strain [80].  
 
By regulating the balance between vasoconstriction and vasodilatation, the 
endothelium helps to optimise blood pressure and maintain undisturbed 
laminar flow. This is achieved by a fine balance between the release of 
substances that encourage vasoconstriction, such as endothelin 1 (ET-1), 
angiotensin II (AngII) and some reactive oxygen species (ROS) and those 
that do the opposite, such as nitric oxide (NO) [79]. These, and other 
mediators, also modulate platelet function, cell adhesion, inflammation and 
smooth muscle function, thus influencing the processes of atherosclerosis 
and plaque maturation, which underlie the majority of cardiovascular 
disease. Given that the endothelium is insulin-responsive, the interplay 
between the insulin signalling axis and wider endothelial biology may 
influence cardiovascular risk, rendering this a subject of significant interest.  
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 Nitric Oxide (NO) Generation 1.3.2
Nitric oxide (NO) is arguably the most important mediator of vascular health, 
and achieves this by a variety of actions that are anti-atherogenic, anti-
thrombotic and anti-inflammatory. In 1980, Furchgott and Zawadski 
concluded from seminal in vitro experiments that acetylcholine-mediated 
vasodilatation of mammalian vasculature depended on the presence of an 
intact endothelium, by virtue of an unknown substance that caused smooth 
muscle relaxation [81]. This “endothelium-derived relaxing factor” was later 
noted to be nitric oxide, a volatile gas [82, 83].   
 
NO is produced by the action of three nitric oxide synthase (NOS) enzymes: 
endothelial (e)NOS, inducible (i)NOS and neuronal (n)NOS [84]. These 
share a dimeric structure with C-terminal reductase domains that bind 
nicotinamide adenine dinucleotide phosphate (NADPH) and N-terminal 
oxygenase domains that bind the main substrate (L-arginine) as well as 
haem and tetrahydrobiopterin (BH4) [84]. In between these domains lies a 
calmodulin-binding domain, common to all three isoforms. However, subtle 
differences in structure and function distinguish the three isoforms from one 
another.  
 
The most relevant isoform in the context of cardiovascular physiology is 
eNOS, which is upregulated in response to various stimuli including hypoxia, 
alterations in shear stress, insulin, vascular endothelial growth factor (VEGF) 
and oxidative stress. eNOS is encoded on the NOS3 gene [85] and is 
composed of two identical 134kDa monomers which form a biologically 
active dimer under the influence of haem [84]; it is thought that the dimer is 
rendered more stable by BH4 [80]. Thus dimerised, eNOS is able to bind and 
hydroxylate a urea cycle product called L-arginine, ultimately converting it to 
L-citrulline and NO in a complex redox reaction. Initially, NADPH binds to the 
reductase domain, causing flavin-dependent electron transfer from the 
former to a hydroxylated intermediate of L-arginine; this is then oxidised in 
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the N-terminal domain using BH4 as an essential co-factor, generating L-
citrulline and NO [84]. Additionally, the calmodulin-binding domain and 
presence of free calcium ions both appear critical in enzyme activation [80]. 
Similarly, Akt-mediated phosphorylation of serine 1177 on eNOS has been 
shown to augment enzyme activity [86], even at sub-physiological 
concentrations of calcium, suggesting a calcium-independent pathway for 
eNOS activation in addition to the calmodulin-mediated, calcium-dependent 
pathway described above [87]. The process of NO generation is presented 
diagrammatically in Figure 1-6.  
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Figure 1-6 Nitric Oxide Generation 
P (orange circle) represents phosphorylation; eNOS = endothelial nitric oxide synthase; BH4 = tetrahydrobiopterin; NO = nitric oxide.
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Endothelial NOS possesses certain properties that are distinct from the other 
two isoforms of NOS and allow it to respond to a variety of environmental 
stimuli that are relevant to the cardiovascular system. For example, 
experiments using bovine endothelial cells have shown increased eNOS 
activity in response to hypoxia [88], and after 24 hours of shear stress [89] in 
vitro. Post-translational modifications at the enzyme’s N-terminus direct 
eNOS to a subcellular location where it can interact with plasma membrane 
phospholipids [80, 90]. It is thought that palmitoylation of eNOS allows it to 
interact with caveolin-1 and thus aids trafficking of the enzyme towards 
caveolae, as demonstrated in human umbilical vein endothelial cells 
(HUVECs) [91]. This location brings eNOS into the same cellular 
microenvironment as proteins downstream of G-protein-coupled receptors 
and the insulin receptor, allowing it to be released in response to triggers 
transduced by these receptors [91, 92]. Experiments using bovine eNOS 
have shown that it binds caveolin-1 directly, diminishing synthase activity; 
once free of the caveolae, catalytic activity is regained, allowing the 
generation of NO [93].  
 
 Physiological Action of NO 1.3.3
NO is a gaseous, lipophilic molecule with low molecular weight, properties 
which allow it to diffuse easily across plasma membranes [78] to adjacent 
target cells such as vascular smooth muscle cells (VSMC) and blood 
constituents like platelets. In these effectors, it exerts a variety of anti-
atherosclerotic actions [84] via activation of soluble guanylate cyclase and 
production of cyclic guanosine monophosphate (cGMP) [94]. In VSMCs, NO 
regulates cytoplasmic calcium concentrations, encouraging VSMC relaxation 
and therefore vasodilatation. Consequent alterations in vessel diameter can 
affect vascular flow and shear stress. This mechanism is thought to be of 
particular physiological importance as the infusion of levo-N-monomethyl 
arginine (L-NMMA; an inhibitor of NOS) results in raised systolic blood 
pressure in a rabbit model, with reversal of vasoconstriction after exposing 
ex vivo aortic segments to L-arginine [95]. In human studies, forearm 
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infusion of L-NMMA has been found to result in blunted flow-mediated 
vasodilatation in healthy volunteers [96]. NO also has an antiproliferative 
effect on VSMCs [85].  
 
NO has been repeatedly demonstrated to be upregulated in response to 
haemodynamic triggers: for example, eNOS expression is increased in 
response to shear stress in bovine aortic endothelial cells [89] and eNOS 
mRNA and protein expression were noted to rise after vacuum-induced 
deformation of flexible membranes, mimicking cyclic strain [97]. These 
features become important in the maintenance of vascular tone and 
permeability. For example, in conditions of undisturbed laminar flow, the 
unopposed movement of blood within vasculature results in a physiological 
level of shear stress, which allows endothelial cells to flatten and assume a 
conformation that places them in line with the direction of blood flow. In 
areas of low shear stress, blood flow can become erratic or even assume a 
retrograde direction, resulting in misalignment of cells. This, along with 
subtle alterations in cytoskeletal integrity, can result in widening of spaces 
between individual endothelial cells, thus disrupting the physical barrier to 
permeation of blood-borne substances across the monolayer. Relative blood 
stasis, along with a concomitant inflammatory reaction, increases the 
chances of atherosclerosis and thrombosis [78]. Conversely, supra-
physiological shear stress can result from turbulence caused by 
atherosclerotic plaque. This can hasten plaque maturation and eventually 
lead to damage, as well as exposure of the endothelium to erosive forces, 
thus increasing the chance of plaque rupture and subsequent thrombotic 
occlusion of the vessel lumen [78]. The production of NO in these situations 
triggers beneficial vasodilatation and inhibits the inflammatory infiltrate, thus 
resulting in attempted normalisation of flow, blood constituents and vascular 
tone.  
 
NO is also protective against thrombosis. It inhibits platelet adhesion to the 
endothelium [98] and reduces platelet aggregation [99], thus reducing the 
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risk of thrombus formation on vulnerable plaques. For example, mice with 
knockout of the NOS3 gene (and thus reduced eNOS activity) lack the 
physiological inhibition of secondary platelet recruitment into evolving 
thrombi, suggesting a role for NO in limiting thrombus propagation in health 
[100]. When platelets derived from these mice were transfused into 
thrombocytopenic eNOS-deficient mice, haemostasis was improved 
compared with wild-type platelet infusion, suggesting specifically that 
platelet-derived NO reduces platelet activation [99, 100]. Additionally, by 
interfering with platelet activation, NO indirectly leads to reduced 
concentrations of trophic factors such as platelet-derived growth factor 
(PDGF), which ordinarily promotes proliferation in VSMCs [99]. Similarly, NO 
is a negative regulator of cell adhesion molecule and cytokine expression, 
thus reducing the recruitment of inflammatory [101] and pro-thrombotic cells 
to areas of atheroma [78]. Specific cell surface molecules that are 
downregulated in response to NO include P-selectin, vascular cell adhesion 
molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) [99].   
 
Taken together, these descriptions show that NO has wide-ranging effects 
on vascular tone, cytokine release, monocyte recruitment into maturing 
atheroma and acute thrombosis after plaque rupture. Thus, any deficiency in 
its bioactivity can negatively impact on all stages of atherosclerosis and 
eventually promote myocardial infarction or stroke. Reduced NO 
bioavailability is thus a key contributor to the pathogenesis of vascular 
disease and can occur as a result of reduced generation, which is directly 
relevant to the insulin signalling axis, or due to increased sequestration by 
reactive oxygen species (ROS), which will be discussed in more depth later.  
 
 Endothelial Dysfunction and Insulin Resistance 1.3.4
As previously mentioned, the endothelium maintains a delicate balance 
between vasoconstrictive and pro-thrombotic mediators such as ET-1 and 
angiotensin and molecules like nitric oxide, which have a portfolio of anti-
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coagulant and vasodilatory properties [40]. A disturbance of this balance is 
referred to as endothelial dysfunction. This is a key initiating step in 
atherosclerosis [102] and has been shown to be an independent predictor of 
cardiovascular disease in studies using both human forearm flow-mediated 
vasodilatation and invasive measures of coronary artery dilation responses 
[103, 104]. 
 
The endothelium is an insulin-responsive tissue: once insulin binds with its 
cell surface receptor, parallel intracellular signalling pathways are activated, 
in turn stimulating NO and ET-1 release [40] (Figure 1-4). Conditions of high 
glucose can, in vitro, reduce signalling in the PI3K pathway in human aortic 
endothelial cells, potentially implicating this pathway in the pathogenesis of 
endothelial dysfunction in the setting of diabetes [105]. In insulin resistance, 
there is selective downregulation of the PI3K pathway, resulting in reduced 
eNOS activation, and therefore NO production, as demonstrated in both rat 
[106] and human [107] experiments. This appears to be physiologically 
important in man: insulin resistant human subjects display blunted 
endothelium-dependent vasodilatation in response to both insulin [108] and 
acetylcholine [109]. At the same time, flux through the MAPK pathway is 
undisturbed or even augmented due to compensatory hyperinsulinaemia; 
therefore, ET-1 synthesis is not diminished [106, 107]. It has been observed 
that humans with metabolic syndrome in fact have higher concentrations of 
ET-1 than healthy controls, suggesting a potential link, albeit not necessarily 
a causal one, with upregulated ET-1 synthesis [110]. Physiologically, studies 
in rats have shown that ET-1 antagonism improves endothelium-dependent 
vasodilatation in both ex vivo aortic segments and after chronic 
pharmacological blockade using bosentan, suggesting that at least in animal 
models, this mechanism may be a relevant contributor to altered vascular 
tone [111]. Furthermore, ET-1 can inhibit PI3K signalling and accentuate the 
reduction in NO production [112]. Finally, the MAPK pathway promotes 
expression of cell adhesion molecules such as VCAM-1, which can 
encourage leukocyte infiltration, and thus promote atherosclerosis [40]. 
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Collectively, one may surmise that the pathway-specific nature of insulin 
resistance encourages endothelial dysfunction via a two-fold mechanism: 
firstly, by reducing NO, and secondly, via the concomitant deleterious effects 
of raised ET-1 and leukocyte adhesion. Whilst the applicability of MAPK 
pathway overactivation in man is not entirely established, there seems to be 
circumstantial evidence that ET-1 levels are raised in insulin resistant 
humans, and it is feasible that this contributes to a disruption in the balance 
of vasoactive mediators, favouring vasoconstriction and atherogenesis.  
 
Much can be inferred from work focussing on the interplay between insulin 
resistance and endothelial function using murine models. As previously 
discussed, homozygous loss of the insulin receptor results in early post-natal 
death, limiting the use of this model for studies of adult physiology [57, 58]. 
However, mice with heterozygous insulin receptor knockout (IRKO) display a 
milder phenotype, with normal weight gain and only post-prandial (as 
opposed to basal) hyperinsulinaemia [60]. These features make the IRKO 
mouse a useful model for pre-diabetes without the potential confounding 
influences of hyperglycaemia and obesity. Interestingly, this modest 
disturbance in parameters is accompanied by a convincingly deranged 
vascular phenotype: IRKO mice are hypertensive compared with wild-type 
(WT) controls and display marked endothelial dysfunction in ex vivo assays 
of aortic vasomotor responses in organ bath apparatus [60]. Six month-old 
IRKO aortic rings pre-exposed to phenylephrine, an endothelium-
independent vasoconstrictor, showed a reduced dilation response to 
acetylcholine after insulin incubation compared with rings from WT 
littermates. Crucially, this vasomotor dysfunction was shown to be related to 
reduced NO bioavailability as evidenced by a diminished incremental 
constriction response after incubation with the NOS inhibitor L-NMMA [60]. 
Examination of downstream intracellular signalling in this study showed 
equivalent eNOS mRNA expression in IRKO and WT but reduced insulin-
induced eNOS phosphorylation in IRKO [60].  
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IRKO mice display the above vascular phenotype in association with whole 
body haploinsufficiency for the insulin receptor; the specific role of the 
endothelium within this has been studied using two separate murine 
modelling approaches. In 2003, one group used Cre-lox recombination to 
knock out the insulin receptor from vascular endothelial cells in the 
VENIRKO model [113]. These mice showed no difference from WT in terms 
of glucocompetence, but reduced eNOS mRNA expression was observed in 
endothelialised organs such as heart and aorta in the VENIRKO mice. This 
interference at mRNA level was in contrast to the findings in the IRKO study 
above [60]. Our laboratory employed a different approach to study a similar 
theme by generating a transgenic mouse with endothelium-specific mutant 
insulin receptor overexpression (ESMIRO). This model utilised a Tie-2 
promoter-enhancer in order to express a mutant kinase-defective human 
insulin receptor within endothelial cells [114]. ESMIRO mice behaved 
similarly to IRKO mice: they exhibited preserved glucoregulation, but 
showed a blunted vasodilator response to acetylcholine, reduced insulin-
mediated vasorelaxation and diminished insulin-induced eNOS 
phosphorylation [114]. As with IRKO mice, there was no difference in eNOS 
mRNA expression between ESMIRO and WT. In this study, raised levels of 
reactive oxygen species (ROS) were noted in endothelial cells from ESMIRO 
mice, and the endothelial dysfunction seen in aortic ring experiments could 
be reversed using anti-oxidants [114].  
 
Taken together, these studies imply a key role for endothelial insulin 
receptor function and signalling in maintaining vascular function. Whilst the 
exact mechanism appears to differ between the above models, they all 
suggest a defect at the level of eNOS, which may be a direct consequence 
of reduced signalling through the insulin receptor. However, as previously 
mentioned, another possible explanation for reduced NO bioavailability is 
sequestration by ROS, which may be relevant given the results of previous 
work in ESMIRO mice and older IRKO mice [114, 115]. A discussion of the 
role of ROS in endothelial function and cardiovascular health follows.   
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 Reactive Oxygen Species  1.3.5
Reactive oxygen species are a group of molecules generated in redox 
reactions either in mitochondrial electron transport chains or via the activity 
of endogenous enzymes such as NADPH oxidase (or NOX), lipoxygenase, 
xanthine oxidase, and even eNOS. In these reactions, electrons are 
transferred sequentially to molecular oxygen, generating molecules such as 
the superoxide anion (O2
-), hydrogen peroxide (H2O2) and hydroxyl radicals 
(OH-) [116] (Figure 1-7). Some types of ROS contain unpaired electrons and 
can thus act as free radicals, with damaging effects on mammalian cells; 
others are not strictly free radicals but can still exert deleterious but perhaps 
milder pro-oxidant effects [117]. ROS are traditionally viewed as harmful, but 
work done in recent years has yielded increasing recognition of a beneficial 
and necessary role for ROS in intracellular redox signalling and vascular 
health at physiological concentrations [118]. However, in the context of 
insulin resistance, various mechanisms can lead to enhanced production or 
reduced breakdown of ROS, and their resultant accumulation to harmful 
concentrations (oxidative stress) [116].  
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Figure 1-7 Generation of Reactive Oxygen Species 
NO = nitric oxide; ONOO = peroxynitrite; O2 = oxygen; O2
- = superoxide 
anion; Cl- = chloride ion; OH- = hydroxyl radical; H2O2 = hydrogen peroxide; 
HOCl = hypochlorous acid; H2O = water; NOX = nicotinamide adenine 
dinucleotide phosphate oxidase; XO = xanthine oxidase; mit = mitochondria; 
eNOS = endothelial nitric oxide synthase (in this case, uncoupled); SOD = 
superoxide dismutase; Fe3+ = iron (III) ion; MPO = myeloperoxidase. Red 
boxes denote reactive oxygen species, green boxes and blue oval denote 
less toxic sources and metabolites.  
 
The primary source of vascular ROS is the family of NOX enzymes, which 
use NADPH as the substrate and source of electrons for transfer to oxygen 
molecules [118]. Whilst there are several NOX isoforms, it appears that 
NOX1, NOX2 and NOX4 are of particular importance in vascular and 
endothelial cell biology [79]. The action of these enzymes is to generate 
hydrogen peroxide and superoxide anions which, in supra-physiological 
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quantities, can result in vascular damage through a variety of mechanisms. 
Superoxide reacts with NO to form peroxynitrite, another pro-oxidant which 
can nitrosylate proteins and thus interfere with phosphorylation, cell 
signalling and function [99]. Thus, the effect of this is two-fold, as it causes 
sequestration of bioavailable NO and reduction of its beneficial vascular 
effects, while the direct effects of peroxynitrite on endothelial cells can be 
harmful in themselves [119]. Superoxide can also interfere with normal 
function of BH4, a key component of eNOS. Not only does this reduce NO 
generation, but modifying BH4 can cause uncoupling of eNOS into 
monomers, which preferentially generate more superoxide, further 
potentiating the effect [120]. It can also promote oxidation of the zinc-
thiollate core of eNOS, with similar reduction in enzyme activity and 
therefore diminished NO generation [79]. Finally, NOX-derived ROS can 
enhance mitochondrial ROS generation [121], resulting in a ‘vicious cycle’ of 
ROS overproduction to the point where endogenous antioxidants are unable 
to compensate and harmful concentrations are reached [79].  
 
Appraisal of animal models lends validity to the suggestion that these effects 
are pathophysiologically relevant in insulin resistance. For example, Duncan 
et al described the phenotype of a transgenic mouse in which a mutated 
human insulin receptor (at threonine 1134) was targeted to the vascular 
endothelium using a Tie-2 promoter-enhancer sequence [114]. These 
ESMIRO mice exhibited diminished vasorelaxation of explanted aortic rings 
to acetylcholine, with associated blunting of insulin-induced eNOS 
phosphorylation. Aortic relaxation could be restored to wild-type levels with 
the administration of the superoxide dismutase mimetic 
manganese(III)tetrakis(1-methyl-4-pyridyl) porphyrin pentachloride 
(MnTMPyP), implicating oxidative stress as a causative factor in endothelial 
dysfunction. In this study, NOX2 and NOX4 were demonstrated to be key 
sources of ROS in both aortic samples and in cultured microvascular 
endothelial cells [114]. Elevated superoxide concentrations have also been 
shown in aortae and cultured endothelial cells from IRKO mice; in the same 
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study, endothelial dysfunction in aortic vasorelaxation experiments could be 
reversed using MnTMPyP [115].  
 
The relevance of this manipulation has been explored in further detail using 
existing murine models of vascular disease. In our laboratory, ESMIRO were 
crossed with atherosclerosis-prone apolipoprotein E knockout mice (ApoE-/-); 
in addition to endothelial dysfunction, these animals displayed significantly 
higher atherosclerotic burden at the aortic sinuses and arch than ApoE 
knockout controls [122]. These findings suggest that, as well as manifesting 
as endothelial dysfunction in ex vivo experiments, the increase in oxidative 
stress is relevant to an in vivo marker of adverse vascular risk. Again, a 
convincing elevation in superoxide concentrations was observed, though this 
time, multiple enzyme sources were implicated: the heightened superoxide 
signal could be suppressed using gptat (which inhibits NOX enzymes), 
rotenone (which quenches mitochondrial ROS production) and L-NMMA 
(which abrogates the effects of uncoupled eNOS) [122]. In a further study 
from our group, the use of gptat was found to reverse the endothelial 
dysfunction and raised superoxide concentrations seen in both ESMIRO and 
IRKO mice when administered acutely in vitro [123]. In IRKO aortic rings, 
this was associated with increased NO bioavailability. This ‘rescue’ was 
recapitulated with chronic administration of gptat into ESMIRO mice via a 
subcutaneously implanted ‘minipump’, which gradually released the 
antioxidant over a 28-day period [123]. Finally, chronic ROS inhibition was 
modelled genetically by crossing ESMIRO with mice with NOX2 inactivation 
(ESMIROxNOX2y/-), yielding the same beneficial effects on aortic vasomotor 
function [123]. This study therefore utilised acute and chronic 
pharmacological inhibition as well as genetic deletion to demonstrate the 
relevance of NOX-derived ROS on vascular function [123].  
 
A similar adverse vascular phenotype has also been induced with high fat 
feeding in mice [124]. This group showed that high-fat fed mice had features 
akin to the human metabolic syndrome, accompanied by increased levels of 
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ROS, NOX2 expression and endothelial dysfunction, all of which was 
abrogated both with pharmacological antioxidant therapy using apocynin, as 
well as in NOX2 knockout mice subjected to the same high-fat diet [124]. 
Similar work in cholesterol-fed, atherosclerotic rabbits has shown that 
acetylcholine-induced vasorelaxation can be rescued by infusing 
polyethylene-glycated superoxide dismutase (SOD) [125]. Importantly, this 
was not found with sodium nitroprusside-induced vasorelaxation, implying a 
key role for specifically endothelium-derived superoxide. 
 
Human studies appear to support the presence of increased vascular ROS 
in insulin-resistant states: for example, it has been shown that arteries and 
veins from patients with diabetes contain more superoxide and uncoupled 
eNOS than tissue from matched controls, with restoration of superoxide 
concentrations to physiological levels after exposure to supplemental BH4 
[126]. Similarly, human subjects with metabolic syndrome show increased 
NADPH oxidase activity and superoxide production in peripheral blood 
mononuclear cells compared with healthy controls, correlating with plasma 
insulin levels [127]. Similar findings of increased NOX activity in obese 
humans and those with heart failure lend further validity to the implication of 
ROS in cardiovascular and metabolic disease states [79]. Whilst these 
studies do not specifically demonstrate a dysfunctional human vascular 
phenotype, there is a strong suggestion that such a disturbance exists; 
increased ROS is linked with reduced NO bioactivity, which has been shown 
to be a crucial contributor to endothelial dysfunction and thus hypertension 
and atherosclerosis in humans.  
 
 Atherosclerosis 1.3.6
The key reason for studying oxidative stress, nitric oxide bioavailability and 
endothelial dysfunction is that these are key events in the development of 
atherosclerosis. Whilst hypercholesterolaemia has long been recognised as 
a risk factor for atherosclerosis and subsequent cardiovascular events, 
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research over the last few decades has shown that the development of 
plaques is more complex than simply the laying down of layers of lipid in the 
arterial wall [102, 128]. An overview of the pathogenesis of atherosclerotic 
plaque development will now be presented.  
 
Atherosclerosis is a process that can begin in an individual’s childhood or 
teenage years with the development of fatty streaks [129]. These are 
predominantly inflammatory lesions that begin with a monocyte infiltrate but 
mature over time to become more complex entities which gradually protrude 
into the vessel lumen and disturb the flow of blood to distal structures. As 
plaques evolve, they can also undergo erosion and become unstable and 
prone to rupture; this exposes circulating clotting factors and platelets to 
highly thrombogenic plaque contents and can result in acute thrombotic 
occlusion of vessels, leading to distal ischaemia and infarction [130].  
 
The initiating event in atherosclerosis is often disturbance of laminar flow at 
specific sites within an artery, such as bifurcations or areas of curvature or 
tortuosity. In these areas, turbulence can rise and shear stress can be 
altered, and it is thought that these stimuli can increase the expression of 
genes for several cell surface molecules that modulate the local immune 
response. For example, genes for ICAM-1 and platelet-derived growth 
factor-B can be induced in endothelial cells [102, 131] in response to low 
shear stress. The collective action of a variety of such molecules is to 
encourage an inflammatory cell infiltrate and to promote the docking of 
monocytes in particular onto the endothelium. Cell adhesion molecules such 
as ICAM-1 and VCAM-1 facilitate rolling and adhesion of monocytes, which 
eventually undergo diapedesis and are incorporated into subendothelial 
locations. As in other anatomical locations, monocytes are able to reside in 
these plaques and the receptor-ligand interactions discussed above allow 
them to become activated and to differentiate into macrophages [102]. 
Furthermore, production of chemokines such as monocyte chemoattractant 
protein (MCP) leads to propagation of the influx of inflammatory cells, 
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initiating and maintaining a cycle of ongoing cell accumulation. 
Immunohistology of surgically obtained arterial specimens from humans has 
confirmed the presence of a marked inflammatory infiltrate rich in 
macrophages in areas of atheroma, with fewer of these cells noted in 
adjacent healthy endothelium [132].  
 
Alongside this cellular infiltrate, low density lipoprotein (LDL) can also 
accumulate in early plaques after interaction with the LDL receptor on the 
endothelial surface [133]. With endothelial dysfunction and inflammation, 
vascular permeability is increased, leading to excessive internalisation of 
LDL. Once this has accumulated, it can be oxidised by ROS derived from 
activated macrophages. Oxidised LDL is a profound chemotactic stimulus for 
inflammatory cells; for example, modified LDL can stimulate gene 
expression for macrophage colony stimulating factor and MCP and thus 
propagate the cellular infiltrate [130]. Furthermore, inflammatory mediators 
such as tumour necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1) have 
been shown to increase LDL receptor gene expression and promote binding 
of LDL to endothelial cells, which could maintain a spiral of increasing 
inflammation and lipid deposition [134].  
 
As LDL accumulates in the subendothelial space, it can also become 
internalised by resident macrophages, which contain cell-surface scavenger 
receptors for lipoproteins. This encourages the formation of cholesterol 
esters, which accumulate within the macrophages and cause them to 
develop into foam cells. These can undergo necrosis, which causes further 
release of pro-inflammatory and chemotactic mediators into the circulation 
[133]. Thus, the combination of lipid deposition, lipoprotein modification and 
chronic inflammation appears to induce the development of metabolically 
active lesions which can interfere with normal vascular anatomy and 
physiology. Consistent with a role for ROS in the harmful oxidation of LDL, 
antioxidant treatment has also been shown to reduce atherosclerotic burden 
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in hypercholesterolaemic macaques [135], though clinical trials have failed to 
reproduce these encouraging findings in humans [136].  
 
Another downstream effect of the early inflammatory response is the 
production of growth factors and vasoactive cytokines. This can stimulate 
local vascular smooth muscle cells to migrate and proliferate at the site of 
damage, which often leads to development of fibrosis around affected areas. 
Thus, the potentially thrombogenic and toxic core of an atheromatous plaque 
can be separated mechanically from the blood by a “fibrous cap”, which can 
lend stability to the lesion, at least in the early stages of plaque development 
[130]. Human atheromatous lesions have been noted to be more rich in 
smooth muscle cells than neighbouring healthy endothelium, suggesting an 
important role for these cells in plaque maturation [132]. Fibrosis in the 
arterial wall can also be promoted by sustained hypertension, potentially due 
to the trophic effects of chronic exposure to angiotensin II on VSMCs [137]. 
Interestingly, angiotensin II can also augment lipoxygenase activity in 
VSMCs, which in turn stimulates inflammation and can result in further 
oxidation of LDL [102]. The initial response of arteries to this degree of 
fibrosis is to undergo a period of remodelling and compensatory 
vasodilatation in an attempt to preserve luminal morphology and thus distal 
blood flow [130]. However, with increasing inflammation and fibrosis, there 
comes a point at which remodelling can no longer preserve an adequate 
luminal diameter and the thickened arterial wall encroaches into the lumen 
[102]. At this stage, provided that the fibrous cap maintains its integrity, 
necrotic plaque contents are not exposed to blood and platelets so the risk 
of thrombus formation remains low; however, the stenosed artery may not 
be of sufficient calibre for adequate tissue perfusion at times of stress, 
leading to phenomena such as stable angina and intermittent claudication.  
 
With further plaque maturation, macrophages and foam cells can undergo 
apoptosis or necrosis, with consequent release of multiple inflammatory 
mediators and, importantly, proteolytic enzymes. A wider inflammatory 
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response can also ensue due to the antigen presentation by major 
histocompatibility complexes on macrophages; this causes local recruitment 
of T-lymphocytes, which stimulate collagenase and matrix metalloproteinase 
release from viable macrophages [128]. The result of this enhanced 
proteolytic activity is gradual degradation of the fibrous cap, rendering it 
unstable and vulnerable to erosion and ulceration in the face of ongoing 
disturbed blood flow [128]. The long-term action of locally-secreted 
collagenase can also induce structural reconfiguration in the tunica media of 
atheromatous arterial segments. In these areas, extracellular matrix 
composition can therefore change from an organised collagen matrix to a 
pathological one, predominantly containing proteoglycans interspersed with 
chaotically-distributed collagen fibrils [102]. The weakened and complicated 
plaque is therefore at high risk of rupture, with exposure of its internal 
thrombogenic core to circulating platelets and coagulation factors. This is the 
underlying basis of acute coronary syndrome and cerebrovascular events, 
wherein thrombus formation on a ruptured plaque can quickly propagate, 
leading to acute vascular occlusion and distal infarction. 
 
Atherosclerosis is a multifactorial and complex phenomenon, which is clearly 
influenced by endothelial dysfunction and consequent reduction in NO 
bioavailability at every stage in the disease process. Thus, studying the 
interaction between insulin resistance and endothelial dysfunction is of 
crucial importance in understanding and developing treatments for 
cardiovascular risk in this group of patients. Vascular injury is both a 
causative factor in atherogenesis and a consequence of plaque rupture, and 
so the next section of this project will consider vascular regeneration and 
repair and their interplay with diabetes and insulin resistance.   
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1.4 Vascular Injury and Regeneration 
 Vascular Regeneration in Health 1.4.1
Diabetes and insulin resistance both lead to accelerated atherosclerosis, 
and it is therefore important to understand the impact of these conditions on 
the processes of vascular injury and endogenous endothelial repair. In order 
to appreciate the complexities of vascular regeneration and identify targets 
for therapeutic manipulation, it is important to have knowledge of the 
processes involved in blood vessel formation in physiological circumstances. 
 
 
1.4.1.1 Vasculogenesis 
In mammalian development, the earliest example of normal vascular 
development this is the de novo synthesis of blood vessels in utero, a 
process known as vasculogenesis [138]. This involves the maturation of 
angioblasts, sometimes referred to as endothelial progenitor cells (EPCs), 
which share an origin with haematopoietic cells [139]. These EPCs form 
primitive capillary networks that eventually coalesce to form the primordial 
vasculature [140]. There is little doubt that this process is relevant to 
embryonic development, but studies published in the last 15 years have 
raised discussion as to the possibility of a novel role for post-natal 
vasculogenesis in the response to endothelial injury in adulthood [141, 142]. 
This is a controversial subject and will be discussed in more depth later.  
 
1.4.1.2 Angiogenesis and Arteriogenesis 
Quite distinct from de novo vessel formation, angiogenesis is strictly defined 
as the extension of vasculature by new blood vessels sprouting from an 
existing vascular network [138, 139]. There is confusion in the wider 
biomedical literature about this, as angiogenesis is often incorrectly used to 
refer indiscriminately to new vessel formation in any context [138]. In this 
thesis the term will be used solely with reference to the first definition. In 
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adult life, most vascular beds are in a quiescent state; however, in the 
setting of vascular insults such as myocardial infarction or stroke, the 
resultant hypoxic and inflammatory milieu can drive angiogenesis and thus 
aid recovery [139]. Equally, disorders such as diabetic retinopathy and age-
related macular degeneration demonstrate that aberrant angiogenesis can 
also be harmful as it can encourage formation of vascular networks that do 
not perfuse appropriately despite increased quantity [139]. Similarly, 
“unwanted” angiogenesis can aid tumour metastasis by way of vascular 
invasion of neoplastic lesions, providing a route for distant spread. In the 
context of diabetes and insulin resistance, angiogenesis is relatively 
ineffective [143] and therefore study of its intricate mechanisms may yield 
therapeutic targets for reduction of cardiovascular risk in these conditions.  
 
Arteriogenesis is the third process that occurs during the generation of blood 
vessels, and refers to the maturation of new capillary networks within conduit 
vessels. These neovessels must assimilate with perivascular mesenchymal 
cells in order to transform into mature vascular tissue with lumina capable of 
accommodating and transporting blood and a vessel wall that is able to 
withstand haemodynamic stress [139]. Arteriogenesis is therefore an 
important contributor to eventual vascular development but remains 
incompletely understood and will not form a significant consideration in this 
project.  
 
 Vascular Repair  1.4.2
In contrast to vascular regeneration, the term “vascular repair” refers to re-
endothelialisation in a pathological setting in which established and mature 
conduit vessels undergo injury. This can occur endogenously as a 
consequence of recurrent biochemical insult: for example, in diabetes, the 
accumulation of advanced glycation end products can lead to oxidative 
stress and endothelial cell loss [144]. Chronic hyperglycaemia can also 
induce senescence and apoptosis in endothelial cells [145]. Dead 
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endothelial cells then detach, either as whole cells or as endothelial 
microparticles, leaving behind a denuded endothelium that triggers an 
inflammatory response in an attempt to induce repair and regain structural 
integrity [144]. Whilst a degree of inflammation is helpful for repair, the 
overactivation of this cascade can also encourage the development of 
atheroma in the denuded area. Conversely, a similar process of endothelial 
denudation can occur after acute vascular events in areas of established 
atherosclerosis, such as plaque rupture. Iatrogenic causes are also relevant 
in human disease: therapeutic balloon angioplasty and stent implantation 
into stenosed arteries can both induce a degree of endothelial injury [138, 
146]. Whilst sustained hyperglycaemia is likely to be restricted to frank 
diabetes, several other mechanisms outlined above, such as plaque rupture 
and oxidative stress, are likely to be relevant in the context of insulin 
resistance as well.  
 
The process of vascular repair can be modelled in mice in various ways 
[146]. An electrical current can be applied to exposed femoral arteries, 
resulting in total endothelial denudation as well as removal of smooth muscle 
cells in the tunica media, and also the formation of mural thrombosis due to 
local platelet activation [147]. Whilst this method is attractive due its 
relatively low technical difficulty, one could argue that the mechanism of 
injury and the significant damage incurred to non-endothelial structures here 
reduce the clinical relevance of this model and induce a more severe 
phenotype than that usually encountered in man. Other researchers have 
described slightly more targeted endothelial injury following unilateral carotid 
artery ligation, which offers the advantage of a lack of thrombosis, thus 
allowing assessment of the response to injury without the confounding 
influence of local platelet biology [148].  More recently, Roque et al 
described a model of arterial injury utilising an angioplasty guide wire to 
denude the femoral artery endothelium [149]. This model, whilst challenging 
to perform in animals as small as mice, could be argued to induce more 
selective endothelial damage than in the previous models, and in a manner 
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that is perhaps more likely to simulate a realistic disease process in man. 
Similarly, balloon injury can also be induced in small animals, with several 
studies reported in rats using this technique [150, 151].  
 
Such models have allowed us to employ genetically modified mice in the 
study of the pathophysiological mechanisms involved in the response to 
injury. Traditionally, it has been believed that regeneration of injured 
endothelium principally depends on mitosis and migration of adjacent 
healthy endothelial cells, which simply bridge the gap. Murine studies using 
the femoral arterial injury model support this, with evidence of a specific role 
for VEGF in driving endothelial cell proliferation and angiogenic inhibitors 
such as endostatin in promoting endothelial cell apoptosis [152, 153]. 
However, endothelial cells are terminally differentiated and retain only limited 
capacity for proliferation, suggesting that other mechanisms may contribute 
to repair. Much work in the last 15 years has challenged the traditional view 
of solely endothelial cell-mediated repair, highlighting a potential role for 
circulating bone-marrow derived cells (i.e. EPCs) in a process akin to post-
natal vasculogenesis [154, 155]. This has in turn been disputed recently by 
other authors, who have concluded from murine experiments that EPCs do 
not permanently incorporate into injured endothelium and that the 
aforementioned traditional mechanism is the sole contributor to healing 
[156]. Whilst the overall suggestion is that EPCs are probably not directly 
involved in repair, these findings do not rule out a “bystander” role by way of 
paracrine stimulation of local endothelial regenerative mechanisms.  
 
Vascular repair is an important area of study in the specific context of the 
cardiovascular risk associated with diabetes and insulin resistance [157]. In 
humans with diabetes, percutaneous coronary intervention (PCI) is 
associated with less promising outcomes due to re-endothelialisation in the 
stented segment: a study using intravascular ultrasound demonstrated that 
exaggerated intimal hyperplasia can contribute to this phenomenon [158]. 
This may be related to insulin resistance: obese Zucker rats exhibit 
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increased neointimal hyperplasia after balloon arterial injury compared with 
lean counterparts [151]. Importantly, two separate studies failed to recreate 
the same phenotype in rats rendered diabetic in an insulin-deficient fashion 
with streptozotocin, implicating hyperinsulinaemia (rather than 
hyperglycaemia) as a possible aetiological factor in the process [151, 159]. 
Similarly, Sprague Dawley rats (with no inherent metabolic derangements) 
infused with subcutaneous insulin developed pathological remodelling after 
balloon injury to the aorta and carotid arteries, unlike control animals who 
received no insulin [150]. These findings are in contrast to those of Breen et 
al, who instead propose a protective role for insulin in various studies of 
arterial injury in rats [160-162]; in their experiments, neointimal hyperplasia 
was reduced in rats exposed to more insulin, while re-endothelialisation of 
injured segments was augmented. In the last of these three studies, the 
beneficial effect of insulin was shown to be dependent on eNOS and nitric 
oxide through infusion of the NOS inhibitor L-NMMA [162]. The 
discrepancies between this group’s work and the studies implicating insulin 
in pathological remodelling may arise from differential techniques for 
inducing hyperinsulinaemia, and the fact that circulating insulin 
concentrations in the animals concerned may not have been consistent 
between experiments.  
 
Studies of carotid arterial injury in diabetic mice demonstrate that vascular 
repair mechanisms can be impaired in this pathological setting; importantly, 
the insulin resistant spectrum also appears to result in in vitro and in vivo 
EPC dysfunction [163]. Similarly, our laboratory’s work has shown 
diminished re-endothelialisation after femoral artery wire injury in IRKO mice 
compared with WT littermates, demonstrating that even relatively mild insulin 
resistance can be associated with a significantly impaired repair phenotype 
in the context of essentially normal glucoregulation [164]. Interestingly, 
numbers of circulating and culture-derived EPCs (which will be defined in 
more detail below) were reduced in IRKO mice in this study, and the 
mobilisation of these cells to intraperitoneal VEGF administration was also 
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blunted. Finally, transfusion of c-kit-positive cells (with a putative EPC 
phenotype) from WT mice restored IRKO vascular healing to WT levels, 
whilst IRKO-derived c-kit-positive cells provided partial recovery. These 
findings suggest that, even if EPCs are not of crucial importance in health, 
their dysfunction is prominent in the setting of insulin resistance and 
contributes to diminished endothelial repair. Our group’s work in insulin 
resistant (but otherwise healthy) South Asian men has also shown impaired 
progenitor cell mobilisation compared with white European control males 
[165]. Taking these studies together, it is tempting to speculate that insulin 
resistance, even at the milder end of the spectrum, is associated with 
impaired endothelial repair which is likely to involve, at least in part, a defect 
in EPC quantity and function. These issues will now be discussed in more 
depth.  
 
 Endothelial Progenitor Cells  1.4.3
In 1997, a group from Boston hypothesised that haematopoietic and 
endothelial cells shared a common stem cell precursor that could 
differentiate into either cell type [141]. They selected a shared cell surface 
antigen [cluster of differentiation (CD)34 or VEGF receptor 2 (VEGFR2)] that 
would be typical of mature endothelial cells but that would disappear on 
maturation to haematopoietic lineage. Cells with this phenotype could be 
isolated from human peripheral blood using magnetic bead separation and, 
when cultured in vitro, developed an antigen profile overlapping with human 
umbilical vein endothelial cells (HUVEC). Furthermore, the cells could form 
tube-like structures on fibronectin-coated culture plates. Finally, these cells 
were labelled and injected into athymic mice that had undergone hind-limb 
ischaemia after unilateral femoral artery excision. It was found that labelled 
cells had incorporated into new vessel walls, identifying a potential role in 
angiogenesis both in vitro and in vivo.  These cultured cells were later 
termed EPCs and it was postulated by other authors that they were able to 
promote vascular repair and/or regeneration in humans [142]. Clinical 
studies have also shown that reduced numbers of circulating cells bearing 
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the progenitor markers the Boston group selected for (determined using flow 
cytometry) correlate with cardiovascular death [166]. The definition of these 
circulating entities has evolved over time and current understanding is that 
they co-express CD34, CD133 and VEGF receptor 2, or kinase domain 
receptor (KDR); an antigen profile that may distinguish them from both 
haematopoietic cells and from mature endothelial cells [138]. Their biology is 
also altered in insulin resistance: in the aforementioned study of femoral 
artery injury in IRKO mice, a murine equivalent of these cells (Sca1+Flk1+) 
was reduced in abundance and mobilisation potential in the IRKO group 
[164]. For the remainder of this thesis, this particular EPC subset, as defined 
by flow cytometry, will be referred to as circulating progenitor cells (CPC).  
 
Various subsets of EPCs have also been described in vitro using variants of 
the originally described cell culture conditions [138]. Using density-gradient 
centrifugation of whole blood, homogenised spleen or bone marrow, a 
mononuclear cell fraction can be isolated and cultured in endothelial growth 
medium [167]. Over four to seven days, these cells differentiate into early-
outgrowth EPCs (EEPCs) that retain a monocyte/macrophage phenotype 
and have limited capacity for proliferation or incorporation into neovessels 
[167]. However, they do express some endothelial cell markers such as 
CD31 and VEGFR2. It is now recognised that these cells were described in 
the seminal report of Asahara et al above [141]. A role for EEPCs in the 
paracrine modulation of angiogenesis has been suggested: for example, 
endothelial growth medium conditioned in spleen-derived EEPCs has been 
shown to augment tube formation in human umbilical vein endothelial cells 
(HUVECs), with a reduction in this angiogenic capacity seen in IRKO-
derived EEPC medium [164]. With a subtle alteration in initial cell culture, a 
different subset of circulating mononuclear cells differentiates into colony 
forming units (EPC-CFUs, or CFU-Hill cells), which show characteristics 
typical of T-lymphocytes [138]. These behave similarly to EEPCs in that they 
may indirectly exert positive paracrine effects on vascular repair but appear 
not to incorporate themselves into new endothelium. Human studies have 
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shown that the abundance of these EPC-CFUs inversely correlates with 
Framingham risk score and endothelial vasomotor function [168]. 
 
After prolonged culture (up to twenty-one days), a third EPC phenotype is 
observed: the late-outgrowth EPC (LEPC) [138]. These are morphologically 
similar to mature endothelial cells, expressing essentially the same antigen 
profile, while they do not ingest bacteria, suggesting a divergence from the 
monocyte/macrophage phenotype seen in earlier EPCs. LEPC have the 
capacity to form capillaries in a VEGF-dependent manner when infused in 
vivo, and display significant proliferative potential with a clear progenitor 
hierarchy. An important caveat in the study of these cells is that they are a 
culture-derived entity that may or may not bear resemblance to circulating 
progenitor cells that have been studied in whole blood; as with all EPCs, this 
brings their endogenous relevance into question. However, LEPCs are of 
particular interest because they offer a model for in vitro study of 
neovascularisation and may represent a future autologous cell-based 
cardiovascular repair therapy.  
 
The different subsets of EPC can be easily confused and nomenclature in 
the literature is inconsistent. For this reason, their characteristics are 
compared and contrasted in Table 1-1. 
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 CPC CFU-Hill Early 
Outgrowth 
EPC 
Late 
Outgrowth 
EPC 
Isolation 
Technique 
    
Derivation 
Technique 
Flow 
cytometry 
   
Morphology 
in Culture 
N/A Spindle 
shaped cells 
cluster at day 
4-9 
No colony 
formation 
Cobblestone 
shaped 
colonies at 
day 7-21 
Defining 
Features 
Cell 
surface 
expression 
of CD34, 
CD133, 
VEGFR2 
Ability to form 
colonies in 
culture 
Uptake of 
acetylated 
LDL and Ulex 
europeaus 
lectin 
Classical 
endothelial cell 
surface 
markers and 
progenitor 
hierarchy in 
single cells 
Angiogenic 
Potential 
Form 
capillary-
like 
structures 
in vitro 
with 
unclear 
role in vivo 
No 
spontaneous 
neovessels 
formation; may 
have paracrine 
effects 
No 
spontaneous 
neovessels 
formation; may 
have paracrine 
effects 
Can form 
capillary-like 
structures in 
vitro and aid 
vascular repair 
in vivo 
Table 1-1 Comparison of Endothelial Progenitor Cell Subsets 
Not to scale. Blue-topped tube with antibody/fluorochrome denotes flow 
cytometric cell isolation, while orange-topped tubes denote density gradient 
centrifugation as isolation method, with culture of cells in buffy layer (in 
grey). Orange cells represent selection of non-adherent population after 
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seeding on fibronectin-coated plates; blue cells denote those that remain 
adherent. EPC = endothelial progenitor cell; CFU = colony forming unit; CPC 
= circulating progenitor cell; CD = cluster of differentiation; VEGFR = 
vascular endothelial growth factor receptor; LDL = low density lipoprotein. 
Data assimilated from Hirschi et al [167] and Cubbon et al [138].  
  
Page | 70 
 
 Endothelial Progenitor Cells in Insulin Resistance 1.4.4
Several studies have assessed the role of progenitor cells in the response to 
vascular injury, in addition to work from our laboratory group described 
above [164]. Working on the basic paradigm that these cells are 
manufactured in the bone marrow and mobilise to sites of injury, there are 
various steps during which the multiple deleterious effects of insulin 
resistance can influence indices of EPC behaviour.  
 
Hyperglycaemia in itself can hinder EPC function, as evidenced by in vitro 
experiments and assays using umbilical cord blood from human diabetic 
pregnancies [169]. Furthermore, exposing peripheral blood from healthy 
volunteers, patients with diabetes and those with coronary artery disease to 
high glucose concentrations affects EPC abundance in a manner related to 
increased MAPK pathway activation [170]. Similarly, cultured early and late 
outgrowth EPCs from healthy volunteers have been demonstrated to 
undergo senescence and display reduced proliferative and migratory 
capacity after exposure to glucose in vitro, with concomitant reductions in 
phosphorylated Akt, FOXO and eNOS, implicating the PI3K insulin signalling 
pathway [171]. Patients with type I diabetes also show reduced abundance 
of CPCs, as determined by flow cytometry, than healthy counterparts [172], 
with concomitant reductions in flow-mediated vasodilation. Although these 
studies vary widely in methodology, they attempt to separate the effects of 
hyperglycaemia from those of insulin resistance and, in doing so, provide 
some evidence to suggest a contributory role for elevated glucose 
concentrations in EPC dysfunction.   
 
Work from our laboratory has provided some evidence implicating insulin 
resistance, in the absence of frank hyperglycaemia, in EPC dysfunction, as 
previously discussed [164, 165, 173]. In brief, murine insulin resistance 
results in diminished vascular repair associated with reduced abundance of 
both CPCs and culture-derived blood EPCs compared with WT mice; in 
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these experiments, there was reduced CPC mobilisation to parenteral VEGF 
administration, as well as an absence of eNOS in bone marrow lysates, 
potentially highlighting a mechanism underlying the failure to mobilise 
progenitors to sites of injury [164]. Human studies involving insulin-resistant 
(but otherwise healthy) South Asian men showed that NO is critical in the 
mobilisation of CPCs in the response to exercise [165], and that cultured 
LEPCs from a similar population display impaired vascular repair potential 
related to reduced Akt signalling [173]. In the latter study, re-
endothelialisation after femoral artery wire injury in mice could be enhanced 
with transfusion of EPCs from healthy white Europeans but not from South 
Asians, a deficit which could be reversed by expressing a constitutively 
active form of Akt in the South Asian EPCs [173]. The PI3K insulin signalling 
cascade, again, appears to be critical in the dysfunction noted in insulin 
resistant states. In addition to the above studies, work in obese and insulin-
resistant Zucker rats has shown diminished Akt phosphorylation in EEPCs 
exposed to tumour necrosis factor-alpha (TNF-α), with an increased 
propensity to apoptosis in these cells [174]. Interestingly, these authors were 
able to correlate this defect with vascular repair: when the poorly functioning 
EPCs were treated with a nuclear factor kappa B (NF-κB) inhibitor and 
transfused into rats post-angioplasty, they were able to reduce pathological 
neointimal hyperplasia in the injured segments.   
 
The involvement of TNF-α and NF-κB in EPC dysfunction is not entirely 
surprising, considering that insulin resistance is closely linked with 
chronically overactivated indices of inflammation [138].  Other acute phase 
proteins, such as C-reactive protein (CRP), have also been implicated: 
EPCs incubated with CRP in vitro were shown to become prone to oxidative 
stress and apoptosis, with impaired endogenous antioxidant activity [175]. A 
similar study found increased EPC apoptosis when these cells were cultured 
in the presence of CRP; in keeping with previous findings regarding the PI3K 
pathway, this phenomenon was eNOS dependent. Interestingly, this 
exposure to CRP was also associated with reduced expression of 
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endothelial markers like VE-cadherin and Tie-2, suggesting a relative failure 
of differentiation towards an endothelial cell-like phenotype [176]. This group 
also found impaired EPC-induced angiogenesis in Matrigel assays, 
suggesting that the phenotypic changes observed are likely to be relevant to 
vascular regeneration.  
 
Other features of the insulin resistant syndrome may be relevant in EPC 
function. For example, insulin resistance is associated with lower serum 
levels of adiponectin, a cytokine derived from adipose tissue (or adipokine) 
in health. Adiponectin can stimulate EEPC differentiation towards an 
endothelial phenotype and inhibit EPC senescence, as well as augmenting 
Akt and eNOS activation in a hyperglycaemic environment, suggesting a 
protective effect on progenitor function that may be blunted or lost in insulin 
resistance [138]. Conversely, leptin and visfatin are examples of adipokines 
found in higher concentrations in insulin resistant states and which may have 
deleterious effects on EPC function; in the case of the latter, the mechanism 
may be NF-κB-dependent, again hinting at an overlapping role for 
inflammation [177]. Finally, the hypertension and dyslipidaemia that form 
part of the metabolic syndrome can also contribute. For example, oxidised 
LDL can promote EPC apoptosis by interfering with Akt signalling, and CPC 
abundance has been shown to correlate directly with HDL and inversely with 
LDL cholesterol levels in serum [138]. Equally, angiotensin II disturbs EPC 
function in vitro and can inhibit arterial repair in mice after carotid injury, a 
deficit that was shown to be rescued by transfusing EEPCs with angiotensin 
receptor 1 knockout [178].  
 
Despite all the above data, it is still not entirely clear how much EPCs 
contribute to vascular repair after endothelial injury, if at all. The culture-
derived entities described may not exist in identical form in vivo and, whilst 
the flow cytometric definitions of CPCs do represent cells that are present in 
mammalian blood, their exact physiological role is yet to be ascertained. 
Some convincing evidence exists to suggest that endothelial cells are the 
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predominant contributors to vascular repair after injury [156]; however, even 
if EPCs do not directly incorporate themselves into injured vasculature, they 
may play a role in paracrine stimulation of endothelial cell-mediated healing 
and thus remain of interest. Their dysfunction has been recurrently 
demonstrated in insulin resistant humans and animal models and they may 
therefore represent a novel therapeutic target for vascular health in insulin 
resistance. Given the promising results seen in murine studies of EPC 
transfusion, it may be feasible for EPCs to be developed as an autologous 
cell-based therapy in the future.  
 
 Role of Endothelial Insulin Sensitivity in Vascular Repair 1.4.5
Studies of endothelial function and vascular repair using the IRKO model are 
of great interest as they allow us to differentiate between the effects of 
insulin resistance per se and hyperglycaemia. However, given that the 
endothelium is an insulin-responsive organ, one of the limitations of whole-
body insulin receptor knockout is the potential for the observed effects to be 
mediated by dysfunction in other tissues.  
 
To date, models such as the VENIRKO and ESMIRO, which are 
endothelium-specific, have suggested that dysfunction of this tissue alone 
can result in a similar phenotype to whole-body insulin resistant models 
[113, 114]. This has led to interest in the possibility that enhancing insulin 
sensitivity specifically within the endothelium may be beneficial in addressing 
the cardiovascular sequelae of global insulin resistance. To address the 
value of this therapeutic paradigm, our laboratory has generated a murine 
model that overexpresses a human insulin receptor specifically on 
endothelial cells: the HIRECO mouse. This model makes use of the Tie-2 
promoter-enhancer, which codes for an angiopoietin tyrosine kinase receptor 
that shows relative specificity for endothelial cells (expression is also noted 
in a subset of myeloid cells) and a degree of asymmetry for arterial over 
venous endothelium [179]. Unpublished data from our laboratory have 
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confirmed the nature of endothelium-specific overexpression of the human 
insulin receptor but, interestingly, we have demonstrated that this results in 
reduced NO bioavailability, endothelial dysfunction and accelerated 
atherosclerosis. HIRECO mice display increased expression of the NOX2 
isoform of NADPH oxidase, and also elevated superoxide generation, versus 
wild-type controls; additionally, expression of proline-rich tyrosine kinase 
(PYK2) was higher in HIRECO endothelial cells, with concomitant inhibitory 
phosphorylation of eNOS [180].  
 
Whilst these data suggest endothelial insulin sensitisation in the context of 
otherwise undisturbed whole-body insulin signalling is deleterious, there 
remains a possibility that this manipulation could rescue the vascular 
phenotype associated with systemic insulin resistance. In order to 
investigate this, we have crossed the HIRECO mouse with IRKO to generate 
offspring with systemic insulin resistance, but rescue of endothelial insulin 
sensitivity. This work will form the basis of this PhD thesis.  
 
  
Page | 75 
 
Chapter 2 Aims and Hypotheses 
The aim of this project was to expand on data from existing animal models of 
insulin resistance by ascertaining whether endothelial insulin sensitisation is 
a valid therapeutic target. In order to address this, our laboratory generated 
a colony of mice that includes the HIRECOxIRKO cross, which we anticipate 
to be globally insulin resistant, but with selective restoration of endothelial 
insulin signalling due to the targeted expression of a human insulin receptor 
transgene in endothelial cells.  
 
Specifically, I aimed to assess the impact of this manipulation by:  
 
1. Investigating the morphological and metabolic characteristics of 
HIRECOxIRKO mice as compared with IRKO littermates.  
 
2. Interrogating murine and human insulin receptor expression in 
endothelial cells from both groups. 
 
3. Assessing whether HIRECOxIRKO mice display improved vascular 
repair after denuding endothelial injury.  
 
4. Comparing the numbers and function of endothelial progenitor cells 
across genotypes.  
 
5. Studying endothelial function in the HIRECOxIRKO cross using organ 
bath assays of aortic vasomotor function and nitric oxide 
bioavailability.  
 
6. Using assays of eNOS activity, reactive oxygen species, intracellular 
signalling and markers of endothelial cell function in vitro to ascertain 
a mechanism for any differences that are observed.  
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Using these methods, I sought to examine the following hypotheses: 
 
1. Selective restoration of endothelial insulin signalling can result in 
normalisation of blood pressure and vasomotor function.  
 
2. HIRECOxIRKO mice exhibit improved vascular repair after denuding 
femoral artery injury.  
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Chapter 3 Materials 
3.1 Animal Husbandry 
 Chow feed      B&K Universal Ltd.; Hull, UK 
3.2 Genotyping 
 Sodium hydroxide    Fisher; Loughborough, UK 
 Tris-HCl      Fisher; Loughborough, UK 
 Molecular grade H2O   BD Biosciences; Nottingham,  
UK 
 Biomix Red “Mastermix”   Bioline; London, UK 
 Primers (see Methods)   Invitrogen; Carlsbad, CA 
 Tris base     Fisher; Loughborough, UK 
 EDTA      Sigma-Aldrich; St Louis, MO 
 PCR reaction tubes/lids   Thermo Scientific; Rockford,  
IL 
 PTC-200 Thermal Cycler   MJ Research; Ramsey, MN 
 Agarose      Bioline; London, UK 
 Glacial acetic acid    Fisher; Loughborough, UK 
 Ethidium bromide    Sigma-Aldrich; St Louis, MO 
 100 base pair ladder   Thermo Scientific; Rockford 
 Syngene G-box imaging system  Syngene; Cambridge, UK 
  
3.3 Gross Morphological Measurements 
 Microcentrifuge tubes   Eppendorf; Stevenage, UK 
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3.4 Glucocompetence Testing  
 Accucheck glucometer/test strips  Aviva; Mannheim, Germany 
 D-glucose     Sigma; St Louis, MO 
 Actrapid insulin    Novo Nordisk; Bagsvaerd,  
Denmark 
 Dulbecco’s phosphate-buffered   Sigma; St Louis, MO 
Saline (PBS) 
3.5 Blood Pressure Measurement  
 Coda Non-invasive Tail BP system  Kent Scientific; Torrington,  
CT 
 
3.6 Blood Sampling from Saphenous Vein Puncture 
 Veet hair removal cream   Reckitt-Benckiser; Slough,  
UK 
 Vaseline® Paraffin-based ointment Unilever; Leatherhead, UK 
 14G needle      Terumo; Bagshot, UK 
 Microvette tubes (powdered  Sarstedt; Numbrecht,  
lithium heparin)     Germany   
 Microvette (EDTA-tripotassium)  Sarstedt; Numbrecht  
 Liquid heparin sodium   Wockhardt; Wrexham, UK 
 
3.7 Plasma Insulin Measurement (ELISA) 
 Ultrasensitive mouse insulin ELISA Crystal Chem; Downers  
kit (#90080)     Grove, IL 
 Dynex MRX plate reader and   Dynex Technologies,  
Revelation v4.21    Chantilly, VA 
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3.8 Quantitative PCR  
 Tissue Lyser     Qiagen; Venlo, Netherlands 
 6mm cone balls (RS.22.455.0003C) Retsch; Castleford, UK 
 RNAse Away spray    Molecular Bio Products; San  
Diego 
 TRIzol® (Tri reagent)   Sigma; St Louis, MO 
 Phenol chloroform    Sigma; St Louis, MO 
 Isopropanol     Sigma; St Louis, MO 
 Ethanol     Fisher; Loughborough, UK 
 RNAse free H2O    Life Technologies; Paisley 
 NanoDrop® ND1000    Thermo Scientific; Rockford 
Spectrophotometer  
 ND-1000 v3.1 software   Thermo Scientific; Rockford 
 High capacity cDNA reverse  Applied Biosystems;  
transcription kit    Warrington, UK 
 96 well optical reaction plate  Applied Biosystems 
 ABI Prism 7900 HT PCR cycler  Applied Biosystems 
 SDS v2.2 software    Applied Biosystems 
 RT-PCR primers (SYBR green)  Invitrogen; Carlsbad, CA 
 Power SYBR® green PCR   Applied Biosystems 
Mastermix  
 Taqman® Gene Expression  Applied Biosystems 
Mastermix 
 RT-PCR primers (Taqman®)  Applied Biosystems 
 Molecular grade H2O   BD Biosciences; Nottingham 
 
3.9  Vascular Injury 
 Buprenorphine    Alsatoe Animal Health; York,  
UK 
 Isoflurane     Abbott Logistics BV; Short  
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Hills, NJ 
 Irripod (sterile 0.9% saline)   Unither; Paris, France 
 Lignol (1% lignocaine + adrenaline) Arnolds; Harlescott, UK 
 Dissecting microscope OPMI 1-FC Zeiss; Livingston, UK 
 Veet hair removal cream   Reckitt-Benckiser; Slough 
 0.75% providone-iodine   Animal Care; York, UK 
 Vicryl absorbable 8.0/6.0 suture  Ethicon; Somerville, NJ 
 Iris Scissors and needle holder  World Precision Instruments;  
                                                   Sarasota, FL 
 Dry sterilizer #500121   World Precision Instruments  
 Lubrital #31329    Dechra; Northwich, UK 
 Vannas spring scissors   Fine Science Tools;  
Heidelberg, Germany 
 Dumont micro-blunted, atraumatic Fine Science Tools 
tipped forceps #11253-25 
 Round handled suture tying forceps Fine Science Tools  
 Hitorque Cross-it 200XT guide wire Abbott Vascular; IL 
 Evans Blue #195550050   Acros Organics; Geel,  
Belgium 
 4% paraformaldehyde   Fisher; Loughborough, UK 
 30% hydrogen peroxide   Sigma; St Louis, MO 
 Insulin syringe / 27Gx13mm needle Terumo; Bagshot, UK 
 Olympus Dissecting Stereo   Olympus; Southend-on-Sea, 
Microscope SZ61    UK  
 QiCam Olympus digital camera  Olympus; Southend-on-Sea  
 ImagePro Plus 7.2     Media Cybernetics;  
Bethesda, MD 
 
3.10 Enumeration of Circulating Progenitor Cells (CPCs) 
 Heparin 1000IU/mL    Wockhardt; Wrexham, UK 
Page | 81 
 
 Microvette (EDTA-tripotassium)   Sarstedt; Numbrecht 
 Pharmlyse red cell lysis buffer   BD Biosciences; Nottingham 
 Syringe filter (0.2µm membrane)  Pall Life Science;  
Portsmouth, UK 
 Corning centrifuge tubes   Sigma; St Louis, MO 
 Foetal bovine serum (FBS)  Biosera; Boussens, France 
 Bovine serum albumin (BSA)  Sigma; St Louis, MO 
 Fc block (CD16/CD32 rat anti-mouse; BD Biosciences; Nottingham 
553142)  
 FITC (rat IgG2a Isotype Control;   BD Biosciences; Nottingham 
553929)  
 Sca1-FITC (rat IgG2a κ Ly6A/E;  BD Biosciences; Nottingham 
557405)   
 PE rat (IgG2a κ Isotype Control;  BD Biosciences; Nottingham 
553930)       
 Flk1-PE (Flk1 VEGFR2; 555308)  BD Biosciences; Nottingham 
 APC (rat IgG2b κ Isotype Control;  BD Biosciences; Nottingham 
553991)  
 APC (rat anti-mouse CD117; 553356) BD Biosciences; Nottingham 
 Fortessa Flow Cytometer   BD Biosciences; Nottingham
     
3.11 Isolation and Enumeration of Early Outgrowth EPCs 
 Insulin syringe / 29Gx13mm needle Terumo; Bagshot, UK 
 Sodium citrate from 4mL blood   Greiner Bio-One; 
collection tubes    Kremsmünster, Austria 
 4mL EDTA blood tube   Greiner Bio-one 
 23G needle     Terumo; Bagshot, UK 
 70µm nylon cell strainer   Greiner Bio-one 
 5cm Petri dish    BD Falcon; Oxford, UK 
 Histopaque-1083    Sigma; St Louis, MO 
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 EGM-2 basal medium/bullet kit  Lonza; Blackley, UK 
 Foetal bovine serum   Biosera; Boussens, France 
 Antibiotic/antimycotic supplement  Invitrogen; Carlsbad, CA 
 Trypan blue     Sigma; St Louis, MO 
 Neubauer Counting Chamber  Hawksley; Lancing, UK  
 24-well/6-well fibronectin coated   BD Biocoat; Redford, MA 
cell culture plates 
 DiI-ac-LDL     Life Technologies; Paisley,  
UK  
 FITC-lectin      Sigma; St Louis, MO 
 CKX-41 fluorescent microscope  Olympus; Southend-on-Sea  
 Cell B software     Olympus; Southend-on-Sea  
 Image J v1.46r    National Institutes of Health 
 
3.12 Isolation and Culture of Pulmonary Endothelial Cells 
 Scalpel blades size 22   Swann-Morton; Sheffield, UK 
 Dulbecco’s Modified Eagle’s  Life Technologies; Paisley 
Medium (31966-021)       
 Hank’s Balanced Salt Solution   Sigma; St Louis, MO 
(with calcium/magnesium; H9269) 
 Collagenase/Dispase #11097113001 Roche; Basel, Switzerland 
 Bovine skin gelatin    Sigma; St Louis, MO 
 Bovine serum albumin 7.5%  Sigma; St Louis, MO 
 MACSmixTM tube rotator   Miltenyi Biotec; Cologne,  
Germany 
 14G Cannula     BD Biosciences; Nottingham  
 10mL syringe    BD Biosciences; Nottingham 
 Endothelial cell growth medium MV2 PromoCell; Heidelberg,  
plus endothelial supplements  Germany 
 Foetal bovine serum   Biosera; Boussens, France 
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 Antibiotic/antimycotic supplement  Invitrogen; Carlsbad, CA 
 Rat anti-mouse CD31 (553369)  BD Biosciences; Nottingham 
 Rat anti-mouse CD102 (553326)  BD Biosciences; Nottingham 
 Sheep anti-rat IgG Dynabeads  Life Technologies; Paisley 
 Magnetic particle concentrator  BD Biosciences; Nottingham 
 T25 Corning® cell culture flask  Sigma; St Louis, MO 
 Trypsin-EDTA 0.25%   Sigma; St Louis, MO 
 35mm imaging µ-dish   Ibidi; Martinsried, Germany 
 Triton X-100     Sigma; St Louis, MO 
 4% paraformaldehyde   Fisher; Loughborough, UK 
 Isolectin B4-Alexa Fluor 488 (I21411) Invitrogen; Carlsbad, CA 
 Hoechst 33342 (#H1399)   Invitrogen; Carlsbad, CA 
 LSM700 confocal microscope  Zeiss;  Livingston, UK  
 
3.13 Endothelial Cell Proliferation Assay 
 Click-iT® EdU Alexa Fluor® 488   Life Technologies; Paisley 
Imaging Kit (#C10337) 
 Propidium iodide/RNAse   Cell Signaling; Danvers, MA 
 
3.14 Endothelial Cell Migration Assay (Boyden Chamber) 
 Recombinant murine vascular   Peprotech; London, UK 
endothelial growth factor A 165 
 Polycarbonate Boyden chamber  Scientific Lab Supplies;  
inserts (8µm pore size)   Hessle, UK 
 24 well plastic culture vessels  BD Falcon; Oxford, UK 
 Haematoxylin/Eosin    Sigma; St Louis, MO 
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3.15 Endothelial Cell Migration Assay (Scratch Wound) 
 ImageLock 96 well plate   Essen Biosciences; Ann  
Arbor, MI 
 WoundmakerTM 96-pin tool   Essen Biosciences  
 Integrated Cell Migration    Essen Biosciences 
Analysis Module (9600-0012) 
 IncuCyteTM Imaging System  Essen Biosciences 
 Alconox/Vircon cleaning solutions  Sigma; St Louis, MO 
 
3.16 Vasomotor Studies of Aortic Rings 
 8-chamber organ bath system  Panlab; San Diego, CA 
 LabChart Pro Software   Panlab; San Diego, CA 
 Light microscope Olympus SZ61  Olympus; Southend-on-Sea,  
 Sodium chloride    Fisher; Loughborough, UK  
 Potassium chloride    Fisher; Loughborough, UK 
 Monopotassium phosphate  Fisher; Loughborough, UK 
 Sodium hydrogen carbonate  Fisher; Loughborough, UK 
 Magnesium sulphate heptahydrate VWR®; Lutterworth, UK 
 Calcium chloride    Fisher; Loughborough, UK 
 D-glucose     Sigma; St Louis, MO 
 Phenylephrine    Sigma; St Louis, MO 
 Acetylcholine     Sigma; St Louis, MO 
 Sodium nitroprusside   Sigma; St Louis, MO 
 Actrapid insulin (100mU/L)   Novo Nordisk; Bagsvaerd 
 L-NMMA     Merck Millipore; Darmstadt,  
Germany 
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3.17  Superoxide Assay 
 Clear 96 well cell culture plate  Thermo Scientific; Rockford 
 Dihydroethidium D11347   Life Technologies; Paisley 
 HEPES sodium salt    Sigma; St Louis, MO 
 Flex Station 3 Multi-mode    Molecular Devices;  
Microplate Reader    Sunnyvale, CA 
 SoftMax® Pro v5.4.5   Molecular Devices 
 
3.18 Western Blotting 
 Tris-HCl     Fisher; Loughborough, UK 
 Glycerol     Sigma; St Louis, MO 
 EDTA      Sigma; St Louis, MO 
 Sodium dodecyl sulphate   Sigma; St Louis, MO 
  
 Phosphatase inhibitors 2&3  Sigma; St Louis, MO 
 Tween®-20     Sigma; St Louis, MO 
 Bovine serum albumin (BSA)  Sigma; St Louis, MO 
 Pierce® BCA protein assay kit  Thermo Scientific; Rockford 
 96 well clear microplate   Greiner Bio-One 
 Micro-amp® optical adhesive film  Life Technologies; Paisley 
 NuPAGE® LDS sample buffer  Invitrogen; Carlsbad, CA 
 NuPAGE® sample reducing agent Invitrogen; Carlsbad, CA 
 NuPAGE® MES SDS running buffer Invitrogen; Carlsbad, CA 
 Criterion XT 4-12% Bis-Tris Gel  Bio-Rad Laboratories;  
Hercules, CA 
 Criterion Cell Tank    Bio-Rad Laboratories  
 
 Amersham Tracker Tape (#RPN2050) GE Healthcare; Little  
Chalfont, UK 
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 Primary antibodies (Table 4-12)  Cell Signaling; Danvers, MA
      BD Biosciences; Nottingham 
 Secondary antibodies (Table 4-12) Dako; Ely, UK 
 Immobilon Western Chemiluminescent  Merck Millipore; Darmstadt 
HRP Substrate 
 Immobilon®-P transfer membrane Merck Millipore; Darmstadt 
 Syngene G-box imaging system  Syngene; Cambridge, UK  
 RestoreTM PLUS Western Blot  Thermo Scientific; Rockford 
stripping buffer 
 Dynex MRX plate reader and   Dynex Technologies  
Revelation v4.21 
 Image J v1.46r    National Institutes of Health 
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Chapter 4 Methods 
4.1 Animal Husbandry 
 General  4.1.1
All murine work was undertaken under the auspices of the Experimental 
Animals (Scientific Procedures) Act 1988 as per United Kingdom Home 
Office regulations. This was performed under personal licence 40/10387 and 
project licence 40/3523. Mice were housed at the University of Leeds animal 
facility, under standard laboratory temperature and humidity conditions and a 
12-hour light-dark cycle. They were fed standard chow diet and normal 
drinking water, both unrestricted. Mice were weaned and underwent ear 
notching 2-3 weeks after birth to provide a means of identification and also 
to provide tissue with which to perform genotyping. Males and females were 
split at this stage and generally females were sacrificed after weaning, 
unless required for the establishment of new breeding colonies. Females 
were not used in experiments for a number of reasons: for example, the use 
of females may introduce confounding effects from cyclical variation in 
female sex hormones. More importantly, the Hprt locus (see below) used in 
this model is on the X chromosome and so the effects of Lyonisation in 
heterozygotes and double transgene expression in homozygotes could 
cause variability in the data. Male littermates were split into cages of up to 
five mice each. Mice aged 2-6 months were used for the majority of 
experiments and work was planned to avoid leaving animals alone in cages.  
 
 Insulin receptor knockout (IRKO) mice 4.1.2
Mice with haploinsufficiency of the insulin receptor were used as the 
principal control group for this project as their phenotype with respect to 
endothelial function and vascular repair and regeneration has previously 
been studied extensively [60, 123, 164].  
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IRKO mice were initially developed at the National Institutes of Health, 
Bethesda, USA [57]. Briefly, the insulin receptor gene was targeted using a 
vector that incorporated a premature chain termination at exon 4, in 
association with a cassette encoding neomycin resistance. Embryonic stem 
(ES) cells were transfected with this mutant allele using electroporation and 
the gene incorporated using homologous recombination. ES cells were 
grown in the presence of neomycin, allowing selection for the mutated allele; 
surviving cells were expanded prior to injection into mouse embryos at day 
3.5. See Figure 4-1 for a diagrammatic summary of this process. 
 
Figure 4-1 Technique for Introducing Mutant Insulin Receptor Allele 
The red allele represents the null insulin receptor allele and neomycin (Neo) 
resistance cassette introduced into chromosome 8. This is transfected into 
embryonic stem (ES) cells which are selected using neomycin (Neo) before 
injection into a blastocyst for implantation into a C57 black 6 female.  
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These embryos were implanted into dark-coated female C57 black 6 
(C57BL/6) mice, resulting in chimaeric progeny that could be identified using 
coat colour. Resulting chimaeric males expressing the null allele were bred 
into a C57 black-6 (C57BL/6) background. Mice receiving both null alleles, 
and thus homozygous for IR deletion, do not survive beyond early neonatal 
life due to profound diabetic ketoacidosis [57], but heterozygotes are viable 
and can thus be used for research.  
IRKO mice were initially generated externally and purchased from Jackson 
laboratory stocks, following which they were bred with C57BL/6 females 
from our own colonies at the University of Leeds for 12 generations. This 
avoided any need for genetic manipulation at this site. All the mice used in 
this project were obtained from breeding colonies already established at this 
site. The local IRKO breeding trios comprise two C57BL/6 females with one 
transgenic IRKO male.  
 
 Human insulin receptor endothelial cell over-expression 4.1.3
(HIRECO) 
In order to enhance endothelial insulin sensitivity, the type A isoform of the 
human insulin receptor was overexpressed selectively in endothelial cells 
under transcriptional control of the Tie-2 promoter-enhancer sequence, 
which is regarded as being relatively specific for endothelial cell lineage 
[179]. Human insulin receptor complementary DNA was obtained from the 
National Institutes of Health (Bethesda, USA) and this gene, along with the 
Tie-2 promoter, a polyadenylation site and a core enhancer, was inserted 
into the hypoxanthine phosphoribosyl transferase (Hprt) locus in embryonic 
stem cells using a specific homologous recombination technology known as 
“Quick Knock-inTM” (GenOway; Lyon, France) [181]. The Hprt protein that 
the target gene encodes is an enzyme that synthesises purines from 
degraded nucleotides in what is known as the “salvage pathway”. ES cells 
containing the Hprt locus can be selected from a wider population using 
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growth medium containing aminopterin as Hprt-deleted cell lines rely on the 
alternative “de novo” purine synthesis pathway in the presence of this drug. 
For this reason, ES cells were cultured in hypoxanthine, aminopterin and 
thymidine (HAT) medium and therefore only those cells expressing the 
human insulin receptor construct in the Hprt locus survived. Appropriate 
transgene expression was confirmed using Southern blotting and surviving 
ES cells expressing the transgene were then injected into blastocysts that 
were implanted into C57BL/6 surrogate mothers prior to breeding in a similar 
manner to that described for IRKO mice. For a summary, see Figure 4-2. 
 
By virtue of the Hprt approach utilised, male mice exhibiting expression of 
the transgene were hemizygous for the manipulaton. Females expressing 
the HIRECO transgene were bred with wild-type males in trios comprising 
one female and two males. Established colonies at the University of Leeds 
were used for all experiments in this project, obviating the need for genetic 
manipulation by the author.  
 
Page | 91 
 
Figure 4-2 Technique for Introducing Human Insulin Receptor 
Transgene 
The orange gene represents the transgene in association with the Tie2 
promoter, introduced into chromosome X. This is transfected into embryonic 
stem (ES) cells which are selected using media containing hypoxanthine, 
aminopterin and thymidine (HAT) before injection into a blastocyst for 
implantation into a C57 black 6 female.  
 
 Generation of a HIRECOxIRKO colony 4.1.4
Male IRKO mice were bred with female HIRECO mice from established 
colonies at the University’s animal unit. This gave rise to either WT, IRKO, 
HIRECO or HIRECOxIRKO progeny. Genotyping was performed on ear 
notches as described below, and HIRECOxIRKO mice were compared with 
IRKO for all experiments, and additionally with WT in some in order to 
ensure reproducibility of the key phenotypic changes seen previously in 
IRKO mice. HIRECO mice were not used in this project as a separate 
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project was being used to characterise their phenotype. A schematic 
diagram illustrating the various tissue sensitivities to insulin in these progeny 
is presented in Figure 4-3.  
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Figure 4-3 Offspring from HIRECO x IRKO Colony 
Brown mice = systemic insulin sensitivity, i.e. wild-type and HIRECO (human insulin receptor endothelial cell overexpression). Black 
mice = systemic insulin resistance, i.e. IRKO (insulin receptor knockout) and HIRECOxIRKO. The blue and orange genes denote the 
insertion of a human insulin receptor targeted to the endothelium. Note that these colours do not correlate with coat colour and are 
simply used to illustrate tissue-specific insulin sensitivity; all mice are on a C57 background and have black coats.  
Page | 94 
 
 Animal euthanasia 4.1.5
Animals were sacrificed using one of two Home Office approved techniques, 
depending on the specific tissue requirements. Prior to obtaining solid 
organs, or when mice were sacrificed without removing tissue, mice were 
exposed to rising concentrations of carbon dioxide in a 12 minute cycle, 
which rendered them unconscious. Subsequently, death was confirmed 
using blunt cervical dislocation, allowing the subsequent dissection of 
tissues as required.  
For EPC isolation experiments, 1mL of blood was required and the 12 
minute cycle in the carbon dioxide chamber resulted in widespread 
intravascular thrombosis, making blood collection very difficult from either 
the inferior vena cava (IVC) or via intracardiac puncture. These mice 
therefore underwent terminal inhalation anaesthesia with isoflurane, after 
which exsanguination was performed and any necessary tissue was 
obtained and stored on ice, or “snap-frozen” in liquid nitrogen, for transfer 
back to the laboratory. The technique for general anaesthesia is described in 
detail in Chapter 4.9 below.   
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4.2 Genotyping 
 DNA Extraction 4.2.1
Ear notches were incubated in 100µL of 25mM NaOH/EDTA (pH 12) and 
heated to 95°C in 0.5mL microcentrifuge tubes for 25 minutes. Following 
this, 100µL of 40mM Tris-HCl (pH 5) were added and the sample was 
vortexed thoroughly to disperse deoxyribonucleic acid (DNA). Samples were 
kept refrigerated to allow repeat genotyping if required.  
 
 Polymerase Chain Reaction (PCR) 4.2.2
4.2.2.1 General 
A stock solution comprising a commercially obtained pre-made Biomix Red 
“Mastermix” and variable volumes of primers and distilled water was 
prepared for each PCR; details are presented below. This was done in a 
laminar flow hood to minimise the risk of contamination, and DNA was 
added using dedicated pipettes. The pre-made Mastermix contained PCR 
buffer, Magnesium chloride, a deoxynucleotide triphosphate (dNTP) mixture 
and Thermophilus aquaticus (Taq)-derived DNA polymerase.  
 
Primer stocks were obtained commercially from Invitrogen, reconstituted in 
TE buffer (10mM Tris, 1mM EDTA; pH 8) and diluted 1:10 using distilled 
water. All components were mixed and 24µL reaction volumes were 
measured into PCR tubes. 1µL of DNA was added to each, along with 
positive and negative controls. Specific programmes for IRKO and HIRECO 
DNA were performed in thermal cyclers with heated lids and the results of 
both reactions combined to determine the final genotype.  
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4.2.2.2 IRKO PCR 
The IRKO PCR protocol had previously been optimised in our laboratory and 
incorporated three primer sequences specific for the gene targeting 
cassette:  
 
 TTA AGG GCC AGC TCA TTC CTCC (forward)  
 AGC TGT GCA CTT CCC TGC TCAC (forward)  
 TCT TTG CCT GTG CTC CAC TCT CA (reverse).  
 
0.5µL of each primer (in a 1:10 dilution with TE buffer) was added to 10µL of 
Mastermix and 12.5µL of distilled water. The PCR comprised the following 
cycles:  
 
 One denaturation cycle: 94°C for four minutes 
 31 amplification cycles: 94°C for one minute, 62°C for one minute and  
72°C for one minute 
 One completion cycle: 72°C for four minutes. 
 
Following this, PCR products were refrigerated at 4°C until they were ready 
to be loaded onto agarose gels for electrophoresis (see below). On 
ultraviolet (UV) imaging, WT DNA fluoresced as a single band at 232 base 
pairs and IRKO DNA comprised a double band with the WT band and an 
extra band at 255 base pairs.  
 
4.2.2.3 HIRECO PCR 
For HIRECO PCR, two primers were used to detect the transgene:  
 
 ACG TCA GTA GTC ATA GGA ACT GCG GTCG (forward) 
 TGC CTT GAT TCA CCA GAT GCT GAGG (reverse). 
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0.5µL of each primer (again at 1:10 dilution) was added to 10µL of 
Mastermix and 13µL of distilled water. The HIRECO PCR comprised the 
following cycles: 
 
 One denaturation cycle: 94°C for two minutes 
 35 amplification cycles: 94°C for 30 seconds, 65°C for 30 seconds 
and 68°C for two minutes 
 One completion cycle: 68°C for eight minutes.  
 
As with IRKO, PCR products were stored at 4°C and underwent subsequent 
gel electrophoresis. WT DNA showed no bands on UV imaging and HIRECO 
DNA fluoresced as a single band at 762 base pairs.  
 
4.2.2.4 Gel Electrophoresis and Imaging 
A 15g/L agarose gel was made in Tris-acetate-EDTA (TAE; 40mM Tris, 
20mM glacial acetic acid, 1mM EDTA in distilled water; pH 8.6) buffer and 
heating at 800W for 90 seconds in a microwave. 3µL of ethidium bromide 
solution were added to the heated agarose-TAE mixture in order to allow 
fluorescence of PCR products under ultraviolet (UV) light and the liquid 
agarose was poured into a gel tray with a comb to allow the formation of 
wells into which DNA samples could be loaded. After allowing this to set for 
two hours, the gel was inserted into a tank containing 700mL of TAE buffer. 
15µL of a 100 base-pair ladder were loaded as a reference for PCR product 
size and 20µL samples of PCR product were pipetted into adjacent wells. 
Electrophoresis was performed at 110V for 60 minutes and imaging was 
done using the Syngene G-box imaging system. 
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4.3 Gross Morphological Measurements 
 Body Weight 4.3.1
Mice of all four genotypes were weighed from weaning until the age of four 
months, at which point their weights were generally found to plateau.  
 
 Wet Organ Weight 4.3.2
Mice were weighed on the day of sacrifice before dissecting and weighing 
the heart, lungs, spleen, liver and kidney in 1.5mL microcentrifuge tubes. 
Samples were then stored at -80°C for future protein or RNA extraction. All 
wet organ weights were normalised to total body weight.  
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4.4 Metabolic Testing  
 Glucose tolerance testing (GTT) 4.4.1
Mice were fasted overnight in fresh cages to avoid them consuming chow 
fragments from cage floors; access to water was maintained throughout. The 
following morning, mice were consciously restrained in syringe-like devices 
with free air flow by gently coaxing them in head-first and allowing tails to 
protrude from the end of the device. Mice had been habituated to these on 
previous occasions to prevent excessive stress during tolerance tests. Once 
mice were accustomed to the restrainer, measurements of capillary blood 
glucose (CBG) were made using 1-2µL droplets of blood from superficial tail 
incisions using a sterile scalpel and an Accuchek glucometer and test strips. 
A fasting measurement was made before the intraperitoneal (IP) injection of 
glucose dissolved in distilled water at a dose of 1mg/g. CBG was measured 
at 30, 60, 90 and 120 minute time points after glucose challenge. In 
between, mice were removed from restraint and returned to their cages, 
where they were able to drink water freely but not given access to chow until 
after the final time point.  
 
 Insulin tolerance testing (ITT) 4.4.2
ITTs were performed a week after GTTs to ensure normalisation of 
homoeostasis and restoration of circulatory volume. A similar protocol was 
employed to the GTT as above, but mice were fasted for four hours rather 
than overnight. After a fasted CBG measurement, IP insulin was 
administered at a dose of 0.75 International Units (IU)/kg using a stock of 
200mIU Actrapid insulin in 5mL Dulbecco’s phosphate-buffered saline 
(PBS). Mice were observed closely in between measurements in case of 
hypoglycaemia, with a solution of glucose available for immediate 
intraperitoneal injection in the event of profound or symptomatic 
hypoglycaemia.   
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4.5 Blood Pressure Measurement  
Mice aged 2-4 months underwent blood pressure (BP) measurement using 
tail cuff plethysmography using the Coda Non-invasive Tail BP (Kent 
Scientific, USA) system. Occluder and sensor cuffs were inspected and 
formally tested for adequate inflation prior to each session, with re-threading 
of the bladder if the automated test suggested unsatisfactory function of the 
device. Mice were trained on two separate occasions prior to the day of 
measurement. Each time, conscious animals were restrained in dedicated 
tubes as described above, and placed in a heat chamber set at 32°C to 
encourage tail vasodilatation. The device protocol included ten 
acclimatisation cycles followed by three sets of six measurement cycles with 
five seconds of recovery time in between. Data were only recorded from the 
third session to avoid including artificially high readings prior to habituation to 
the device and environment. Mean systolic readings were taken from as 
many recordings as feasible after appraisal of each plethysmography trace 
for adequacy of tail volume, lack of movement artefact and shape of curve. 
Agitated mice were removed and re-tested at a later session to avoid 
excessively high BP measurements related to stress.  
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4.6 Blood Sampling from Saphenous Vein Puncture 
Conscious mice were habituated to restraint prior to the day of 
venepuncture. Once the restrained mouse grew accustomed to the device, 
the right leg was gently removed and gripped lightly using the operator’s left 
hand. A hair removal cream (Veet) was applied for no more than 30 seconds 
to avoid skin burns and the leg was then gently shaved using tissue paper, 
allowing clear visualisation of the distal saphenous veins. A paraffin-based 
ointment (Vaseline) was applied over the vein to encourage formation of a 
blood globule and a fresh 14G needle was used to puncture the vein lightly. 
Blood for plasma extraction was drawn into Microvette tubes lined with 
powdered lithium heparin using capillary action. When whole blood was 
required, Microvette tubes with EDTA-tripotassium were pre-filled with 50µL 
of sterile liquid heparin (1000 IU/mL) and 100-150µL blood were collected 
using gravity. The removal of this volume adhered to standard murine 
welfare guidance from the Home Office. Haemostasis was quick and 
effective using simple light pressure, and further venepuncture was not 
performed from the same leg until full healing had occurred and with due 
delays to allow restoration of circulatory volume.   
Page | 102 
 
4.7 Plasma Insulin Measurement (ELISA) 
 Blood Collection  4.7.1
Mice were fasted overnight prior to collecting blood for this experiment. 
Whole blood (typically 90-100µL) was obtained using saphenous vein 
puncture as described above, collecting using capillary action into tubes 
lined with powdered lithium heparin. Blood was stored on ice and transferred 
to the laboratory with minimal delay. Samples were centrifuged at 6000 
revolutions per minute (rpm) for six minutes to obtain a plasma layer and this 
was removed and stored at -80°C until enough samples had been obtained 
for an enzyme-linked immunosorbent assay (ELISA).  
 
 ELISA 4.7.2
4.7.2.1 Preparation and First Reaction 
Ready-made ELISA kits for mouse insulin (Crystal Chem) were used, using 
the “low-range” assay conditions (0.1-6.4ng/mL). An antibody-coated 
microplate was set up by reverse pipetting with 95µL of sample diluent from 
the ELISA kit into each well. Serial dilutions of a working lyophilised mouse 
insulin standard (reconstituted in distilled water) were prepared as per 
manufacturer instructions, diluting in sample diluent. These were measured 
out in 5µL in duplicate for the first eight pairs of wells allowing a standard 
curve to be constructed from 0-6.4ng/mL of insulin. Remaining wells were 
filled with 5µL in duplicate of each plasma sample. These were incubated at 
4°C for two hours to allow antibody binding.  
 
4.7.2.2 Washing and Second Reaction 
Each well was then washed five times with 300µL of wash buffer provided in 
the ELISA kit, ensuring full removal of solution using a glass aspirator pipette 
each time. Before the fifth wash was aspirated, an anti-insulin enzyme 
conjugate was prepared by mixing together defined quantities of a pre-made 
stock solution and diluent from the ELISA kit as per manufacturer 
Page | 103 
 
instructions. The fifth wash was then aspirated and the conjugate was 
immediately pipetted into the ELISA wells at 100µL per well. This was 
incubated at room temperature for 30 minutes.  
 
4.7.2.3 Washing and Third Reaction 
This time, wells were washed seven times with 300µL of wash buffer. After 
full aspiration of wash contents, 100µL of enzyme substrate solution were 
added to each well. The plate was incubated in the dark at room 
temperature for 40 minutes, following which the reaction was aborted by 
adding 100µL of a “stop” solution to each well.  
 
4.7.2.4 Colorimetric Analysis 
A Dynex MRX plate reader and Revelation version 4.21 software were used 
to perform colorimetric analysis at a wavelength of 450nm. The mouse 
insulin standards were used to construct a standard curve, which was 
appraised for linearity and correlation co-efficient (r2), the latter accepted 
only when > 0.99. Sample insulin concentrations were extrapolated 
automatically using this curve and values were accepted at a co-efficient of 
variation (CV) between duplicates of < 10%.  
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4.8 Quantitative PCR 
 RNA Extraction 4.8.1
Ribonucleic acid (RNA) extraction was performed with care to avoid DNA 
contamination and RNA degradation, including the use of laboratory 
equipment dedicated to RNA work and the prior cleaning of all work surfaces 
with “RNAse away” spray.  
 
Organ samples were obtained from mice euthanised using rising carbon 
dioxide concentrations. A laparotomy and/or thoracotomy was performed 
and organs of interest were carefully dissected and “snap” frozen in liquid 
nitrogen prior to storage at -80°C. Cell lysates were harvested from 
pulmonary endothelial cell (PEC) cultures at P2, having been seeded onto 6 
well plates coated with 20g/L gelatin. Once these cells reached 95% 
confluence, 500µL of Tri reagent (Trizol®) were added to each well and the 
cells removed using a cell scraper. Samples were stored at -80°C prior to 
RNA extraction. 
  
Organs underwent mechanical homogenisation using a Qiagen tissue lyser. 
Samples were transferred to 2mL microcentrifuge tubes along with a 6mm 
stainless steel cone ball and 1mL of Tri reagent. Sample tubes were closed 
securely and loaded into the homogeniser for three cycles at 30Hz, each 
lasting two minutes. Following this, the liquidised portions were transferred 
into fresh 1.5mL microcentrifuge tubes, with any remaining solid debris and 
the cone ball discarded. This was not done to cell lysates, which were 
instead gradually defrosted on ice and dispersed thoroughly using a vortex 
mixer prior to use. Both tissue types were handled in a similar fashion from 
hereon in.  
 
Samples were centrifuged at 4°C for 10 minutes at 10,000g, following which 
the supernatants were transferred into fresh microcentrifuge tubes. The 
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samples were left to dry at room temperature for five minutes before 200µL 
of phenol chloroform were added to each. All tubes were agitated for 30 
seconds to ensure sufficient mixture of the tri reagent and phenol 
chloroform, then left at room temperature for three minutes before a 15-
minute spin at 12,000g, again at 4°C. This resulted in the samples 
separating into three strata: a clear top layer (RNA-containing aqueous 
phase), a thin lipid interphase and a protein rich organic phase. The 
aqueous phase was transferred to a fresh microcentrifuge tube and 500µL of 
isopropanol were added to each sample. These tubes were gently mixed 
and then left to rest at room temperature for ten minutes before a 12,000g 
centrifuge step for ten minutes at 4°C.  
 
At this stage, the supernatants were discarded and 1mL of 750mL/L ethanol 
was added to each pellet before a further centrifuge step at 7500g (five 
minutes at 4°C). As much ethanol as possible was removed from the pellet, 
which was then left to air dry for ten minutes at room temperature. Following 
this, 20µL of RNAse-free water were added to each tube. Pellets were left on 
ice for 20 minutes to dissolve. After this, 2µL samples from each sample 
were tested using NanoDrop® apparatus to measure the RNA 
concentration, with use of ethanol to clean the probe in between each 
sample.  
 
 Reverse Transcription 4.8.2
Reverse transcription of RNA to complementary (c)DNA was performed in a 
dedicated PCR laboratory with equipment used only for RNA work. A 
“mastermix” was created using a High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems), with constituents as summarised in Table 4-1. The 
RNA concentrations measured using the NanoDrop® were used to calculate 
the volume of RNA solution needed to load 2µg per sample into a PCR plate 
(topped up to 10µL with distilled water). 10µL of the mastermix were added 
to each sample, resulting in reaction volumes of 20µL. The reverse 
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transcription was then performed in a thermal cycler using the following 
conditions: 
 25°C (10 minutes) 
 37°C (2 hours) 
 85°C (5 minutes) 
 End 
Samples were then frozen at -20°C until real-time PCR was performed.  
 
Constituent Volume/µL (for 10µL mastermix) 
Water 4.2 
Buffer 2 
Random primers 2 
MultiScribeTM RT enzyme 1 
dNTPs 0.8 
Table 4-1 Constituents of Reverse Transcription mastermix 
dNTP = deoxynucleotide triphosphate; RT = reverse transcriptase. 
    
 Quantitative (real-time) PCR 4.8.3
Samples were analysed using quantitative PCR with two separate sets of 
probes, both using murine beta-actin as a housekeeping control. For 
analysis of human insulin receptor messenger RNA (mRNA), a Synergy 
Brands (SYBR) Green probe was used, while murine insulin receptor mRNA 
was detected using a Taqman® probe (Applied Biosystems). Mastermixes 
were created, containing 24µL in the SYBR green protocol and 19µL for 
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Taqman®, as per manufacturer instructions (see Table 4-2 and Table 4-3 for 
Mastermix details and Table 4-4 and Table 4-5 for the sequences of each 
primer). Taqman probes were commercially purchased, with primers pre-
attached; see Chapter 3.8 for details. The reaction volumes were measured 
into 96 well PCR plates and 1µL of cDNA was added in triplicate for each 
sample. For the SYBR Green probe, cDNA was diluted 1:20 but was added 
neat for the Taqman® experiments. A series of “blank” samples, containing 
distilled water rather than cDNA, was also loaded for each primer, as a 
negative control to rule out nucleic acid contamination of the mastermixes. 
 
 Constituent Volume/µL (for 24µL mastermix) 
Water 8.5 
SYBR Green 12.5 
Forward primer 1.5 
Reverse primer 1.5 
Table 4-2 Constituents of SYBR Green Mastermix 
 
Constituent Volume/µL (for 19µL mastermix) 
Water 8 
Taqman® mastermix 10 
Probe 1 
Table 4-3 Constituents of Taqman® Mastermix 
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Gene Forward Primer Reverse Primer 
Beta-actin 
CGT GAA AAG ATG ACC 
CAG ATCA 
TGG TAC GAC CAG AGG 
CAT ACAG 
Human Insulin 
Receptor 
TGC CAC CAA CCC CTC 
TGT 
CGG AGG GTG GTT TCC 
ACTT 
Table 4-4 SYBR Green Primers for Quantitative PCR 
A = adenine; C = cytosine; G = guanine; T = thymine 
 
 
Gene Assay Number Supplier 
Beta-actin Mm 00607939 Applied Biosystems 
Murine Insulin Receptor Mm 01211875_m1 Applied Biosystems 
Table 4-5 Taqman® Primers for Quantitative PCR 
 
Quantitative PCR was performed in a thermal cycler (ABI Prism 7900HT). 
The average cycle threshold (Ct) for the three repeats of each sample was 
recorded from SDS v2.2 software and compared with the average Ct for 
beta-actin for the same sample. Samples for which the three replicates were 
not close together were discarded on the basis of differential cDNA loading 
and pipette error. The difference in Ct (ΔCt) between the gene of interest 
and the housekeeping gene was recorded and expressed as a relative 
quantity (RQ) using the following formula:  
 
    RQ = 2-ΔCt x 100. 
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4.9 Vascular Injury 
Vascular injury experiments were performed by Dr Nadira Yuldasheva, using 
recovery anaesthesia with inhaled isoflurane. The technique for vascular 
injury experiments is as follows. 
 
 General Anaesthesia 4.9.1
The University of Leeds animal facility contains three operating theatres for 
murine surgery, each of which has a warmed table and pre-operative area 
as well as anaesthetic apparatus. An isoflurane vaporiser is connected via a 
series of tubes to both an anaesthetic induction chamber and a nose cone 
which acts as a mask for the mouse on the operating table. A valve controls 
the proportion of isoflurane and oxygen that is diverted to each outlet.  
 
Mice were initially identified, weighed and then placed into the induction 
chamber. Oxygen was turned on at a rate of 2 litres/minute, which was 
maintained throughout. Isoflurane was then initiated at a concentration of 4-
5% and diverted to the induction chamber, with close observation of the 
mouse throughout. Adequate anaesthesia could be inferred from loss of 
consciousness and then slowing of the respiratory rate, at which point flow 
was diverted to the nose cone and the mouse was secured in position on the 
operating table using surgical tape. For recovery experiments, the table was 
warmed to 38°C. Analgesia was initiated at the start of the surgical 
procedure with the intraperitoneal injection of buprenorphine (0.25mg/kg).  
 
During the operation, the mouse’s respiratory rate and response to tail-tip 
stimuli were used to appraise the depth of anaesthesia, and isoflurane dose 
was adjusted as required, usually between 1.5-2.5%. In the event of any 
signs of response, the concentration was adjusted and the mouse’s position 
in the nose cone was gently optimised until full anaesthesia had been 
achieved, and only at this point was surgery recommenced.  
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At the point of recovery, mice were switched to inhaled oxygen and had 
300µL of 0.9% saline injected intraperitoneally to maintain hydration. They 
were supervised closely in a post-operative recovery area with warmed 
tables. Soaked diet was provided for the first 24 hours and mice were 
checked daily until the end of the experiment.  
 
 Arterial Injury 4.9.2
Surgery was performed with the aid of a dissecting microscope (Zeiss OPMI 
1-FC). Mice were anaesthetised as described and secured in a supine 
position to an operating table warmed to 38°C. This position allowed 
abduction and extension of the lower limbs, exposing them adequately for 
fur removal using Veet cream. Asepsis was maintained and 0.75% 
providone-iodine solution was used to sterilise the surgical field. A small mid-
thigh incision was used to enter the left femoral canal and subcutaneous 
tissues and fat pads were gently removed with care not to disturb the 
epigastric artery, which maintained limb perfusion when the femoral artery 
was ligated. The femoral artery was then identified and carefully isolated 
from within the neurovascular bundle, following which it was loosely tied 
using 8.0 suture material and a proximal clamp was secured onto the 
neurovascular bundle. A drop of 1% lignocaine was applied on the arterial 
surface to reduce the chance of arteriospasm and an arteriotomy was then 
made with iris scissors.  
 
After gaining access into the femoral artery, a 0.014 inch diameter 
angioplasty guide wire (Hitorque Cross-it 200XT) was introduced and, after 
clamp removal, the wire was gently advanced 1.5-2.0cm for three passes. 
The wire was removed and the suture tightened to ligate the vessel proximal 
to the arteriotomy. The overlying skin was closed with a continuous Vicryl 
6.0 suture. The contralateral (right) lower limb was then exposed to a sham 
operation without wire passage. The mouse then underwent a monitored 
recovery period with analgesia and thermal support as outlined above.  
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 Assessment of Endothelial Regeneration 4.9.3
Four days after injury, the operating area was prepared for vessel harvest 
and mice were anaesthetised again as described above. The inferior vena 
cava was exposed using an incision along the linea alba. Three minutes 
prior to harvesting, Evans blue (50-75µL of 50g/L in saline) was injected via 
the inferior vena cava. This dye binds with high affinity to circulating albumin, 
which cannot cross an intact endothelium, so the dye cannot interact with 
matrix proteins deep to the endothelium. Thus, only areas of denudation 
appear blue when perfused with Evans blue stain.  
 
Perfusion fixation was then carried out using 40g/L paraformaldehyde in 
phosphate-buffered saline (pH 7.2). A 27G needle was used to introduce this 
into the left ventricle under physiological pressure, following which the 
animal’s muscles began to fasciculate. Once perfusion fixation was 
confirmed, both femoral arteries and surrounding soft tissue were excised as 
far as the bifurcation of the aorta and stored in 40g/L paraformaldehyde.  
 
Excised arteries were separated from surrounding fascial layers under 
microscopy (Olympus Dissecting Stereo Microscope SZ61) and imaging was 
performed using a QiCam Olympus digital camera. Using a 20x 
magnification, a 5mm segment of artery was identified at a distance of 5mm 
from the proximal end (near the aortic bifurcation) of the length of vessel. 
Figure 4-4 shows an injured and a sham vessel after excision. Areas of 
endothelial regeneration, i.e. those that did not stain blue, were demarcated 
on images analysed on ImagePro Plus 7.2 software (Media Cybernetics), 
and this allowed electronic calculation of percentage regeneration. A 
representative image showing this analysis is presented in Figure 4-5. 
. 
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Figure 4-4 Image of Femoral Arteries after Vascular Injury  
Image courtesy of Dr Nadira Yuldasheva, from wild-type mouse 210. Magnification: x20. The bottom (sham) vessel is the contralateral 
artery from the same mouse, which was not injured, showing no staining with Evans Blue and thus an intact endothelium. Distance A 
denotes the excised vessel, from the origin of the common femoral artery to the femoral artery bifurcation. The injured segment (B) 
starts 5mm from the origin of the femoral artery and is itself 5mm long. Areas of persistent endothelial denudation stain blue, with 
areas of recovery appearing white. 
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Figure 4-5 Representative Image Showing Quantification of Endothelial Regeneration  
Image from WT mouse 210. Magnification: x20. The analysed segment (D2 above) commences 5mm distal to the origin of the 
common femoral artery (left edge). Areas of persistent denudation, stained blue, were quantified in a 5mm segment of stained artery 
by Dr Yuldasheva using ImagePro Plus software as shown, and used to calculate the percentage regeneration in each wound. 
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4.10 Enumeration of Circulating Progenitor Cells (CPCs) 
 Blood Collection  4.10.1
200µL of sterile heparin (1000 IU/mL) were measured into Microvette tubes 
lined with EDTA-tripotassium, agitated to encourage adequate lining of the 
tube, and then 150µL were removed and discarded, leaving a residual 50µL 
of heparin in the tube. 3mL of 1:10 sterile PharmlyseTM red cell lysis buffer 
were measured into 15mL centrifuge tubes, one for each blood sample. This 
ammonium chloride-based buffer is diluted from a commercially obtained 
10x stock solution using distilled water that had undergone syringe filtering; it 
lyses erythrocytes without affecting viability of the leucocyte population. 
 
These tubes were transported on ice to the animal facility, where habituated 
mice were consciously restrained for saphenous venepuncture as described 
previously. 150µL of whole blood were carefully collected into the Microvette 
tubes with care to avoid thrombus formation. Blood samples were 
immediately transferred and mixed with the 3mL aliquots of sterile lysis 
buffer, which were swiftly transferred in ice to the laboratory for processing.  
 
 Incubation with Antibodies 4.10.2
Samples in lysis buffer were removed from ice and centrifuged at 300g for 
10 minutes, following which the supernatant was aspirated. The peripheral 
blood mononuclear cell (PBMC) pellet was resuspended in 1mL of 
fluorescence activated cell sorter (FACS) buffer (50mL/L foetal calf serum, 
5g/L bovine serum albumin in PBS; pH 7.4) in fresh 1.5mL microcentrifuge 
tubes.  
 
Samples were centrifuged again, and a 1:10 dilution of Fc block was 
prepared in FACS buffer. Cell pellets were resuspended in 100µL of the 
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Fc/FACS solution to reduce non-specific antibody binding. These were 
incubated at 4°C in the dark in a refrigerator for 10 minutes.  
During this incubation, three separate antibodies (Ab) or corresponding 
isotype controls (IC) were diluted in FACS buffer from stock solutions (BD 
Biosciences). The three anti-mouse antibody-fluorochrome combinations 
were as detailed in Table 4-6.  
 
Antibody Fluorochrome 
Stem cell antigen 1 (Sca1) 
Fluorescein 
isothiocyanate (FITC) 
Foetal liver kinase 1 (Flk1) R-phycoerythrin (PE) 
c-kit/CD117 Allophycocyanin (APC) 
Table 4-6 Antibody-fluorochrome Combinations used for Flow 
Cytometry 
CD = cluster of differentiation. 
 
Previous work from our laboratory defined CPCs as those expressing both 
Sca1 and Flk1, but transfusion studies conducted in that project utilised c-
kit+ PBMCs. Pilot data obtained in conjunction with Dr Noman Ali (University 
of Leeds) demonstrated that the population of triple labelled cells is 
negligible, but that Sca1+Flk1+ cells and c-kit+ cells could be enumerated 
separately in meaningful quantities using flow cytometry.  
 
After 10 minutes, the samples incubated with Fc block were removed and 
their volume was doubled by adding 100µL of fresh FACS buffer. This was 
split evenly between two new microcentrifuge tubes, one to be incubated 
with 10µL of each IC cocktail and the other with 10µL of the Ab cocktail. 
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Antibodies were applied in darkness and the samples were again 
refrigerated for 10 minutes. Following this, 1mL of FACS buffer was added to 
each tube and they were spun for 10 minutes at 300g to wash off unbound 
antibody. Pellets were resuspended in 500µL of FACS buffer, transferred 
into FACS tubes and quickly transferred to the flow cytometer on ice.  
 
 Fluorescence Activated Cell Sorting (FACS) 4.10.3
CPC enumeration was performed using a BD-LSR Fortessa flow cytometer. 
The lymphocyte gate was defined as shown in Figure 4-6 and the number of 
dual-labelled cells (Sca1+Flk1+;  
Figure 4-7) and, separately, c-kit+ cells (Figure 4-8) were counted within 
100,000 lymphocyte events. If fewer than 100,000 events were recorded, 
results were normalised to this event rate. The event number recorded in the 
IC specimens was subtracted from that obtained in the Ab specimens to 
control for non-specific fluorescence.  
Figure 4-6 Definition of lymphocyte gate on flow cytometry 
A = lymphocytes, B = monocytes, C = granulocytes. 
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Figure 4-7 Definition of Sca1+Flk1+ circulating progenitor cells (CPC) 
Upper panel shows isotype control and lower panel shows antibody-labelled 
sample. Cells co-labelled with stem cell antigen-1 (Sca1) and foetal liver 
kinase-1 (Flk1) are presented as Q2 events, in blue.  
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Figure 4-8 Definition of c-kit+ circulating progenitor cells (CPC) 
Upper panel shows isotype control and lower panel shows antibody-labelled 
cells. Those expressing c-kit are counted in the P2 region. 
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4.11  Isolation and Enumeration of Early Outgrowth EPCs 
 General Anaesthesia 4.11.1
Tissue for EPC culture was obtained under terminal general anaesthesia, as 
described above. Briefly, mice were identified and anaesthesia was induced 
in a chamber with oxygen (2L/minute) and isoflurane (3-4%), with peri-
operative maintenance at 1-2% isoflurane via a mask on the operating table.  
 
 Tissue Harvest (blood, spleen, bone marrow) 4.11.2
Once the mouse was satisfactorily anaesthetised, a midline laparotomy was 
performed and bowel was moved aside to expose the inferior vena cava 
(IVC). This was carefully punctured using a 1mL insulin syringe containing 
50µL of sterile sodium citrate (obtained from citrated blood collection tubes). 
1mL of blood was removed in this manner and immediately expelled into 
4mL of sterile PBS, stored on ice in a blood collection tube.  
Next, the spleen was identified and carefully dissected out, with removal of 
any obvious areas of infarction that had developed after IVC puncture. Care 
was taken to dissect off any adherent adipose tissue. The spleen was then 
transferred to a 15mL centrifuge tube containing 5mL of sterile PBS and 
stored on ice. 
Finally, the coat, fascial layers and muscle were dissected from each hind 
limb until the femur and tibia on both sides was exposed. The bones were 
cleaned of any adherent connective tissue and the fibulae were 
disconnected from the lower limb and discarded. Scissors were used to 
make cuts at the metaphyses of the femora and tibiae, after which each long 
bone was flushed three times with 5mL of sterile PBS using a syringe and a 
23G needle into a 15mL centrifuge tube before being stored on ice.  
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 Mononuclear Cell Isolation  4.11.3
All samples were rapidly brought back to the cell culture laboratory on ice 
and isolation of mononuclear cells was performed in aseptic conditions in a 
flow-controlled cell culture hood. Blood was expelled into a 50mL centrifuge 
tube through a 70µm cell strainer to eliminate any thrombus, and washed 
with 2mL of sterile PBS. Spleens were placed in 3mL of fresh sterile PBS in 
a Petri dish and mechanically minced through 70µm cell strainers until only 
non-specific cellular debris remained in the sieve. The filtrate suspension 
was then injected through the cell strainer into a 50mL centrifuge tube and 
the Petri dish was washed with a further 2mL of sterile PBS, which was 
added to the suspension. Similarly, the marrow suspension was 
mechanically minced and then filtered through a cell strainer with a 2mL 
PBS wash of the Petri dish.  
Each cell suspension was then carefully layered onto 5mL of Histopaque-
1083, prior to undergoing density-gradient centrifugation at 400g for 30 
minutes with slow deceleration. This resulted in the formation of a buffy layer 
containing the mononuclear cell fraction, which was carefully aspirated using 
a 1mL pipette tip and expelled into new centrifuge tubes. The buffy layer was 
washed twice (for spleen and marrow) and three times (for blood) with 10mL 
of sterile PBS at 400g for 10 minutes.  
 
 Seeding for EPC Culture 4.11.4
The resulting pellets were resuspended in dedicated EPC growth medium, 
composed of EGM-2 basal medium supplemented with 200mL/L foetal calf 
serum and EGM-2 bullet kit (Lonza). Blood- and marrow-derived pellets 
were resuspended in 500µL of medium and those derived from spleen were 
reconstituted in 2mL of medium. 20µL samples were taken from each and 
added to equal volumes of trypan blue. These were loaded onto a 
haemocytometer and viable cells (those that did not take up the trypan blue) 
were counted. Mononuclear cells were seeded onto 24-well fibronectin-
coated cell culture plates at the following densities: 1 x 106 cells/well for 
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marrow, 5 x 106 cells/well for blood and 8 x 106 cells/well for spleen. EPC 
growth medium was added to make a total suspension volume of 1mL for 
blood and marrow and 2mL for spleen. If possible, each sample was seeded 
in triplicate to reduce data variability.  
 
Cells were kept in a 37°C incubator with 5% CO2 for seven days such that 
the resultant cell population was akin to published studies of early outgrowth 
EPCs. On day 4, wells were washed with sterile PBS in order to remove 
non-adherent cells and growth medium was refreshed. Imaging was 
undertaken on day 7.  
 
 EPC Imaging 4.11.5
On day 7, each well was washed twice with sterile PBS prior to imaging. 
Cells were defined as EPCs if they exhibited dual staining with 1,1’-
dioctadecy-3,3,3’,3’-tetramethyllindocarbocyanine-labelled acetylated low-
density lipoprotein (DiI-ac-LDL) and lectin obtained from Ulex europaeus 
conjugated with fluorescein isothiocyanate (FITC). This technique has been 
used in previous work enumerating EPCs in culture [164]. DiI-ac-LDL was 
initially added in darkened conditions at a concentration of 10µg/mL (diluted 
in EPC growth medium). Cells were incubated with this for 3 hours at 37°C 
prior to further washes with PBS and then fixation with 40g/L 
paraformaldehyde for 10 minutes. This was washed with PBS again, after 
which lectin-FITC was added at the same concentration but diluted in PBS. 
Cells were incubated with lectin in the dark for an hour, following which they 
underwent a final wash prior to imaging.  
 
Imaging was performed using an Olympus CKX-41 fluorescence 
microscope. Five images per well were taken at 100x magnification as 
follows: phase contrast, red fluorescence (DiI), and green fluorescence 
(lectin-FITC) using Cell B software. Images were saved and then overlain 
using Image J software (version 1.46r). EPC were denoted as cells staining 
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yellow on composite images and these were quantified using the Cell 
Counter tool in Image J. Cell counts were taken from five to ten separate 
fields chosen at random and mean number of cells per image was 
calculated. Representative images are shown in Figure 4-9.  
 
Figure 4-9 Endothelial Progenitor Cells from a Wild-type Spleen  
Top left = phase-contrast imaging; top right = fluorescein isothiocyanate-
lectin; bottom left = DiI-acetylated-LDL; bottom right = composite image. 
Yellow-stained cells represent endothelial progenitor cells. Magnification: 
x100.  
 
  
Page | 123 
 
4.12 Isolation and Culture of Pulmonary Endothelial Cells 
Murine pulmonary endothelial cells (PECs) were isolated using a technique 
described in detail by Sobczak et al [182]. Following a two-step magnetic 
bead separation using antibody coated microbeads, cells were used in 
various assays, including studies of proliferation (Chapter 4.12), migration 
(Chapters 4.14 and 4.15), superoxide production (Chapter 4.18), messenger 
RNA expression (Chapter 4.8) and Western blotting (Chapter 4.19).  
 
 Antibody-coated Microbead Preparation 4.12.1
Commercially purchased sheep anti-rat immunoglobulin (Ig)G Dynabeads 
were coated with antibodies in advance of cell isolation as follows. For the 
first bead separation, these beads were incubated with antibodies targeted 
at platelet endothelial cell adhesion molecule 1 (PECAM-1; also known as 
CD31). The second enrichment of PECs was done using intercellular cell 
adhesion molecule (ICAM-2; also known as CD102). Antibodies to both of 
these agents were acquired from BD Biosciences (details in Chapter 3.12). 
 
A magnetic particle concentrator (MPC) was assembled in a sterile cell 
culture hood with an autoclaved 1.5mL microcentrifuge tube within the 
magnetic column. 200µL of Dynabeads were added into the microcentrifuge 
tube and a solution of sterile PBS supplemented with 1g/L BSA was used as 
a wash buffer in volumes of 1mL per wash. After each wash, beads were 
allowed to adhere to the magnet for 30-60 seconds, following which a sterile 
glass aspirator was used to remove the supernatant; this process was 
carried out four times. Following this, the beads were resuspended in 500µL 
of PBS/BSA and 20µL of either anti-PECAM-1 or anti-ICAM-2 antibody 
solution were added to the tube. This was rotated in a MACSmixTM rotator 
for two hours at room temperature, following which a further four washes 
were performed in the MPC in a sterile manner. After the fourth wash, a final 
volume of 200µL of PBS/BSA was used to reconstitute the beads for 
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eventual use in PEC enrichment. Beads were refrigerated and used for up to 
a month.  
 
 PEC Growth Medium Preparation 4.12.2
Growth medium was also prepared in advance. Basal MV2 growth medium 
was purchased along with endothelial growth supplements (Lonza). For 
every 500mL of basal medium, the growth supplements were added in 
sterile conditions along with 50mL of batch-tested foetal bovine serum 
(Biosera) and 10mL of antibiotic-antimycotic solution; these were mixed 
thoroughly and the medium was used in aliquots for up to a month to avoid 
alterations in composition and reduce the risk of microbial contamination.  
 
 Lung Harvest and PEC Isolation 4.12.3
Mice aged 4-6 weeks were euthanised using rising concentrations of CO2 
and death was confirmed with blunt cervical dislocation, as per Home Office 
UK regulations. A thoracotomy was performed and lungs were dissected 
with care to avoid large thrombi or excessive connective tissue. These were 
stored in ice-cold Hank’s Balanced Salt Solution (HBSS) and transferred to 
the cell culture facility, where they were transferred to 10cm Petri dishes in a 
cell culture hood. A solution of 1mg/mL collagenase/dispase was prepared in 
Dulbecco’s Modified Eagle Medium supplemented with glucose and 
pyruvate (DMEM) and a 200µL drop was placed over the lung tissue in the 
Petri dishes to aid enzymatic digestion during mechanical homogenisation. 
During this mincing step, 10mL of the 1mg/mL solution of 
collagenase/dispase in DMEM were warmed to 37°C in a water bath in 
15mL centrifuge tubes.  
 
Once lung tissue was adequately homogenised, it was transferred to the 
collagenase/dispase-DMEM mixture and the Petri dish was washed to 
collect any remaining cell fragments. Centrifuge tubes were then loaded onto 
the MACSmixTM rotator for 45 minutes at 37°C. After this, a 14G cannula and 
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10mL syringe were used to agitate the tissue gently until a single cell 
suspension was obtained. This suspension was then injected through a 
70µm cell strainer into a fresh 50mL centrifuge tube and the 
collagenase/dispase was neutralised with the addition of 5mL of PEC growth 
medium. The resulting filtrate was then centrifuged at 800g for ten minutes 
and the supernatant gently poured off. The pellet was reconstituted in 3mL 
of PBS/BSA and mixed thoroughly before adding 20µL of PECAM-1-coated 
microbeads (prepared as per Chapter 4.12.1). Samples were vortexed and 
rotated on the MACSmixTM rotator for 15 minutes at room temperature.  
 
During this rotation step, 25cm2 cell culture flasks were coated with 20g/L 
gelatin (in distilled water) that had been prepared and autoclaved in 
advance. The magnetic particle concentrator was assembled in the cell 
culture hood with three autoclaved 1.5mL microcentrifuge tubes per sample. 
Once the cells had rotated with the antibody-coated beads, the 3mL sample 
was divided between the three tubes on the MPC. After 30-60 seconds, the 
supernatant was aspirated using a glass pipette and beads were 
resuspended in a fresh 1mL of PBS/BSA. Five of these washes were 
performed, after which the beads were resuspended in 1mL of PEC growth 
medium. These cells were added to the gelatin-coated T25 flasks and the 
total volume of PEC growth medium was made up to 5mL per flask. Cells 
were incubated at 37°C with 5% CO2.  
 
A complete media refreshment was performed 24 hours after isolation, 
following which half of the media was changed on alternate days until cells 
reached 80-90% confluence, typically after 7-10 days. A representative 
phase-contrast image of P0 cells at the point of confluence is presented in 
Figure 4-10 (from IRKO mouse 641).  
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Figure 4-10 Pulmonary Endothelial Cells  
Passage 0; magnification x40 
 
 Second Antibody-coated Bead Separation 4.12.4
Growth medium was aspirated when cells were sufficiently confluent to 
contemplate further enrichment, and flasks were washed with warm, sterile 
PBS to remove all traces of media. 4mL of a pre-warmed 2.5g/L 
trypsin/EDTA solution were added to each flask and these were incubated at 
37°C for up to two minutes, following which cell detachment was confirmed 
using light microscopy. 8mL of PEC growth medium were added to 
neutralise the trypsin and the mixture was centrifuged at 400g for eight 
minutes. Pellets were resuspended in 2mL of PBS/BSA and 10µL of 
Dynabeads coated with anti-ICAM-2 antibody. In a similar fashion to the first 
bead separation, these samples were rotated for 15 minutes at room 
temperature and underwent magnetic bead separation in two 1.5mL 
microcentrifuge tubes per sample. After this, the beads were resuspended in 
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PEC medium and transferred to fresh gelatin-coated T25 flasks. Typically, 
90% confluence was reached within seven days, at which cells could be 
detached and re-seeded at various densities for the assays that follow.  
In this thesis, cells that have undergone the ICAM-2 separation are referred 
to as passage number one (P1) and those that are subsequently passaged 
for assays are referred to as being at P2.  
 
 Determination of PEC Purity 4.12.5
Once P1 cells had reached confluence, these were detached using trypsin-
EDTA and counted using trypan blue as described in Chapter 4.11.4. 15,000 
cells were seeded into 35mm imaging dishes (Ibidi) and incubated at 37°C 
for 24 hours. At this stage, cells were washed twice in warm PBS and then 
fixed in 1mL of 40g/L paraformaldehyde in PBS for 15 minutes at 37°C. 
Immunohistochemistry was performed in conjunction with Dr Richard 
Cubbon. Following fixation, cells were permeabilised and blocked using a 
solution of 2.5g/L Triton X-100 and 10g/L BSA in PBS. They were then 
incubated with an isolectin B4-Alexa Fluor® 488 conjugate at 10µg/mL for 
two hours at room temperature, after which three PBS washes were 
performed, for five minutes each. Finally, a nuclear counterstain with 5µg/mL 
Hoechst 33342 in PBS was applied for ten minutes at room temperature, 
and another five-minute PBS wash was performed. An LSM700 confocal 
microscope (Zeiss) was used to image the cells. A representative image of 
these cells is shown in Figure 4-11.   
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Figure 4-11 Murine pulmonary endothelial cells  
Confocal microscope image showing pulmonary endothelial cells (passage 
2) stained with isolectin B4 (green) and Hoechst (blue). 
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4.13 Endothelial Cell Proliferation Assay 
Murine PECs were detached from confluent cultures at P1 and counted 
using trypan blue and a haemocytometer as previously described. 24-well 
cell culture plates were coated with 20g/L gelatin and cells were seeded onto 
two wells per mouse, at 20,000 cells per well. These were incubated 
overnight at 37°C, resulting in 80-90% confluence the following day. At this 
stage, a commercially available Click-iT® kit (Life Technologies) was used to 
perform a proliferation assay using 5-ethynyl-2’-deoxyuridine (EdU), a 
nucleoside analogue that incorporates into the DNA of cells undergoing 
mitosis. The EdU is conjugated to an alkyne which is detected with an Alexa 
Fluor® 488-conjugated azide used in the kit.  
On first use, the constituents of the kit were prepared and stored as per the 
manufacturer’s instructions, summarised in Table 4-7.  
 Reagent Preparation Storage 
A EdU Reconstitute in DMSO and 
aliquot 
-20°C 
B Alexa Fluor® azide Reconstitute in DMSO -20°C, 
dark 
C DMSO Use to reconstitute A/B 4°C 
D Click-iT® Buffer Dilute 1:10 in deionised water 4°C 
E Copper sulphate Use neat 4°C 
F Click-iT® Buffer 
Additive 
Reconstitute in deionised water; 
freshly dilute 1:10 for each use 
-20°C 
G Hoechst Not used in this project 4°C 
Table 4-7 Components of Click-iT® EdU assay kit 
EdU = 5-ethynyl-2’-deoxyuridine; DMSO = dimethyl sulfoxide 
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On the day of the assay, cells were washed twice with warm PBS and 
replaced with 1mL per well of fresh PEC medium containing EdU at a 1:1000 
dilution. This was added for two hours and cells were incubated at 37°C 
before being washed again with PBS. Cells were then fixed in 40g/L 
paraformaldehyde in PBS for 15 minutes at room temperature. During this 
incubation the Click-iT® Buffer Additive (component F) was defrosted and a 
1:10 solution was made in deionised water. The paraformaldehyde was 
washed off with PBS and then cells were permeabilised using 1mL of PBS 
with 5g/L Triton X-100 per well; this was left for 20 minutes at room 
temperature. In this time, the Click-iT® cocktail was composed as per 
manufacturers’ instructions, taking care to add the reagents in the specified 
order. These instructions are summarised in Table 4-8.  
  
Component Volume (µL) 
Click-iT® Buffer 430 
Copper sulphate 20 
Alexa Fluor® 488 azide 1.2 
Click-iT® Buffer Additive 50 
Total 500 
Table 4-8 Composition of Click-iT® cocktail (volumes for one well) 
 
Once permeabilised, cells were washed with PBS and then 500µL of cocktail 
were measured into each well. The plate was kept protected from light at 
room temperature for 30 minutes. After this, and a further PBS wash, 500µL 
of propidium iodide/RNAse were added per well as a nuclear counterstain. 
The plate was protected from light and kept at room temperature for a 15 
minute incubation, following which cells were washed with PBS and then 
imaged with 500µL of PBS in each well using an Olympus CKX-41 
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fluorescent microscope. Five images per well were captured at 100x 
magnification using Cell B software. Images were saved and then 
proliferating cells (nuclei fluorescing green) and the total number of cells 
(nuclei fluorescing red) were enumerated using Image J (v1.46r; NIH). 
Proliferating cells were quantified as a percentage of the total number of 
cells. Figure 4-12 shows representative images from a wild type mouse 
(674), including an example of how counting was performed in Image J. For 
consistency between samples, cells on the edge of the image were counted 
and any cells that appeared to undergoing cytokinesis were counted as two 
separate cells; examples of each are shown in the figure.   
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Figure 4-12 Representative Images of EdU Assay 
A: Nuclei stained with propidium iodide 
B: Proliferating nuclei stained with 5-ethynyl-2’-deoxyuridine (EdU) 
Magnification: x100. 
 
A 
B 
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4.14 Endothelial Cell Migration Assay (Boyden Chamber) 
Confluent cells at P1 were washed in warm PBS and then incubated for four 
hours in serum-free growth medium (supplemented with an 
antibiotic/antimycotic solution) on the day of the Boyden chamber assay. 
Following this, cells were detached using trypsin-EDTA, centrifuged and 
pellets were reconstituted in 1mL of basal endothelial growth medium (MV2; 
Lonza) supplemented with 10mL/L FCS. From this 1mL sample, 200,000 
cells per mouse were allocated for this assay.  
 
A modified Boyden chamber apparatus was assembled using cell culture 
inserts with 8µm pores forming the upper compartment and a well of a 24 
well cell culture plate forming the lower chamber, as depicted in Figure 4-13. 
For each animal, two wells were set up as controls containing 750µL of PEC 
growth medium supplemented with 10mL/L FCS. Two further wells were 
prepared with vascular endothelial growth factor (VEGFA165) at 50ng/mL in 
the same medium, in order to set up a chemotactic gradient. A cell culture 
insert was carefully lowered into each well using sterile forceps, ensuring 
that no large bubbles formed that could hinder cell migration through the 
pores in the membrane. The cells in suspension were agitated well to ensure 
even dispersal, and a volume corresponding to 50,000 cells was measured 
into each insert. The plate was incubated at 37°C for 24 hours. 
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After 24 hours, the cell culture inserts were carefully lifted out of the wells 
and fixed in 750µL of 700mL/L ethanol. Once fixed, a clean cotton wool bud 
was used to remove any non-migrating cells from the upper surface of the 
membrane and the insert was immersed in water, then stained sequentially 
in haematoxylin and eosin for 30 seconds each. 500µL of PBS were 
measured into each insert before imaging using an Olympus CKX-41 
microscope. Five images per well were captured at 100x magnification using 
Cell B software. Images were saved and then stained migrant cells were 
counted using Image J (v1.46r; NIH). Data were expressed as net migration 
by subtracting the mean number of migrant cells in the control wells from the 
mean migration noted in the wells containing VEGF. A representative image 
is presented in Figure 4-14.   
Figure 4-13 Schematic Showing Structure of Boyden Chamber 
PEC = pulmonary endothelial cell (50,000 cells/well); EGM = endothelial 
growth medium; VEGF = vascular endothelial growth factor 
Page | 135 
 
 
Figure 4-14 Image from Boyden Chamber  
Image taken from HIRECOxIRKO mouse 771. Circular pores can be seen in 
the membrane and migrant cells, stained with haematoxylin and eosin, were 
counted when both the nucleus and cytoplasm had been clearly visualised. 
Magnification: x100.  
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4.15 Endothelial Cell Migration Assay (Scratch Wound) 
In addition to the Boyden chamber experiment, PEC migration was studied 
using an assay of scratch wound closure. A mechanical scratch was made 
on a confluent layer of PECs at P2 and serial imaging was undertaken using 
the IncuCyteTM Imaging System (Essen Biosciences) to determine real-time 
wound closure while cells remained in a 37°C incubator.  
 
Confluent PECs at P1 were trypsinised and counted as previously 
described. Meanwhile, Essen ImageLock 96 well plates were coated with 
20g/L gelatin. From previous experiments undertaken with primary murine 
PECs in this laboratory, it was determined that the quality of wound creation 
was optimal at 40,000 cells per well, with gelatin coating and using fully 
supplemented PEC medium. Cells were therefore seeded at 40,000 cells per 
well, with three wells per mouse, topped up to 100µL per well with PEC 
growth medium. Cells were incubated overnight at 37°C and would ordinarily 
have reached 90% confluence by the following morning.  
 
The next morning, cells were washed in PBS and incubated at 37°C for four 
hours with serum-free PEC medium. After this, cells were scratched 
mechanically using the WoundmakerTM 96-pin tool, ensuring that all empty 
wells contained 100µL PBS to prevent pin damage. This created a 
longitudinal scratch across the middle of each well, which was appraised 
under light microscopy to ensure that enough cells had detached to allow 
appropriate analysis. Each well was washed three times with PBS in order to 
remove loose cell debris and PEC growth medium was added after the final 
wash. Cells were placed in the IncuCyteTM and the WoundmakerTM was 
cleaned as per manufacturer instructions.  
 
Integrated Cell Migration Analysis Module software for use with the 
IncuCyteTM was used to obtain two images per well, every two hours, for 12 
hours; previous experiments had demonstrated a plateau in relative wound 
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density after this time. An area under the curve (AUC) was calculated and 
expressed as the mean of all three wells per mouse. Figure 4-15 and Figure 
4-16 show representative images of scratch wounds at the time of creation 
and 12 hours later with partial closure.  
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Figure 4-15 Pulmonary Endothelial Cell (PEC) Scratch Wound (t=0) 
A = Phase-contrast image showing scratch wound. B = Scratch mask image 
showing edges of wound as determined by Essen software. From wild-type 
909. 
A 
B 
A 
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Figure 4-16 Pulmonary Endothelial Cell Scratch Wounds (12 hours) 
A = Phase-contrast image showing partially closed wound. B = Scratch 
mask image showing cell migration beyond original edges of wound. From 
wild-type 909. 
A 
B 
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4.16  Endothelial Migration with EPC-Conditioned Media 
A similar experiment was undertaken in order to compare the functional 
effects of EPCs derived from the three genotypes. In this case, human 
umbilical vein endothelial cells (HUVECs) were used in a scratch wound 
assay, incubated in conditioned EPC media.  
 
Spleen-derived early outgrowth EPCs were cultured as described in Chapter 
4.11; however, cells were seeded at 30 million cells per well on a 6-well 
fibronectin-coated cell culture plate. After the cells were washed on day four, 
the EPC growth medium was replaced with 1mL of basal EPC medium 
supplemented with 10mL/L FCS. This was applied for 24 hours, after which 
the medium was aspirated and centrifuged at 6000 rpm for six minutes. The 
supernatant was frozen at -80°C prior to use in the HUVEC scratch assay.  
 
HUVECs were kindly donated by Mrs Jessica Smith at P3 and seeded at 
18,000 cells per well into a 96-well Essen ImageLock plate coated with 
20g/L gelatin. Three wells were allocated per sample of conditioned medium. 
The following morning, cells were washed in PBS and incubated at 37°C for 
four hours with serum-free endothelial growth medium. Cells were then 
scratched mechanically as described in Chapter 4.15 and washed with PBS. 
After the final wash, 100µL of conditioned EPC growth media were added to 
each well, and the plate was placed in the IncuCyteTM. One image was 
obtained per well every two hours for 12 hours; this timing strategy was 
based on pilot data using WT conditioned media. As with the PEC scratch 
assay, a mean AUC was calculated for each conditioned media sample, in 
this case as an average of the three wells per condition. 
 
 
 
 
Page | 141 
 
4.17  Vasomotor Studies of Aortic Rings 
Organ bath experiments were performed in conjunction with Mrs Stacey 
Galloway. I euthanised mice and dissected their aortae, following which Mrs 
Galloway transported the samples (blinded) to the laboratory and cleaned 
them before operating the organ bath apparatus. I analysed the data output 
from these experiments independently and in a blinded fashion.  
 
 Dissection of Aortae 4.17.1
Mice were euthanised using rising concentrations of carbon dioxide (unless 
IVC blood was to be removed concomitantly, in which case terminal 
anaesthesia was used). Lateral thoracotomies were performed and the heart 
and lungs removed in order to expose the thoraco-abdominal aorta. The 
aorta was carefully dissected off the posterior chest wall with efforts to limit 
stretching or denuding the endothelium in the process. The sample was 
transported to the laboratory in ice-cold Krebs-Henseleit solution (composed 
as per Table 4-9), where Stacey Galloway operated the organ bath 
apparatus to acquire blinded tension data for individual aortic rings.   
 
 Preparation of Aortic Rings 4.17.2
The aorta was visualised under direct light microscopy (Olympus SZ61) and 
any adherent fat or connective tissue was carefully dissected off before 
separating the aorta into four rings, each measuring 3-5mm in length. These 
were mounted onto fine opposing triangular wires using the exposed lumen, 
with care to avoid denuding the endothelium. The wires were then 
suspended in an organ bath apparatus (PanLabs) and connected to a fixed 
support at one end and a high sensitivity pressure transducer at the other. 
Each chamber contained Krebs-Henseleit solution bubbled with 95% oxygen 
and 5% carbon dioxide at 37°C for the duration of the experiment. Four rings 
were suspended per mouse (subject to sufficient high-quality tissue being 
harvested). The organ bath is depicted schematically in Figure 4-17. 
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Constituent Concentration (mM) 
Sodium chloride 119 
Potassium chloride 4.7 
Monopotassium phosphate 1.18 
Sodium bicarbonate 25 
Magnesium sulphate heptahydrate 1.19 
Calcium chloride dihydrate 2.5 
Glucose 11 
Table 4-9 Composition of Krebs-Henseleit solution 
 
 Organ Bath Assessment 4.17.3
The organ bath apparatus was set up as above. Each aortic ring was 
suspended in a chamber with its own micro-environment, allowing exposure 
of different rings from the same animal to a variety of conditions if 
necessary.  
Rings were initially mechanically stretched to a tension of 3g for two hours. 
Endothelium-independent vasoconstriction was then assessed using 
potassium chloride (40 mM KCl; 100µL). If any rings failed to constrict by 
more than 10% (i.e. to 3.3g or above) then they were excluded from 
subsequent analyses. KCl was then washed out by multiple refreshments of 
the Krebs-Henseleit solution in each chamber.  
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Figure 4-17 Schematic of Organ Bath Apparatus 
The organ bath apparatus contains eight chambers, one of which is enlarged 
on the left. The Krebs-Henseleit buffer (light blue) within the chamber is 
infused with 95% oxygen (O2) and 5% carbon dioxide (CO2) (grey bubbles). 
Aortic rings (pink) are mounted onto thin triangular wires (black), suspended 
in buffer as described above.  
 
 Endothelium-dependent Vasodilatation 4.17.4
Rings were exposed to the vasoconstrictor phenylephrine used at a specific 
concentration of 300nM. Again, any rings that did not constrict by 10% or 
more from baseline were excluded. After pre-constriction, tension was re-
equilibrated and incremental concentrations (from 1nM to 10µM) of 
acetylcholine were added to the chamber. Tension readings were noted and 
used to create a dose-response curve, from which an EC50 (concentration 
providing 50% of maximum relaxation) was calculated.   
 
 Endothelium-independent Vasodilatation 4.17.5
To ensure that any effects seen were related to endothelium-dependent 
vasodilatation, a similar dose-response curve was created using sodium 
nitroprusside (SNP; 1nM to 10 µM) after initial phenylephrine pre-
constriction. SNP is a NO donor and thus mediates its vasodilatory effects 
via vascular smooth muscle cells rather than via influences on the 
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endothelium. Agonists were washed out thoroughly after each part of the 
experiment.  
 
 Vasoconstriction 4.17.6
Similarly, cumulative concentrations of phenylephrine (1nM to 10µM) were 
then used to construct a dose-response curve for constriction. This was 
performed once at baseline and then repeated after rings were incubated for 
two hours with 10µL of 0.1M L-NMMA. EC50 values were compared for the 
constriction dose-response curves before and after incubation with L-NMMA 
to assess the degree of insulin sensitivity and NO bioavailability respectively. 
Rings that had been exposed to L-NMMA were not used for any further 
experiments beyond the derivation of post-incubation PE constriction curves.  
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4.18 Superoxide Assay 
In order to measure superoxide concentration in PECs, a Flex Station 3 
microplate reader (Molecular Devices) was used to measure 
dihydroethidium (DHE) fluorescence. DHE, in the presence of superoxide, is 
oxidised to 2-hydroxyethidium and fluoresces red, allowing indirect 
quantification of intracellular superoxide generation.  
 
PECs at P1 were enzymatically detached and counted. Based on 
optimisation experiments, a cell density of 50,000 cells per well on clear, 
uncoated 96-well cell culture plates was found to be optimal for superoxide 
detection. Krebs buffer supplemented with 2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid (HEPES) was the most suitable clear medium in which 
to incubate the cells during DHE exposure and whilst in the microplate 
reader; PEC growth medium was found to generate autofluorescence and 
was not suitable for detection of superoxide. Cells were seeded as such, 
with two wells for controls and two wells for DHE for each mouse. These 
were incubated at 37°C overnight in standard PEC media for up to 24 hours, 
by which time they reached 90% confluence.  
 
Krebs-HEPES buffer was composed as detailed in Table 4-10 and syringe-
filtered in a cell culture hood. Once cells were confluent, they were washed 
in PBS and then incubated either with 100µL of Krebs-HEPES alone (control 
wells) or with 25µM DHE for 20 minutes at 37°C. Following this, all wells 
were washed twice with PBS and 100µL of unlabelled Krebs-HEPES 
medium were added to each well after the final wash. Cells were protected 
from light and transferred to the Flex Station 3 microplate reader.  
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Constituent Concentration (mmol/L) 
Sodium chloride 99.01 
Potassium chloride 4.69 
Dipotassium phosphate 1.03 
Sodium bicarbonate 25 
Magnesium sulphate  1.2 
Calcium chloride dihydrate 2.5 
HEPES-sodium salt 20 
Glucose 5.6 
Table 4-10 Composition of Krebs-HEPES buffer 
HEPES = 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid. 
 
Using SoftMax® Pro (v5.4.5; Molecular Devices) software, fluorescence was 
detected using excitation at 500nm and at an emission wavelength of 600nm 
for two minutes, with readings taken every ten seconds. Prior experiments 
over longer durations had demonstrated that the fluorescent signal did not 
decay over this time period. A mean of all the readings taken over the two 
minutes, in duplicate, was calculated for the DHE-labelled wells and from 
this was subtracted the mean fluorescence in the unlabelled wells.  
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4.19 Western Blotting 
 
Western Blots were performed in conjunction with Dr Romana Mughal. I 
isolated and grew the murine PECs, prepared them for the experiment and 
performed the insulin stimulation. I lysed the cells and passed them to Dr 
Mughal, who then performed the protein quantification assay and processed 
the immunoblots. I then collated the images.  
 
 Sample Preparation 4.19.1
Pulmonary endothelial cells were isolated as outlined above and seeded 
onto 6-well plates coated with 20g/L gelatin. These underwent half media 
changes every alternate day until the cells reached 95% confluence, at 
which point they were rendered quiescent with the use of endothelial growth 
medium supplemented with 10mL/L foetal calf serum (FCS) overnight. The 
following morning, cells were washed with sterile PBS and then 1mL of basal 
PEC medium (with no serum) was added to each well. Some cells were 
stimulated with insulin (100µM working dilution of insulin in 25mM, pH 8.2 
HEPES) and others were left in their basal state. After 15 minutes at 37°C, 
cells were washed in ice-cold PBS twice to ensure cellular processes were 
arrested. Following this, they were harvested using cell scrapers in 100µL of 
radio-immunoprecipitation assay (RIPA) buffer (Table 4-11), supplemented 
with 100µL each of phosphatase inhibitors 2 and 3. Samples were 
immediately taken for storage at -80°C in 0.5mL microcentrifuge tubes. 
Samples were then passed to Dr Mughal. 
 
 Protein Quantification 4.19.2
Cell lysates were removed from freezer storage and defrosted on ice for 30 
minutes. They were then centrifuged at 15,000g for 10 minutes at 4°C before 
transferring supernatants to fresh microcentrifuge tubes and discarding the 
pellets. These supernatants were then loaded in a bicinchoninic acid (BCA) 
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assay for protein quantification using a commercially available assay kit. A 
sample from each lysate was diluted 1:8 using RIPA buffer (with protease 
and phosphatase inhibitors) and vortexed. These were measured in 
duplicate, in volumes of 25µL per well of a 96 well plate, alongside nine 
standards of bovine serum albumin (BSA) at known concentrations, also in 
duplicate. The BCA kit contained two reagents for colorimetry: reagent A 
(sodium carbonate, bicinchoninic acid and sodium tartrate in 0.1M sodium 
hydroxide) and reagent B (40g/L cupric sulphate). These were mixed in a 
50:1 (A:B) ratio and 200µL of the resulting mixture were pipetted into each 
well. The plate was covered and incubated in a 37°C environment for 30 
minutes. A Dynex MRX TC microplate reader and Revelation software 
(version 4.21) were used to perform colorimetric analysis at a wavelength of 
562nm. The BSA standards were used to construct a standard curve, which 
was appraised for linearity and correlation co-efficient (r2), the latter 
accepted only when > 0.99. Sample protein concentrations were inferred 
using this curve and values accepted at a co-efficient of variation (CV) 
between duplicates of < 10%. A correction was performed for the 1:8 dilution 
of the original lysate.  
 
 Gel Electrophoresis 4.19.3
Using the above protein concentrations, 10-15µg of each sample were 
diluted in loading dye (1:4) and sample reducing buffer (1:10) and then 
topped up to a loading volume of 40µL, if necessary, using RIPA buffer. 
These samples were heated at 95°C for five minutes, following which they 
were loaded into a pre-cast, commercially purchased polyacrylamide gel 
along with 6µL of a protein reference ladder. The gel was placed in a 
Criterion Cell tank (Bio-Rad) containing 500mL of running buffer, composed 
of 25mL of 2-(N-morpholino)ethanesulfonic acid/sodium dodecyl sulphate 
(MES SDS) running buffer and 475mL of de-ionised water. Electrophoresis 
was then performed at 100V for two hours or until the sample dye could be 
visualised at the bottom of the gel.  
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 Transfer 4.19.4
The electrophoresed gel was washed briefly in deionised water to remove 
traces of running buffer. Dry transfer of proteins to a nitrocellulose 
membrane was carried out using the iBlot system. The transfer pack was 
assembled so the membrane was sandwiched between filter paper and an 
anode and cathode. A plastic roller was used to remove any air bubbles 
which may hinder transfer to some areas of the membrane. The transfer was 
complete in seven minutes at the standard manufacturer program setting 
(P0).  
 
 Immunostaining 4.19.5
After protein transfer, the membrane was separated from the rest of the 
contents of the “sandwich” and washed in a blocking solution containing 
50g/L BSA in tris-buffered saline (TBST; 50mM Tris, 150mM NaCl, 1g/L 
Tween; pH 7.4) for five minutes. The membrane was then cut at relevant 
points with a clean scalpel using the protein ladder as a guide, so as to allow 
simultaneous immunostaining for more than one protein at different 
molecular weights. Each membrane was labelled using a pencil. Membranes 
were then incubated in 15mL of TBST for one hour at room temperature to 
block any non-specific binding sites.  
The primary antibody was prepared in a BSA-TBST solution at a dilution 
described in Table 4-12. The blocking solution was discarded at the end of 
the hour incubation, following which the primary antibody was applied and 
the specimen was incubated overnight at 4°C. The following morning, the 
antibody solution was recovered for repeat usage (up to three times). The 
membrane was then washed three times, for five minutes each, in TBST.  
The secondary antibody was then prepared (Table 4-12) in BSA-TBST. The 
membrane was incubated in the secondary antibody for one hour at room 
temperature. Following this, the antibody solution was discarded and the 
membrane washed three times in TBST for fifteen minutes each.  
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Finally, the membrane was removed from the universal container and 
carefully straightened out onto cling film. Each membrane was covered with 
1mL Immobilon Western Chemiluminescent HRP Substrate (500uL peroxide 
solution, 500uL enhancer solution) before exposure and imaging using the 
Syngene G imaging system.  
 
 Stripping Membranes 4.19.6
When phosphorylated Akt and eNOS were being probed, this could be done 
on the same membranes as those used for Akt and eNOS blots, by using a 
Restore PLUSTM Western Blot stripping buffer. Membranes were washed to 
remove the chemiluminescent substrate solution, then covered with 10mL of 
stripping buffer and incubated at room temperature under gentle agitation for 
10 minutes. Following this, they underwent three washes lasting five minutes 
each with TBST. They were then incubated in blocking solution (BSA-TBST) 
for an hour before being re-probed with new antibodies.   
 
 
 
 
 
 
 
Table 4-11 Constituents of RIPA Lysis Buffer 
EDTA = ethylenediamine tetraacetic acid; RIPA = radio-immunoprecipitation 
assay.  
Constituent Volume / /Mass 
Tris-hydrochloric acid 500mM 25mL 
Glycerol 20mL 
Distilled water 43mL 
EDTA 100mM 2mL 
Sodium dodecyl sulphate 2g 
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Protein Dilution Manufacturer 
Primary Antibodies 
Phosphorylated Akt (D9E) XP 
(Serine 473) 
1:2000 Cell Signaling #4060 
Total Akt (pan 11E7) 1:1000 Cell Signaling #4685 
Phosphorylated eNOS 
(Serine 1177) 
1:1000 BD Biosciences 
#612393 
Total eNOS 1:1000 BD Biosciences 
#610296 
Beta-actin 1:20,000 Cell Signaling #4970 
HRP-conjugated Secondary Antibodies 
Polyclonal goat anti-mouse 
IgG 
1:1000 Dako #P0161 
Polyclonal goat anti-rabbit 
IgG 
1:1000 Dako #P0217 
Table 4-12 Antibodies used in Western Blots 
eNOS = endothelial nitric oxide synthase; HRP = horseradish peroxidase 
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4.20  Statistical Analysis 
All continuous data sets are expressed as mean with standard error of mean 
(SEM) unless otherwise stated. Graphs and statistical analyses were 
performed using either GraphPad Prism v6 (2012) or Microsoft Excel 2007. 
For the majority of analyses, two-tailed unpaired or paired Student’s t-tests 
were performed as appropriate. For GTT and ITT analyses, the area under 
the curve (AUC) function was calculated. A p-value of <0.05 was deemed 
statistically significant and is represented with a * symbol.  
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Chapter 5 Results 
5.1 Genotyping 
Typical PCR gels for the HIRECO transgene (Figure 5-1) and IRKO cassette 
(Figure 5-2) are demonstrated, with a 1000 base pair ladder for reference.  
Figure 5-1 HIRECO PCR gel image 
DNA was extracted from ear notches and underwent PCR for the human 
insulin receptor endothelial cell overexpression (HIRECO) transgene, 
denoted by a single band at 762 base pairs (bp); wild-type denoted by 
absence of band. Controls on right. PCR = polymerase chain reaction.  
Figure 5-2 IRKO PCR gel image 
DNA was extracted from ear notches and underwent PCR for the Insulin 
receptor knockout (IRKO) gene cassette, denoted by a double band at 232 
and 255 base pairs (bp) with a single band at 235 bp for wild-type. Controls 
on right.  
762bp -> 
255bp ---> 
232bp  ---> 
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5.2 Viability and Morphology 
 
All mice were born at the expected Mendelian frequency and suffered no 
propensity towards increased rates of illness or death in adulthood. Total 
body weight (Figure 5-3) was not found to differ between WT, IRKO and 
HIRECOxIRKO mice. Despite non-significant differences in mass at an age 
of two months, weights converged again as the mice matured. Growth was 
found to plateau at four months, at which point there was no statistically 
significant difference in total body weight between IRKO [27.4 (0.4) g] and 
HIRECOxIRKO [28.3 (1.2) g]; p=0.48 (Figure 5-4).  
Wet organ weight from selected tissues was also recorded at the time of 
sacrifice. Again, no significant differences were observed in individual organ 
weights (normalised to total body weight), as shown in Figure 5-5.  
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Figure 5-3 Total body weight from 1-4 months  
(n=7,6,5) 
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Figure 5-4 Total body weight at four months  
(n=6,5) 
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Figure 5-5 Wet organ weight  
(n=6,5,6)  
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5.3 Metabolic Testing 
 
It has previously been demonstrated that IRKO mice have unperturbed 
glucose handling and insulin tolerance when compared with wild-type (WT) 
littermates [60]. In the current study, the metabolic parameters of fasted 
animals in the HIRECOxIRKO colony to glucose was ascertained using 
periodic capillary blood glucose measurements after the administration of 
intraperitoneal (IP) glucose or Actrapid insulin.  
 
HIRECOxIRKO mice were found to display a very similar profile to IRKO 
littermates after IP glucose injection (Figure 5-6), with no statistically 
significant difference noted in the area under the curve (AUC) analysis. 
Similar findings were noted in the insulin tolerance test (Figure 5-7). These 
findings suggest that, like IRKO mice, HIRECOxIRKO animals do not have 
glucose intolerance or diabetes.  
 
Another method for assessing insulin sensitivity is the measurement of 
plasma insulin concentration after an overnight fast. For this experiment, 
saphenous venepuncture was used to obtain whole blood for ELISA. The 
results (Figure 5-8) suggest no significant difference between IRKO [0.70 
(0.18) ng/mL] and HIRECOxIRKO [0.76 (0.14) ng/mL] mice; p=0.78.  
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Figure 5-6 Glucose Tolerance Test 
Mice were fasted overnight and then given 1mg/g intraperitoneal glucose. 
Capillary glucose measurements were taken at various time points after 
glucose challenge. Upper panel: dynamic tolerance test. Lower panel: area 
under curve. (n=7). 
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Figure 5-7 Insulin Tolerance Test 
Mice were fasted for four hours and then given 0.75 International Units/kg 
intraperitoneal Actrapid insulin. Capillary glucose measurements were taken 
at various time points after insulin challenge. Upper panel: dynamic 
tolerance test. Lower panel: area under curve. (n=10). 
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Figure 5-8 Plasma Insulin Concentration 
Whole blood was removed using saphenous vein puncture and insulin 
concentration was measured in plasma using an enzyme linked 
immunosorbent assay (ELISA) kit. (n=8).  
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5.4 Blood Pressure 
 
Previous research has demonstrated that systolic blood pressure is raised in 
IRKO mice compared with WT [60]. The same phenomenon was observed 
in the HIRECOxIRKO colony in the current project, as shown in Figure 5-9. 
Mean (SEM) systolic BP in WT was 94.8 (3.0) mmHg, with significantly 
higher readings in IRKO [105.9 (3.0) mmHg]; p=0.02. Interestingly, the mean 
systolic BP in HIRECOxIRKO mice was significantly lower than in IRKO 
[97.3 (2.5) mmHg], p=0.04. Blood pressure in HIRECOxIRKO mice was not 
significantly different from that in WT; p=0.53.  
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Figure 5-9 Systolic Blood Pressure  
Blood pressure was measured using tail-cuff plethysmography in conscious 
animals after two habituation sessions. (n=10,19,18). 
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5.5 Quantitative PCR 
Having established the viability and gross metabolic and in vivo vascular 
phenotype of the HIRECOxIRKO mouse, we sought to validate the relative 
expression of murine and human isoforms of the insulin receptor. IRKO are 
haploinsufficient for the murine isoform (mIR); HIRECOxIRKO have 
undergone no additional mIR manipulation so these mice were expected to 
show a similar pattern. Meanwhile, we hypothesised that expression of the 
human insulin receptor (hIR) would be targeted to endothelial cells in 
HIRECOxIRKO mice, with no detectable hIR mRNA in WT or IRKO. To 
examine insulin receptor expression, homogenised solid organs (lungs and 
aortae) and primary cultured endothelial cell lysates were used to perform 
quantitative PCR for mIR and hIR mRNA. Figure 5-10 shows that hIR mRNA 
was undetectable in solid organs harvested from WT and IRKO, confirming 
that insertion of the hIR transgene only affected HIRECOxIRKO mice.  
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Figure 5-10 Expression of human insulin receptor (hIR) in solid organs 
Whole organs were homogenised and RNA extracted. A SYBR Green probe 
was used to perform quantitative PCR using primers directed to the human 
insulin receptor. Quantified relative to beta-actin expression. (n=6,5,5 for 
lung; 3,2,5 for aorta). 
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Figure 5-11 Endothelial expression of human insulin receptor (hIR) 
Pulmonary endothelial cells (PEC) were cultured from murine lungs and 
harvested in Tri-reagent at passage 2. RNA was extracted and a SYBR 
Green probe was used to perform quantitative PCR using primers directed to 
the human insulin receptor. Quantified relative to beta-actin expression. 
(n=6,3,4). 
 
Figure 5-11 demonstrates that, as expected, expression of human insulin 
receptor mRNA in endothelial cells is targeted to HIRECOxIRKO mice, with 
no significant expression in lysates from WT and IRKO endothelial cells. 
Additionally, pilot experiments in our laboratory using monocytes from pure 
HIRECO mice have shown no detectable hIR mRNA, suggesting a lack of 
overlap with myeloid cells using the Tie-2 promoter strategy.  
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Figure 5-12 Endothelial expression of murine insulin receptor (mIR)  
Pulmonary endothelial cells (PEC) were cultured from murine lungs and 
harvested in Tri-reagent at passage 2. RNA was extracted and a Taqman® 
probe was used to perform quantitative PCR using primers directed to the 
murine insulin receptor. Quantified relative to beta-actin expression.  
(n=5,3,6). 
 
As demonstrated in Figure 5-12, the murine insulin receptor is 
downregulated in endothelial cells in IRKO mice, as expected. There was no 
significant recovery in mIR mRNA levels in HIRECOxIRKO endothelial cells. 
These experiments confirm that the hIR is only expressed in HIRECOxIRKO 
mice and these animals appear to show similar levels of endothelial mIR 
expression to IRKO. 
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5.6 Vascular Injury  
 
IRKO mice exhibit impaired vascular repair after denuding arterial wire injury 
[164]. In the current study, HIRECOxIRKO mice appeared to show rescue of 
this impairment [57.8 (3.4) % regenerated] compared with IRKO [47.5 (3.3) 
%]; p=0.04. This represented a return to the level of repair seen in WT mice 
[54.1 (3.3) %]; p=0.50. The summary data are presented in Figure 5-13 and 
representative images from each genotype are shown in Figure 5-14. 
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Figure 5-13 Endothelial Regeneration after Vascular Injury  
Mice underwent denuding femoral artery injury and vessels explanted at day 
four were stained with Evans Blue dye, allowing measurement of percentage 
endothelial regeneration. (n=6,14,12).  
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Figure 5-14 Representative images of femoral arterial injury 
Magnification: x20. Areas stained with Evans Blue denote ongoing 
denudation. Red lines demonstrate details of analysis. Upper panel = Wild-
type 212. Middle panel = IRKO 647. Lower panel = HIRECOxIRKO 186. 
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5.7 Circulating EPC enumeration  
 
One of the postulated mechanisms for impaired vascular repair in IRKO 
mice in the Kahn et al study was that IRKO had reduced numbers of 
circulating progenitor cells (CPC) co-expressing stem cell antigen-1 (Sca1) 
and foetal liver kinase-1 (Flk1) compared with WT. This was recapitulated in 
the current study: WT mice had a mean (SEM) of 235.5 (44.4) per 100,000 
mononuclear cells compared with a mean (SEM) in IRKO of 104.9 (14.9) per 
100,000; p=0.01. However, there was no significant improvement in CPC 
numbers in HIRECOxIRKO [99.0 (9.8) per 100,000]; p=0.74. These results 
are presented graphically in Figure 5-15 with representative images in 
Figure 5-17. 
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Figure 5-15 Circulating Progenitor Cells (CPC) expressing Sca1 and 
Flk1 
Whole blood was removed from mice using saphenous venepuncture. 
Samples were labelled with antibodies directed at Stem cell antigen 1 (Sca1) 
and Foetal liver kinase 1 (Flk1) and underwent fluorescence activated cell 
sorting.  (n=7,8,9).  
 
In the study by Kahn et al, vascular repair in IRKO mice could be restored to 
the level of WT by infusing mononuclear cells expressing the c-kit surface 
antigen (CD117) derived from WT mice [164]. However, the authors did not 
look for differences in numbers of these cells between WT and IRKO mice. 
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For this reason, numbers of mononuclear cells expressing c-kit were 
appraised in all three genotypes in the current study. No significant 
difference was seen: WT [229.5 (41.3) per 100,000 cells], IRKO [212.5 
(43.9)], HIRECOxIRKO [208.9 (30.0)]. These are presented graphically in 
Figure 5-16 with representative images in Figure 5-17. 
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Figure 5-16 Circulating progenitor cells (CPC) expressing c-kit  
Whole blood was removed from mice using saphenous venepuncture. 
Samples were labelled with antibodies directed at c-kit and underwent 
fluorescence activated cell sorting. (n=8,7,9). 
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Figure 5-17  Representative FACS images 
Left hand panels: labelled for Stem cell antigen 1 (Sca1) and Foetal liver 
kinase 1 (Flk1). Right hand panels: labelled for c-kit. Upper panels WT, 
middle panels IRKO, lower panels HIRECOxIRKO.   
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5.8 Early outgrowth EPC culture and enumeration 
As discussed in Chapter 1, EPCs can be isolated using a variety of 
techniques and the cells derived exhibit different behaviours. For this 
reason, we sought to quantify and assess early outgrowth EPCs using dual 
DiI-ac-LDL and lectin-FITC staining as an alternative to simply using flow 
cytometric definitions in our appraisal of progenitor cells. Previous work has 
demonstrated that blood-derived EPCs are fewer in number in IRKO mice, 
despite similar quantities in bone marrow and spleen [164].  
In the current study, it was difficult to culture EPCs from the blood of 
HIRECOxIRKO [0.42 (0.11) EPCs per high-powered field] and IRKO [0.44 
(0.16)]; p=0.91. EPCs were more numerous in WT blood [3.82 (1.09)]; 
p=0.03 for both comparisons with WT (Figure 5-18). The numbers of EPCs 
cultured from spleen and bone marrow were not significantly different across 
the three genotypes (Figure 5-19). 
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Figure 5-18 Endothelial Progenitor Cell (EPC) enumeration in blood 
EPCs were isolated from an inferior vena cava bleed using density gradient 
centrifugation. After seven days in culture, surviving cells from the 
mononuclear layer were dual labelled with DiI-acetylated-LDL and FITC-
lectin. HPF = high powered field. (n=5,5,6). 
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Figure 5-19 EPC enumeration in marrow and spleen 
EPCs were isolated from femoral and tibial bone marrow (upper panel; 
n=5,11,10) and spleens (lower panel; n=5,10,10) as in Figure 5-18. 
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5.9 EPC function (Scratch Wound Assay) 
The above experiments allow an estimation of the impact of endothelial 
insulin sensitisation on the number of EPCs in culture or in circulation. To 
extend this, EPC paracrine function was assessed using their ability to 
influence healing of a scratch wound in endothelial cells. HUVECS exposed 
to conditioned media from WT, IRKO and HIRECOxIRKO mice showed 
similar scratch wound closure, suggesting no alterations in this aspect of 
EPC function. The results are displayed in Figure 5-20.  
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Figure 5-20 Scratch wound closure with EPC conditioned media 
Endothelial progenitor cells (EPC) isolated from spleens using density 
gradient centrifugation were cultured for four days and used to condition 
basal EPC medium for 24 hours. Conditioned media from each genotype 
were applied to human umbilical vein endothelial cells subjected to a 
mechanical scratch wound using the IncuCyteTM system. The data show the 
area under curve metric for relative wound density after 12 hours. (n=5,5,6). 
Page | 175 
 
5.10 Endothelial Cell Proliferation 
HIRECOxIRKO mice show improved vascular repair. The findings in 
Chapters 5.7 and 5.8 suggest the mechanism is unlikely to relate to 
increased EPC production. Therefore, we postulated that HIRECOxIRKO 
endothelial cells may have enhanced proliferative and/or migratory capacity. 
To assess proliferation, EdU uptake was assessed in PECs. The results are 
presented in Figure 5-21. The mean (SEM) percentage of proliferating cells 
seen in WT [6.4 (1.0) %] and IRKO [6.1 (0.6) %] were similar; p=0.79. 
However, HIRECOxIRKO PECs [10.5 (1.5) %] showed significantly more 
proliferation than WT (p=0.04) or IRKO (p=0.03).  
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Figure 5-21 Endothelial cell proliferation  
Pulmonary endothelial cells (PEC) at passage 2 were incubated with EdU in 
a Click-iT® kit assay; proliferating cells were counted using fluorescence 
microscopy. (n=10,8,11).  
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5.11 Endothelial Cell Migration 
 Boyden Chamber Assay 5.11.1
An alternative mechanism for improved repair in the HIRECOxIRKO model 
could be enhanced migration of endothelial cells. This was assessed using 
the modified Boyden chamber assay described in Chapter 3.14. In WT cells, 
net migration to VEGF [7.3 (1.8) migrating cells] was significantly higher than 
in IRKO [1.9 (1.2); p=0.02]. HIRECOxIRKO cells migrated significantly more 
than IRKO [6.3 (1.3); p=0.03], to levels similar to those seen in WT (p=0.65). 
The results are presented in Figure 5-22 with sample images in Figure 5-23.  
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Figure 5-22 Endothelial cell migration (Boyden chamber) 
Pulmonary endothelial cells (PEC) at passage 2 were used in modified 
Boyden chamber assays. Control wells contained low-serum PEC medium 
and the remainder contained 50ng/mL vascular endothelial growth factor 
(VEGF). Migrating cells were counted after 24 hours using haematoxylin and 
eosin; the data show net number of migrating cells (n=9). 
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Figure 5-23 Representative Boyden Chamber Images 
Images from wells containing vascular endothelial growth factor at 50ng/mL. 
Upper panel = WT 765, middle panel = IRKO 781, lower panel = 
HIRECOxIRKO 771.  
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 Scratch Wound assay 5.11.2
 
An alternative method for assessing cell migration involves measuring 
relative wound density; in this case, 12 hours after forming a mechanical 
scratch wound on a confluent cell layer. In this project, the IncuCyteTM was 
used for incubation and imaging as described in Chapter 5. This experiment 
was commenced towards the latter end of this project and data remain 
variable; results to date are presented in Figure 5-24. These data suggest a 
trend towards a subtle reduction in migration in IRKO PECs with potential 
recovery in HIRECOxIRKO, though it is difficult to comment with certainty.  
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Figure 5-24 Endothelial cell migration (scratch wound) 
Pulmonary endothelial cells (PEC) at passage 2 underwent mechanical 
scratch wound creation and imaging was undertaken using the IncuCyteTM 
system. The data represent the area under curve metric for relative wound 
density after 12 hours. (n=8,8,6). 
WT 765 
IRKO 781 
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5.12 Aortic vasomotor studies (organ bath) 
 
In a previous study by Wheatcroft et al [60], the response of IRKO-derived 
aortic rings was appraised in depth and it was found that IRKO aortae 
showed a loss of insulin-induced vasodilatation. Furthermore, rings 
incubated with L-NMMA, a NOS inhibitor, showed the expected incremental 
rise in tension in WT but not IRKO aortae, suggesting diminished nitric oxide 
bioavailability in IRKO mice. In the current study, we sought to assess the 
same set of responses in HIRECOxIRKO rings.  
 
Initially, rings were exposed to sodium nitroprusside (SNP), a NO donor that 
exerts vasodilator effects by releasing NO and causing vascular smooth 
muscle relaxation in an endothelium-independent manner. As expected, 
there were no differences in SNP-mediated vasodilatation between WT, 
IRKO and HIRECOxIRKO rings (Figure 5-25). However, IRKO rings showed 
increased tension when pre-constricted with phenylephrine (PE; Figure 5-26) 
and blunted vasodilatation when exposed to acetylcholine (ACh;  
Figure 5-27) in comparison with WT and HIRECOxIRKO.  
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Figure 5-25 Cumulative relaxation of aortic rings to sodium 
nitroprusside (SNP) 
Aortae were excised from mice and transported to the laboratory in Krebs-
Henseleit medium. These were stripped of adipose tissue and four rings per 
mouse mounted in an organ bath apparatus. Rings were pre-constricted with 
incremental doses of phenylephrine (PE) and then tension was measured at 
various concentrations of SNP. (n=4,7,6). 
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Figure 5-26 Cumulative constriction of aortic rings to phenylephrine 
Aortic rings were prepared as in Figure 5-25. This figure represents the 
constriction response to incremental doses of phenylephrine (PE). 
(n=7,10,8). 
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Figure 5-27 Cumulative relaxation of aortic rings to acetylcholine 
Aortic rings were prepared as in Figure 5-25. After pre-constriction with 
phenylephrine (PE), tension was measured at increasing concentrations of 
acetylcholine (ACh). (n=7,10,8). 
 
As well as appraising the degree of divergence in constriction and relaxation 
curves, one can compare vasomotor responses using the concentration of 
agonist required to achieve 50% contraction or relaxation (EC50). For PE-
mediated vasoconstriction, the mean (SEM) EC50 was significantly lower in 
IRKO rings [6.5x10-7 (7.5x10-8) nM]  than in WT [1.1x10-6 (1.0x10-7) nM; 
p<0.01] and HIRECOxIRKO [9.1x10-7 (6.6x10-8) nM; p=0.03], demonstrating 
a greater propensity towards constriction in IRKO and, therefore, endothelial 
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dysfunction (Figure 5-28). This was corrected to WT levels in the 
HIRECOxIRKO model (p=0.22). The EC50 was not significantly higher for 
ACh-mediated vasorelaxation in IRKO [8.2x10-7 (1.4x10-7) nM] compared 
with WT [6.4x10-7 (2.4x10-7) nM; p=0.49]. However, HIRECOxIRKO rings 
showed a significantly lower EC50 for ACh [3.7x10
-7 (6.1x10-8) nM; p=0.02], 
suggesting improved endothelial vasomotor function in these mice (Figure 
5-29).  
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Figure 5-28 Phenylephrine dose required for 50% ring constriction 
(EC50) 
PE = phenylephrine. (n=7,10,8). 
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Figure 5-29 Acetylcholine dose required for 50% ring relaxation (EC50) 
ACh = acetylcholine. (n=7,10,8). 
 
Taken together, the organ bath results corroborate the previously 
demonstrated finding of endothelial dysfunction in IRKO vasculature, with 
restoration of PE-mediated vasoconstriction and ACh-mediated 
vasodilatation in HIRECOxIRKO rings. Furthermore, there was no difference 
in the behaviour of HIRECOxIRKO compared with WT, suggesting 
restoration of vasomotor function to WT levels. 
 
Given that NO was implicated in the endothelial dysfunction observed in 
IRKO [60], we sought to assess the role of NO in the rescue seen in 
HIRECOxIRKO, by measuring PE-mediated constriction of aortic rings 
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before and after incubation with L-NMMA. This compound should inhibit the 
activity of any NOS present and reduce local NO production, resulting in a 
significant drop in EC50. The lack of such a decrement would suggest 
reduced NO availability.   
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Figure 5-30 Phenylephrine dose for 50% constriction (EC50) after L-
NMMA 
Aortic rings were prepared as in Figure 5-25. The constriction response to 
incremental doses of phenylephrine (PE) was measured before and after a 
two-hour incubation with levo N-monomethyl arginine (L-NMMA). The EC50 
for constriction to PE was compared before and after L-NMMA.  
HxI = HIRECOxIRKO. (n=5). 
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As previously demonstrated, there was no difference in the EC50 for PE-
mediated constriction in IRKO aortic rings after incubation with L-NMMA, 
suggesting a lack of NO bioavailability. However, the HIRECOxIRKO rings 
showed a significant decrement in EC50 after incubation with L-NMMA: less 
PE was required to constrict the rings to 50%, suggesting that these vessels 
contained bioavailable NO at baseline (Figure 5-30). These findings highlight 
a potential role for NOS and NO in the rescue of endothelial function in the 
HIRECOxIRKO model.  
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5.13 Reactive Oxygen Species 
Previous work in IRKO mice has shown increased ROS [115, 123] so it was 
postulated that a molecular mechanism behind restored endothelial function 
in HIRECOxIRKO mice could be a reduction in ROS levels. Superoxide 
concentration was measured in PECs with a fluorescence-based assay 
using dihydroethidium. Numbers are small and further work is required, but 
there is a trend towards increased ROS in IRKO [5.9 (1.3) arbitrary units] 
compared with WT [3.2 (0.6) AU; p=0.08]. HIRECOxIRKO PECs do not 
appear to generate any less ROS than IRKO [7.1 (2.0) AU; p=0.63] and in 
fact display significantly raised levels compared with WT (p=0.04). The 
interim results are presented graphically in Figure 5-31.  
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Figure 5-31 Superoxide concentration in endothelial cells  
Pulmonary endothelial cells (PEC) at passage 2 were labelled with 
dihydroethidium in Krebs-HEPES buffer. Fluorescence was measured on a 
microplate reader after a 20 minute incubation. (n=6,5,3). 
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5.14 Intracellular Signalling 
Several results obtained in this project could be argued to result from 
increased bioavailability of nitric oxide (NO), perhaps as a result of 
enhanced insulin signalling in endothelial cells from HIRECOxIRKO mice. In 
order to interrogate this, Western blots were performed to assess basal and 
insulin-stimulated expression of Akt and eNOS, both of which are relevant to 
the PI3K signalling pathway that culminates in generation of NO. 
Unfortunately, optimisation of this experiment is ongoing and only one set of 
samples was satisfactorily processed. The preliminary results, displayed in 
Figure 5-32, suggest that there may be partial rescue of insulin signalling at 
the Akt level but without a convincing rise in eNOS phosphorylation. 
Figure 5-32 Preliminary Western blot showing differential intracellular 
insulin signalling  
eNOS = endothelial nitric oxide synthase; Akt = protein kinase B; prefix “p-“ 
denotes phosphorylated form (serine 1177 for eNOS and serine 473 for Akt). 
Insulin stimulation with 100nM Actrapid for 15 minutes. (n=1).  
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Chapter 6 Discussion 
 
6.1 Summary of key findings 
 
In this study, we have built upon existing literature surrounding the effects of 
insulin resistance on endothelial function and vascular repair and explored 
the validity of endothelial insulin sensitisation as a potential therapeutic 
target. To address this, we created a murine model overexpressing the 
human isoform of the insulin receptor in endothelial cells, with a systemically 
insulin resistant background. Using a variety of in vivo, ex vivo and in vitro 
methods, we have studied the effects of this manipulation on various 
elements of vascular biology. 
 
The HIRECOxIRKO mouse has been shown to be a viable model with no 
gross metabolic differences compared with IRKO littermate controls. 
Quantitative PCR has confirmed that the human insulin receptor transgene 
is expressed in the endothelial cells of the HIRECOxIRKO mouse.  
 
In a model of femoral artery wire injury, we have demonstrated that 
HIRECOxIRKO mice have restored vascular repair to the levels of their WT 
counterparts. This improvement is not associated with any alteration in EPC 
numbers or function, but instead is accompanied by enhanced endothelial 
cell migration to VEGF and, perhaps, increased proliferative capacity.  
 
HIRECOxIRKO mice also have reduced blood pressure compared with 
IRKO, again to levels similar to WT littermates; in keeping with this, 
experiments using aortic rings show a reversal of the endothelial dysfunction 
seen in IRKO vessels. This appears to be related to augmented NO 
bioavailability, perhaps resulting from enhanced insulin signalling.  
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6.2 Validation of model and metabolic assessment 
 
 Background 6.2.1
 
Insulin receptor knockout (IRKO) mice are globally haploinsufficient for the 
insulin receptor and display preserved metabolic parameters [60] with a 30% 
reduction in insulin signalling [66]; as such, they represent a reasonable 
approximation to the human metabolic syndrome. Accordingly, they display 
hypertension and endothelial dysfunction [60], and much of our 
understanding of vascular disease in the context of insulin resistance per se 
comes from this model as a result. It could be argued that their lack of 
obesity or hyperlipidaemia [60] makes them less representative of the 
human metabolic syndrome than perhaps animal models of high fat diet-
induced insulin resistance. Conversely, it could be said that the benefit of 
this relatively undisturbed metabolism is that it allows us to consider the 
specific contribution of insulin resistance to vascular derangements without 
introducing the confounding that can arise from other elements of the 
metabolic syndrome. Despite normal glucoregulation, IRKO mice display 
endothelial dysfunction and impaired vascular repair after denuding arterial 
injury, suggesting a key role for perturbed insulin signalling in the causation 
of vascular disease [60, 164]. The VENIRKO and ESMIRO models help to 
consolidate our understanding of the endothelium as a key regular of 
vascular health and demonstrate that limiting insulin resistance to this 
location is sufficient to result in vasomotor dysfunction, oxidative stress and 
deranged angiogenesis [113, 114, 123]. These findings lend theoretical 
validation to the study of the endothelium as a therapeutic target.  
 
 Targeting insulin sensitivity to the endothelium 6.2.2
 
This project was focussed on the study of a mouse with systemic insulin 
resistance and somewhat preserved endothelial insulin responsiveness. In 
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order to achieve this combination of insulin sensitivity and resistance, our 
laboratory group had previously established a colony of HIRECO mice with 
overexpression of the human insulin receptor targeted to endothelial cells 
using a Tie-2 promoter. Tie-2 was initially discovered in 1992 as a relatively 
endothelium-specific receptor tyrosine kinase, though it was identified as 
being expressed in endothelial precursors as well [183]. The Tie-2 promoter 
strategy has been used to target the endothelium in the past [184]and 
various authors have attempted to validate its endothelial specificity by 
labelling with green fluorescent protein in a selection of tissues; these have 
suggested predominantly vascular expression, greater in the arterial than in 
the venous compartment of the circulation  [179, 185]. The crossover into 
mononuclear cells (and therefore EPCs) remains a potential limitation of this 
strategy, though in this specific project it would not necessarily have a 
negative impact on the model due to the implication of EPCs as regulators of 
impaired vascular repair in IRKO mice [164]. Furthermore, our laboratory’s 
previous work (unpublished) on pure HIRECO mice has shown no 
detectable hIR mRNA in myeloid cells from these mice, suggesting that 
HIRECOxIRKO monocytes and EPCs are also unlikely to be affected by the 
insertion of the hIR transgene.  
 
The Tie-2 strategy has been used in our laboratory group to render the 
endothelium insulin resistant (the ESMIRO mouse; [114]) and to 
overexpress the insulin like growth factor-1 (IGF-1) receptor in endothelium 
[186], following other groups’ demonstration that targeting the Tie-2 
promoter to the Hprt locus results in effective vascular expression of the 
transgene of interest [187]. We postulated that the sensitisation of 
endothelial cells to insulin signalling could rescue the vascular impairments 
seen in systemic insulin resistance, and thus bred HIRECO mice with IRKO 
to generate the HIRECOxIRKO “double-cross”.  
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 Viability of the HIRECOxIRKO model 6.2.3
 
We established the viability and unaltered growth profile of the 
HIRECOxIRKO model early in the study. Body weight tended to plateau at 
around four months in WT, IRKO and HIRECOxIRKO mice and no 
differences were noted in growth or physical development between the three 
genotypes over this time period. Similar results were noted in terms of wet 
organ weight. These were not especially surprising findings, but identified 
the HIRECOxIRKO model as a viable one in which to perform more detailed 
phenotyping.  
 
 Metabolic assessment 6.2.4
 
Glucose and insulin tolerance testing confirmed that these mice were not 
diabetic and in fact displayed similar metabolism to IRKO littermates, 
allowing us to infer that any differences seen in their vascular parameters 
were unlikely to result from improved glucose clearance. It was 
acknowledged that the use of capillary blood glucose measurements is 
prone to error and therefore we also confirmed that fasting plasma insulin 
concentrations were similar in IRKO and HIRECOxIRKO using ELISA. In this 
technique, one can directly measure insulin levels as opposed to using 
changes in glucose concentration as a surrogate metric for insulin sensitivity. 
This method has the additional advantage of allowing comparison of study 
samples against robust standards. Furthermore, specimens for ELISA are 
plated in duplicate and only those with a low coefficient of variation between 
replicates are accepted, introducing a level of quality control that is difficult to 
achieve using the cruder method of capillary glucose measurement. The use 
of a euglycaemic-hyperinsulinaemic clamp would represent the gold-
standard for measuring insulin sensitivity but, as this cannot be performed at 
our institution, there would need to be a compelling indication for exposing 
animals to the stresses involved in transport and, indeed, an invasive 
procedure. We elected not to perform this experiment as no gross 
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differences had been noted in basic metabolic parameters. A potential 
further limitation in terms of metabolic phenotyping is that plasma 
concentrations of free fatty acids and triglycerides were not determined in 
this project; however, no differences were seen on appraisal of lipids in 
previous work in IRKO mice [60] so there was no obvious reason to suspect 
a difference in HIRECOxIRKO. Again, from the perspective of animal 
welfare, it was deemed prudent to keep blood testing to a minimum as a 
relatively large volume of whole blood was often only sufficient for one 
ELISA due to the need to isolate the plasma fraction, and multiple bleeds 
would have been necessary to investigate a variety of lipid-related 
parameters. Overall, it was felt that the data presented were sufficiently 
reassuring to allow us to discount significant metabolic alterations as the 
causative agents in any improvements noted in vascular endothelial function 
in HIRECOxIRKO mice.  
 
 Endothelial specificity 6.2.5
 
Finally, we sought to characterise the expression of the human and murine 
insulin receptors in endothelial cells and other body tissues. The results of 
quantitative PCR for the human isoform of the insulin receptor (hIR) were 
reassuring as this was only detectable in lungs and aortae from 
HIRECOxIRKO mice and could not be found at all in the organs tested from 
WT or IRKO littermates. When assessing cultured pulmonary endothelial 
cells (PECs), no hIR mRNA was identified in WT or IRKO, whereas 
expression was evident in HIRECOxIRKO cells. These findings suggested 
that the primer used to identify the hIR was sufficiently specific for the 
human isoform and did not show significant cross-reactivity with the murine 
receptor (mIR). Additionally, the finding that hIR expression in endothelial 
cells was essentially limited to HIRECOxIRKO PECs provided some 
preliminary reassurance that our method for isolating endothelial cells was 
indeed providing a reasonably pure population. It would be interesting to 
isolate a population of cells that is essentially devoid of endothelial cells and 
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quantify hIR mRNA here to confirm a lack of expression in the non-
endothelial fragment. However, even this approach could only go some way 
to demonstrating specificity, unless many distinct cell lineages were 
assessed. It is also reassuring to note that in pure HIRECO mice, myeloid 
cells isolated using a CD11b antibody showed no detectable hIR mRNA, 
suggesting that the cell lineage most likely to be affected by lack of Tie-2 
specificity does not suffer from this limitation.  
 
As expected, mRNA expression of the mIR was downregulated in IRKO 
endothelial cells. This was also the case in HIRECOxIRKO PECs and 
suggests that insertion of the hIR transgene is unlikely to have caused a 
large scale alteration in transcription of its murine counterpart. Thus, the 
insertion of human receptors is likely to have increased the total insulin 
receptor protein in HIRECOxIRKO compared with what is expressed on 
IRKO endothelium. Relative quantification of these receptors (or indeed total 
insulin receptor expression) is not feasible using PCR. A very crude estimate 
could be made using the mRNA quantity relative to a housekeeping gene 
such as beta-actin. For example, the relative expression of mIR mRNA in 
HIRECOxIRKO PECs was observed to be in the order of 0.25 times that of 
beta-actin, whereas the corresponding RQ for the human receptor was 
approximately 0.06. On initial appraisal, this may suggest that the insertion 
of the hIR results in a very slight improvement in total insulin receptor 
expression in endothelial cells rather than a full restoration to the level of 
WT. However, this assertion must be regarded with caution. A SYBR green 
probe was used for hIR quantification whereas a Taqman® probe was used 
for the mIR. Additionally, there is a reasonably large degree of error in the 
PCR results, again making it difficult to draw any conclusions beyond the 
binary appraisal of presence versus absence of the human receptor in 
HIRECOxIRKO cells.  
 
Future work to ascertain total insulin receptor protein could include the use 
of Western blotting with densitometry, or quantitative immunofluorescence, 
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using antibodies that do not differentiate between the murine and human 
isoforms of the receptor. We are in the process of evaluating anti-insulin 
receptor antibodies that are in use in our laboratory for this purpose, and aim 
to perform one or both of these techniques to investigate total receptor 
protein in endothelial cells once such products and protocols have been 
sufficiently validated. These experiments may be limited by the fact that 
there is unlikely to be an antibody that has equal affinity for the human and 
murine insulin receptors; they may therefore highlight large differences 
between genotypes simply by virtue of differential affinity for human and 
murine proteins. An approximation of functional insulin receptor expression 
may alternatively be gained through detailed comparison of downstream 
signalling mediators using immunoblotting. Preliminary data using this 
approach will be discussed in more detail below.  
 
 
 Summary 6.2.6
 
We have established the HIRECOxIRKO mouse as a viable model that can 
be used to study the impact of endothelial insulin sensitisation in the context 
of global insulin resistance. Quantitative PCR suggests that the strategy of 
using a Tie-2 promoter to target the human insulin receptor to endothelial 
cells is valid in these mice, with no significant detectable hIR in WT or IRKO 
organs or cells. HIRECOxIRKO mice display broadly similar metabolic 
parameters to IRKO mice, suggesting that any improvements seen in 
vascular health are likely to result from restoration of endothelial insulin 
signalling rather than ameliorations in glucoregulation or insulin sensitivity. 
With certain caveats, these early data represent sufficient validation of the 
model to allow further detailed assessment of the vascular phenotype, which 
will be discussed in the next section.  
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6.3 Vascular repair 
 
 Background 6.3.1
 
Within the spectrum of insulin resistance and diabetes, several pathological 
processes can induce vascular injury, including (but not limited to) 
endothelial cell toxicity from chronic hyperglycaemia, as well as acute events 
such as atherosclerotic plaque rupture. An appropriate physiological 
response to injury is critical in mediating effective endothelial healing; this 
can be studied using models such as femoral arterial wire injury, a technique 
which causes acute and localised endothelial denudation in animals akin to 
that seen in humans, and with which our laboratory group is experienced. In 
previous work from our laboratory, convincing data showed that IRKO mice 
exhibited delayed vascular repair at several time points up to and including 
14 days after wire injury [164]. These data support observations of impaired 
vascular repair in diabetic mice [163], obese, insulin-resistant rats [151] and 
even in insulin-sensitive rats exposed to high concentrations of exogenously 
administered insulin [150]. Diet-induced obesity can also impair vascular 
function in mice: previous work has described increased oxidative stress and 
reduced EPC numbers as noted in IRKO mice, associated with impaired 
angiogenesis after hind limb ischaemia [188]. The phenomenon of reduced 
vascular repair also appears to be relevant in terms of gross pathological 
sequelae: loss of endothelial insulin signalling in a mouse model prone to 
atherosclerosis has been shown to increase atheroma formation [189]. We 
hypothesised that restoring endothelial insulin sensitivity in the context of 
global insulin resistance would restore vascular reparative mechanisms, 
using femoral arterial wire injury as our model. In the current project, we 
picked a four day time point for analysis because a clear divergence was 
observed after three days between WT and IRKO mice in the Kahn et al 
study and it was deemed unreasonable to keep mice alive with an injured 
limb for any longer than necessary, from the perspective of animal welfare.  
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One of the most exciting results of the current project is the demonstration 
that HIRECOxIRKO mice display improved vascular repair compared with 
IRKO littermates; indeed, the degree of recovery observed in 
HIRECOxIRKO was not significantly different to that documented in WT 
mice. A major portion of this project was therefore dedicated to trying to 
understand the mechanisms of enhanced vascular repair in this model and 
to dissect out the relative contributions of endothelial cells and EPCs in the 
augmented healing process.  
 
 Role of EPCs 6.3.2
 
Our laboratory group has previously published evidence in favour of the 
theory that insulin resistance specifically impairs EPC-mediated vascular 
repair [164]. Numbers of circulating progenitor cells (defined as co-
expressing Sca1 and Flk1) were significantly reduced in IRKO mice and the 
same population of cells displayed reduced mobilisation potential after the 
intraperitoneal administration of VEGF. Furthermore, culture-derived EPCs 
were seen in similar quantities in haematopoietic tissues such as bone 
marrow and spleen, whereas numbers of blood-derived EPCs were 
significantly lower. Bone marrow lysates from IRKO mice entirely lacked 
detectable eNOS, which has previously been demonstrated as essential for 
EPC mobilisation in mice [190] and in humans [165]. Finally, the transfusion 
of c-kit-positive cells from WT mice could restore post-injury healing to 
normal WT levels, with only partial recovery when the transfused progenitor 
cells were derived from IRKO mice. Thus, using various distinct and 
complementary techniques, Kahn et al described a potential pathogenetic 
mechanism: IRKO mice display a defect in EPC mobilisation despite 
adequate production in the reticuloendothelial system, with partial recovery 
after the transfusion of cells with a progenitor phenotype [164]. However, this 
study did not address the influence of insulin resistance on the function of 
mature endothelial cells, such as the potential impact on migration and 
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proliferation; therefore, the findings do not rule out a role for additional 
disturbances in endothelial cell-mediated repair.  
 
The wider data regarding EPC-mediated versus endothelial cell-mediated 
dysfunction in insulin resistance are equivocal, as discussed in detail in 
Chapter 1.4.4. There appears to be little doubt that both the number and in 
vitro function of EPCs are disturbed in the insulin resistance spectrum, both 
in humans and in various in vivo animal studies. These support Kahn et al in 
the assertion that EPC dysfunction represents a relevant determinant of the 
impaired response to vascular injury [165, 173, 174]. EPCs derived from 
patients with diabetes have been shown to support re-endothelialisation after 
carotid artery injury in mice less well than EPCs from healthy volunteers; 
furthermore, EPCs from diabetic subjects taking rosiglitazone could rescue 
the deficit, suggesting that insulin sensitisation of these cells can be 
beneficial in restoring vascular repair [191]. Coupled with these findings is 
the observation that endothelial cells are terminally differentiated and may 
therefore not necessarily be expected to participate in very significant 
degrees of proliferation, whereas EPCs may yet differentiate into mature 
endothelial cells at sites of injury or at least provide paracrine support for the 
native endothelium. Conversely, however, other groups have found that 
mature endothelial cells are more relevant in the process of recovery after 
injury, with a limited role for EPCs [156]. The reality may be a compromise 
between the two viewpoints, wherein EPCs are relevant but perhaps do not 
incorporate into wounded vessels, instead establishing a supportive role and 
providing a paracrine milieu that favours healing in native endothelial cells, 
indirectly modulating the response to vascular injury.  
 
Based on the balance of available evidence at the time of planning 
experiments, we hypothesised that the augmented recovery seen in the 
HIRECOxIRKO model would be associated with some degree of 
improvement in the profile of EPCs. However, our experiments using both 
flow cytometry and early outgrowth EPC culture showed no enhancement in 
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EPC numbers in the HIRECOxIRKO mouse; this finding gave an early 
indication that an alternative reparative mechanism was more likely in our 
model. As well as quantifying early outgrowth EPCs in culture and 
enumerating CPCs co-expressing Sca1 and Flk1, we appraised the numbers 
of circulating c-kit-positive cells and found no difference here across the 
three genotypes. As a result of these preliminary experiments, we elected 
not to assess CPC mobilisation to VEGF, interrogate bone marrow lysates 
for eNOS or carry out transfusion studies. The findings may not be surprising 
in this specific context: as well as the conflicting nature of the data 
surrounding EPC dysfunction in vascular repair, another possible reason is 
that an endothelial restricted intervention may not be capable of influencing 
bone marrow-derived cells. With highly selective expression of the hIR in 
endothelium, it could be envisaged that transgene insertion did not affect 
EPCs; therefore, one would not necessarily expect any alteration in their 
numbers or function in our model. One could argue that increased IR 
expression in the bone marrow could restore local eNOS production without 
directly influencing EPCs themselves, thus encouraging more effective EPC 
mobilisation; however, the lack of EPCs or CPCs in blood in our model 
suggests that this putative recovery mechanism was also not relevant in the 
HIRECOxIRKO. Our findings do not necessarily argue against the 
established role of EPC dysfunction in the pathogenesis of impaired vascular 
repair in the IRKO model; rather they suggest that multiple mechanisms may 
be relevant in that pathological setting and that recovery in the context of our 
specific genetic manipulation is likely to be brought about by alternative 
phenomena.  
 
These experiments do not, however, fully exclude alterations in EPC biology 
in the HIRECOxIRKO mouse. Firstly, we only assessed flow cytometrically-
defined CPCs and early outgrowth EPCs in this project. Both of these cell 
types have unclear in vivo relevance and, despite their status as useful 
biomarkers in cardiovascular health, they may not represent the spectrum of 
endothelial progenitors as a whole. We also cannot fully exclude the 
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possibility that EPC function, in contrast to abundance, was improved in 
HIRECOxIRKO mice as we only used one method for modelling this: the 
effects of conditioned EPC media on endothelial scratch wound healing. This 
assay was carried out using HUVECs rather than primary murine endothelial 
cells, which had the advantage of ensuring a high enough yield of 
macrovascular endothelial cells to use the same donor in all experiments, 
along with sufficient replicates per scratch to ensure a robust data set. The 
numbers are relatively low and it would be prudent to perform this 
experiment using more samples of conditioned media from each genotype 
before drawing firm conclusions from the data. Furthermore, one could 
question the ability of EPC-conditioned media from a mouse to influence the 
healing of a scratch wound made in a human cell line, though Khan et al 
showed reduced tube formation in HUVECs using EPC-conditioned media 
from mice, lending some degree of validity to the experiment [164]. The 
relevance of murine paracrine effects on human cells could still be 
questioned. In order to address this, our data on EPC function could be 
supplemented by assessing scratch wounds in primary cultured wild-type 
PECs from mice, exposed to conditioned media derived from mice of all 
three genotypes. A more complete assessment of the paracrine influence of 
EPCs on endothelial cells might also include assays of endothelial cell 
adhesion and proliferation using HUVECs, or indeed PECs, exposed to 
EPC-conditioned media. Co-culture of endothelial cells with EPCs may also 
provide some indication as to whether cell-to-cell interactions are important 
in influencing endothelial repair. Additionally, the cytokine profile in EPC-
conditioned media from WT and IRKO mice could be appraised. In the event 
of IRKO media showing higher concentrations of pro-inflammatory or 
atherogenic mediators that could be envisaged to interfere with effective 
vascular healing, the levels of these could be interrogated in 
HIRECOxIRKO-derived media. Finally, it would also be prudent to look for 
evidence of human insulin receptor expression in cultured EPCs to rule out 
the possibility of insufficiently selective transgene targeting by the Tie-2 
promoter. This could be performed either on EPC-conditioned media or after 
lysis of cultured EPCs.  
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 Role of endothelial cells 6.3.3
 
On the basis of these observations, we felt that our hypothesis regarding 
improved EPC-mediated vascular repair in HIRECOxIRKO had not been 
confirmed by the data presented. Instead of pursuing further experiments 
with EPCs, we therefore elected to study primary cultured endothelial cells to 
look for differences between WT and IRKO and any potential rescue of 
these defects in the HIRECOxIRKO model. In order to heal injured 
vasculature, endothelial cells may proliferate more, show greater capacity for 
migration [192] or a reduced propensity towards apoptosis [193] or necrosis. 
Pilot data from other projects in our laboratory have shown reduced 
migration and vascular network formation in IRKO endothelial cells [194] so 
we opted to begin with these areas of endothelial cell function.  
 
Our laboratory group has previously purified endothelial cells from murine 
lungs using anti-CD146 magnetic beads [186]. To improve the purity of the 
endothelial cell fraction achieved using this technique, a novel protocol 
involving the use of a two-step antibody separation was adopted and 
optimised for this project (see Chapter 4.12). As demonstrated in Figure 
4-11, the population of cells isolated using this two-stage protocol was 
deemed to show acceptable purity and all assays involving endothelial cells 
were therefore carried out using this technique. Despite this, it is important to 
note certain caveats with this protocol. One is that endothelial cells derived 
from mouse lungs are more likely to represent the microvascular than the 
macrovascular endothelium. Given that our in vivo and ex vivo experiments 
are based around femoral arterial injury and aortic vasomotor function, it 
could be argued that endothelial cells from large vessels such as the aorta 
would be more representative of the cellular and molecular phenotypes 
pertinent to these models. Furthermore, these macrovascular tissues are 
high-pressure systems as opposed to the low-pressure environment 
encountered in the lungs, a difference which may influence vascular function 
and repair [195, 196]. The pulmonary vasculature also displays differences 
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in terms of ambient oxygen concentrations [195]. However, there is likely to 
be an overlap between the function of microvascular and macrovascular 
endothelial cells and it was not felt that they two were sufficiently divergent 
to preclude the study of PECs. This strategy was supported by the fact that 
our own previous work, and that of others, tends to demonstrate concomitant 
derangements in the function of both subsets of endothelium [114, 164, 
189]. Moreover, it was not feasible to achieve the endothelial cell numbers 
required for this project by isolating them from the aorta alone, necessitating 
derivation of cells from an organ with a high concentration of endothelial 
cells. Another potential criticism of the two-step separation technique is that 
cells need to be in culture for a relatively long period before they can be 
used in experiments. Firstly, the requirement for two antibody separations 
introduces a delay and an extra passage; secondly, cells take 7-10 days to 
reach sufficient confluence in a T25 culture vessel for passage at each step. 
There is a theoretical possibility that repeated passage and prolonged 
culture could affect cell phenotype; however, we were reassured to see our 
data replicate prior observations from intact IRKO vessels, such as the 
extent of murine insulin receptor mRNA reduction, and enhanced superoxide 
generation.  
 
 Endothelial cell migration  6.3.4
 
With these caveats in mind, two separate assays of cell migration were 
performed. Initially, the modified Boyden chamber method was used to 
assess the responses of serum-starved PECs to a VEGF concentration 
gradient. Whilst VEGF is classically associated with angiogenesis, it also 
plays a role in the chemotactic component of endothelial cell migration [197, 
198] and has been implicated in the response to vascular injury [153]; as 
such, its effects on PECs were of interest. Consistent with unpublished data 
from our laboratory group in a pure colony of IRKO mice, the experiments in 
the current project demonstrated a significant reduction in net migration to 
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VEGF in IRKO PECs compared with those from WT mice, with recovery to 
WT levels in HIRECOxIRKO cells.  
 
Little exists in the literature regarding the specific impact of insulin resistance 
on endothelial cell migration after vascular injury; many studies in this area 
specifically focus on EPCs. Insulin does appear to encourage endothelial 
cell migration in vitro: a study using human microvascular endothelial cells 
revealed insulin-induced increases in cell migration in vitro using a cloning 
ring assay [199]. This was found to be dependent on the presence of a 
functioning insulin receptor and was associated with increased Akt 
phosphorylation; furthermore, the enhanced migration could be abrogated 
using a PI3K inhibitor, implicating this specific signalling pathway. One may 
therefore expect a deficit in endothelial cell migration given that insulin 
resistance causes specific downregulation of the PI3K pathway; indeed, this 
signalling cascade has been shown to be important in the migratory 
response of endothelial cells to VEGF [198]. In particular, Akt1, eNOS and 
NO are important in mediating the intracellular signalling that results in 
endothelial cells assuming a migratory and angiogenic phenotype [197, 200], 
with evidence that migration in the Boyden chamber can be inhibited by 
adding L-NMMA and thus inhibiting eNOS [201, 202]. It is tempting to 
speculate that restoration of endothelial insulin signalling could have a 
beneficial effect on this pathway, perhaps by reinstating a normal 
chemotactic response to VEGF as observed in our experiments. The 
hypothesis that NO-dependent migration is improved in the HIRECOxIRKO 
would also be in keeping with our finding in the organ bath experiments that 
aortic rings from these mice display evidence of increased NO bioavailability 
(see Chapter 5.12). It would be interesting to perform a second set of 
Boyden chamber migration experiments with the inclusion of L-NMMA in 
some wells: if this abrogated the improved migration seen in HIRECOxIRKO 
without affecting the results seen in IRKO cells, it would strengthen the case 
for NO-mediated recovery.  
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One of the criticisms of the Boyden chamber method as a sole technique for 
assessing cell migration is that it is an in vitro model of a very specific 
element of the overall process. In reality, endothelial cell migration involves 
three distinct stages: chemotaxis to a gradient of soluble pro-migratory 
mediators; haptotaxis towards immobilised ligands such as integrins in the 
extracellular matrix; and mechanotaxis, resulting from complex spatial 
rearrangements of the cytoskeletal network of actin filaments [198]. The role 
of VEGF in migration may also not be critical, as evidenced by the failure of 
SU1498, an inhibitor of VEGFR-2, to reduce insulin-induced endothelial cell 
migration [199]. For this reason, we attempted to complement our 
interrogation of cell migration by using a second technique: the scratch 
wound assay. It could be argued that this is a more accurate in vitro 
approximation of the contribution of migration to vascular repair as it 
effectively recreates the macroscopic endothelial denudation that occurs in 
injury models on a cellular level. Furthermore, the cell migration that closes 
the scratch wound is not reliant on the exogenous administration of VEGF 
and instead is likely to draw upon many of the contributory factors that 
influence the three steps mentioned above. The IncuCyteTM imaging system 
adds further refinement to the assay. Scratch wound assays can be 
performed manually using a pipette tip and performing phase-contrast 
imaging at a certain time point after injuring the cell layer. However, this is 
clearly an operator-dependent technique and the mechanical scratch 
induced by the WoundmakerTM represents a more reproducible insult to the 
cell layer. The real-time imaging possible with the IncuCyteTM further 
enriches the data set as it allows the determination of a time-course for 
wound repopulation; an AUC metric can then be used rather than expressing 
differences in migration at a single time-point. In pilot work, various time-
points were appraised and it was felt that AUC analysis over the first 12 
hours would allow us to observe differences in migration effectively. A further 
advantage of the automated imaging software is the calculation of relative 
wound density: this includes an inbuilt correction for the degree of 
proliferation observed in cells along the edge of each wound, thus 
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attempting to reduce the contribution of proliferation to the wound healing 
observed in the assay.  
 
As such, it is unfortunate that we do not have a complete data set from the 
scratch wound experiments. The raw numbers suggest a small reduction in 
relative wound density in IRKO PEC scratch wounds; this is subtle and is not 
statistically significant, so conclusions should not yet be drawn from this 
experiment. However, WT and HIRECOxIRKO cells appear to behave 
similarly and there is a suggestion of slightly improved wound density after 
12 hours compared with the IRKO data. As such, it is tempting to speculate 
that these early data might represent a signal towards a similar result to that 
of the Boyden chamber experiments. Clearly, these experiments should be 
completed, and could be refined with the addition of inhibitory factors such 
as L-NMMA. Additionally, it would be useful to appraise the relative wound 
density metric independently, to ensure that the impact of proliferation on 
wound healing has been sufficiently considered in the automated image 
analysis. This could be done by incubating cells in some wells of each plate 
with mitomycin C to abrogate proliferation and comparing the migration seen 
in these wells with that in control wells.   
 
 Endothelial cell proliferation 6.3.5
 
The migration assays therefore suggest a deficit in IRKO endothelial cells, 
with recovery to WT levels in the HIRECOxIRKO, at least using one of the 
two methods of assessment. However, another potential mechanism to 
explain augmented endothelial cell-mediated vascular repair would be if 
endothelial cells were proliferating more [192]. We appraised this using an in 
vitro assay of EdU uptake which allowed us to image and calculate the 
percentage of cells undergoing active DNA replication. This assay was 
relatively simple to perform using fluorescence microscopy with only 20,000 
cells per well. In comparison with the traditional bromo-deoxyuridine (BrdU) 
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assay, use of the EdU probe depends on a simple azide-alkyne reaction, the 
effects of which are readily detectable in fixed and permeabilised cells 
instead of having to denature DNA and thus compromise its integrity. 
Furthermore, BrdU assays rely on an anti-BrdU antibody, which introduces 
the confounding issue of non-specific binding.  
 
The results of the EdU assay in the current project are somewhat curious. 
IRKO and WT cells showed no significant differences in rates of proliferation, 
but HIRECOxIRKO PECs were seen to proliferate significantly more than 
both other subsets.  It is difficult to know how to interpret this and, as such, it 
would be interesting to assess proliferation using a second technique for 
confirmation of the robustness of this finding. Cellular proliferation can also 
be assessed using cell cycle analysis with flow cytometry. This is another in 
vitro assessment, which could be criticised for lacking relevance to the 
overall animal model. To address this, a further alternative is to label 
proliferating endothelial cells with EdU in vivo; it is anticipated that our 
laboratory group will take both techniques forward. The finding of increased 
proliferation in HIRECOxIRKO may be a true phenomenon despite the 
apparent lack of an accompanying deficit in IRKO cells. Previous 
investigators have suggested that exogenous insulin does not influence 
proliferation in human endothelial cells [199], so it is feasible that insulin 
resistance will have no effect on proliferation. As discussed before, the 
mechanism for augmented vascular repair in HIRECOxIRKO mice appears 
not to be EPC-dependent, despite published data suggesting that EPC 
transfusion can rescue vascular repair in IRKO mice. Therefore, not all 
beneficial effects seen in HIRECOxIRKO mice or cells necessarily needs to 
correlate with a reciprocal deficit in the insulin resistance model.  
A potential explanation for the discrepant proliferation result lies in the 
pathway-specific nature of insulin resistance, wherein the PI3K pathway 
responsible for NO generation is inactivated while the MAPK pathway, which 
encourages growth and mitogenesis, is unaffected. As a result, one may 
expect that proliferation would be undisturbed even in the context of insulin 
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resistance, explaining the lack of a difference between WT and IRKO PECs. 
However, with greater expression of endothelial insulin receptors, one may 
expect heightened intracellular signalling in both cascades, which would 
generate NO in the PI3K arm but also encourage proliferation on the MAPK 
side. This may explain the higher rate of proliferation seen in HIRECOxIRKO 
mice and it is therefore important to use alternative methods for analysis of 
this area of endothelial cell function.  
 
 Summary 6.3.6
 
HIRECOxIRKO mice show improved vascular repair after wire injury than 
their IRKO littermates, with restoration to the levels seen in WT mice. This 
does not appear to be related to improved EPC abundance or function in the 
HIRECOxIRKO mouse. Instead, in vitro assessment of endothelial cell 
function suggests that IRKO cells have reduced migratory capacity to a 
VEGF gradient, with recovery to WT levels in HIRECOxIRKO PECs. It is too 
early to comment with certainty on the results of the scratch wound assay, 
but a similar observation cannot be ruled out. Additionally, HIRECOxIRKO 
cells appear to proliferate more than those from WT or IRKO mice, which 
may represent an additional reparative mechanism, despite the lack of an 
apparent proliferation deficit in IRKO cells. Given that we have not observed 
any improvement in EPC biology in the HIRECOxIRKO mouse, it is tempting 
to speculate that enhanced endothelial cell reparative capacity (by way of 
increased migration, perhaps along with proliferation) represents the primary 
mechanism for the amelioration noted in vascular repair. Other options 
include increased cell survival in the HIRECOxIRKO model, but this was not 
assessed in our project and remains an option for further work.   
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6.4 Endothelial function 
 
 Background 6.4.1
 
The link between insulin resistance and cardiovascular disease in humans is 
well established (see Chapter 1.1.2) and work in a variety of murine models 
has allowed the recreation of a similar phenotype in experimental settings 
[60, 114, 123]. Previous findings from our laboratory demonstrate that IRKO 
mice, despite their essentially unperturbed glucoregulation, are hypertensive 
when compared with WT littermates [60]. Knockout of eNOS has also been 
demonstrated to result in increased systolic blood pressure [203], while rats 
can be rendered hypertensive with the use of L-NMMA [204], suggesting a 
key role for eNOS and NO in maintaining normotension. In addition to effects 
on blood pressure, IRKO-derived aortic rings showed a loss of insulin-
mediated vasodilatation and reduced NO bioavailability in the Wheatcroft et 
al study [60]. Importantly, mice rendered chronically hypertensive via 
subcutaneous administration of norepinephrine did not show the same 
differences between genotypes; nor did rings that had undergone endothelial 
denudation before mounting onto the organ bath apparatus. These findings 
strengthened the assertion that the vasomotor changes noted were 
specifically related to endothelial dysfunction. Other investigators have 
shown increased coronary artery resistance and diminished response to 
ACh in both high fat-fed mice and those with partial or complete knockout of 
eNOS [205]. Signalling via the PI3K pathway was implicated in our 
laboratory’s work: IRKO rings lacked the insulin-induced eNOS 
phosphorylation seen in WT tissue, despite similar quantities of eNOS 
mRNA and basal eNOS protein being detected in both groups. These 
molecular findings were recreated in the ESMIRO mouse, also from our 
laboratory, though these animals were normotensive [114]. Consistent with 
the demonstration of diminished eNOS phosphorylation, Kahn et al also 
showed a reduction in aortic eNOS activity in the L-citrulline assay. Our 
group’s findings are slightly in contrast with those of Vicent et al, who 
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identified reduced basal eNOS expression in the VENIRKO model [113]. 
This may be related to the fact that the VENIRKO mouse displays a 
profound (95%) reduction in insulin receptor mRNA.  
 
These differences notwithstanding, the background data all suggest that 
impaired endothelial insulin signalling results in a defect at the level of eNOS 
and the consequent reduction in NO mediates endothelial dysfunction and, 
in the IRKO mouse, hypertension. In the present study, the hypothesis was 
that restoration of endothelial insulin signalling would ‘rescue’ this pathway 
and result in increased NO bioavailability and reversal of endothelial 
dysfunction. We sought to use a similar combination of in vivo, ex vivo and in 
vitro techniques to evaluate this hypothesis.  
 
 
 Vasomotor function 6.4.2
 
One of the earliest and most interesting findings in the current study was that 
HIRECOxIRKO mice had significantly lower systolic blood pressure than 
IRKO littermates, with restoration to the level seen in WT animals. Given that 
HIRECOxIRKO mice showed no differences in basic morphology or 
metabolic parameters, this provided an early suggestion that our method for 
restoring endothelial insulin sensitivity had been successful in reversing the 
adverse vascular phenotype seen in IRKO. These results were of significant 
interest for two reasons: firstly, given that ESMIRO and VENIRKO mice do 
not exhibit hypertension, our finding that IRKO had higher blood pressure 
than WT was reassuring as it confirmed the arguably contentious earlier 
haemodynamic data from the IRKO mouse [60]. Secondly, as with the 
vascular injury experiments, the improvement in blood pressure represented 
rescue of an important physiological parameter in vivo rather than solely in 
experimental conditions. Ideally, one would wish to take this finding further 
by measuring NO or quantifying its effects in vivo; however, NO levels are 
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difficult to appraise directly given its volatility. Instead, one could observe the 
effects of chronic NOS inhibition in the HIRECOxIRKO, and further work 
could include performing blood pressure measurements in a cohort of mice 
receiving L-NMMA (versus vehicle) using subcutaneously implanted 
‘minipumps’. A caveat in the appraisal of arterial pressure in mice is the 
requirement for fairly large sample sizes in order to detect the small (yet 
consistent) differences that we have thus far observed. Repeating the 
experiment post-L-NMMA would necessitate the use of a large quantity of 
mice and so, in the interests of timing and animal welfare, it was felt prudent 
to model the process initially using an ex vivo organ bath assessment 
instead. Additionally, the quantification of blood pressure in a conscious 
animal under restraint is prone to difficulty and perhaps inaccuracy because 
the measurement can be distressing for the mouse. Attempts were made to 
minimise this by ensuring at least two habituation sessions prior to 
recording, as well as performing the experiment at the same time of day to 
minimise the effects of diurnal variation. The Coda software used also takes 
18 recordings per mouse after ten acclimatisation cycles, allowing a mean 
reading to be calculated over around ten minutes of measurement in an 
attempt to reduce variability. Intra-arterial blood pressure monitoring is 
feasible, but the risks of this invasive approach must be offset against the 
benefits and it was not felt that this was justified in the current project. It was 
therefore important to consolidate our appraisal of endothelial function using 
an alternative method, and we elected to perform organ bath experiments 
using aortic rings for this purpose.  
 
The results from the organ bath experiment were equally exciting: IRKO 
aortic rings displayed endothelial dysfunction and reduced NO bioavailability, 
all of which was reversed in the HIRECOxIRKO model. These findings are in 
keeping with the favourable changes seen in the blood pressure data set 
and provide further evidence that enhancing endothelial insulin signalling 
can help to ameliorate the vascular phenotype seen in systemic insulin 
resistance. The use of acute pharmacological NOS inhibition in these 
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experiments was also helpful in identifying enhanced NO release as a likely 
causative factor in the improvements observed. This will be discussed in 
more depth in the following section but, in brief, we hypothesise that 
restoration of the PI3K signalling pathway in endothelial cells results in 
recovery of eNOS activation and thus NO synthesis.  
 
One must appraise the data from the organ bath experiments with a degree 
of caution given that this is an ex vivo technique that is highly operator-
dependent. In order to maximise the integrity of aortic tissue, great care was 
taken not to stretch the vessel during dissection and it was transported and 
cleaned in Krebs-Henseleit medium to maintain a highly supportive 
environment. Furthermore, another group member (Mrs Stacey Galloway) 
collected specimens directly from the animal facility, before dissection of 
animals was complete, in order to minimise delays in transport. Mrs 
Galloway’s significant experience in performing the remainder of this 
experiment was an additional method for reducing operator error and 
variability, and allowed blinding to genotype during experiments. With these 
measures in place, the technique provided reproducible results and 
replicated most of the differences previously seen between WT and IRKO.  
 
The method for statistical analysis of organ bath data also varies between 
investigators. In this project, EC50 values were presented as it was felt that a 
50% change in constriction or dilatation from baseline was likely to be a 
reasonable reflection of the levels of fluctuation in vessel tone that occur in 
vivo, in contrast with measuring the concentrations of agonist required for 
maximal alteration in tension. Equally, some investigators prefer to make 
serial comparisons of tension at each agonist dose increment but this fails to 
provide an overall appraisal of differences between genotypes across the 
spectrum of agonist concentrations; one could argue that the analysis of 
dose increments is therefore less meaningful. The existence of several 
methods of analysing data in this experiment makes it harder to compare our 
findings with those of others. However, the visual appraisal of divergent 
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dose-response curves appears to be concordant with our statistical analysis 
of differences in EC50 between genotypes. Furthermore, the broad findings 
of endothelial dysfunction and reduced NO bioavailability in IRKO in the 
current study are consistent with the results of Wheatcroft et al [60], 
suggesting reproducibility of this phenotype. Therefore, it was felt that the 
combination of improved vasomotor function in the organ bath and reversal 
of hypertension represented restoration of endothelial function in the 
HIRECOxIRKO, most likely due to an increase in NO bioavailability.  
 
 
 Summary 6.4.3
 
HIRECOxIRKO mice show restoration of the high blood pressure observed 
in IRKO littermates, with levels similar to those of WT animals. To 
accompany this in vivo finding, the current study has shown recovery of 
vasomotor function in the HIRECOxIRKO mouse in experiments involving 
aortic rings. In the latter experiment, HIRECOxIRKO rings displayed 
restoration of NO bioavailability, suggesting that the mechanism for 
improved endothelial function and blood pressure was likely to relate to 
enhanced NO release, possibly as a result of augmented PI3K signalling. In 
the next section, early data targeted at determining a causative molecular 
mechanism will be discussed.  
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6.5 Unifying molecular mechanisms 
 
 Background 6.5.1
 
Previously published data appear to show that the endothelial dysfunction 
observed in insulin resistance results from reduced NO bioavailability. Our 
group’s findings in aortae from IRKO and ESMIRO mice suggest that eNOS 
mRNA and basal eNOS protein levels are similar to WT but, in both models, 
an impairment is seen in eNOS phosphorylation [60, 114]. Consistent with 
this, IRKO mice also show evidence of reduced aortic eNOS activity [164]. 
As discussed in the previous section, the VENIRKO mouse shows a slightly 
different molecular phenotype, in that basal eNOS is reduced in this model 
[113]. It is well established that NO has a key role in mediating endothelial 
function in health and it is therefore not surprising that, regardless of the 
exact mechanism of the deficit in insulin resistance, reduced endothelial NO 
is implicated in the associated vascular dysfunction. A similar finding has 
been described in multiple models of obesity-induced insulin resistance 
[206]. The same impairment also forms an important part of the response to 
vascular injury, be that due to the essential role of NO in EPC mobilisation or 
via its contribution to effective migration in native endothelial cells.   
 
Reduced NO bioavailability can result from two broad pathogenetic 
mechanisms: firstly, reduced expression or activation of eNOS, and 
secondly, sequestration by reactive oxygen species (ROS). In the context of 
insulin resistance, there is ample evidence of impaired PI3K signalling 
resulting in the former, as discussed previously. Oxidative stress has also 
been demonstrated in animal models encompassing both genetically-
induced insulin resistance and that resulting from high fat feeding [114, 115, 
123-125]. Taken together, these findings suggest a combination of reduced 
NO generation and increased sequestration by ROS in the setting of insulin 
resistance. Similarly, NO release and oxidative stress can both have an 
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impact on vascular repair and it is likely that the delayed response to injury 
seen in IRKO mice is again a combination of both factors. Therefore, a key 
question in this project is the mechanism for enhanced NO bioavailability in 
the HIRECOxIRKO model. Our hypothesis was that this results from a 
combination of increased production due to augmentation of the PI3K 
signalling pathway, and reduction in oxidative stress. Unfortunately, we were 
not able to complete the relevant experiments in this area, though early data 
provide some indications.  
 
 
 Insulin signalling 6.5.2
 
Initially, we sought to assess the effects of endothelial insulin sensitisation 
on intracellular signalling. Unfortunately, only one set of Western blot results 
was obtained during the time frame in this project; this is a significant 
shortcoming of this work. Crude appraisal of the blots presented in Chapter 
5.14 suggests an appearance compatible with existing knowledge of insulin 
signalling in IRKO mice, namely the finding of reduced insulin-stimulated 
phosphorylation of Akt and eNOS. There appears to be a preliminary 
suggestion that Akt phosphorylation is improved in the HIRECOxIRKO 
model, though it is impossible to be definitive about this early finding given 
the single sample. From the blot presented, the increase in insulin-
stimulated Akt phosphorylation appears modest and less intense than that 
observed in WT PECs. If this finding is consistent in future samples then it 
may suggest partial restoration of downstream insulin signalling. 
Alternatively, it may be prudent to assess a variety of time points after insulin 
stimulation or to probe other phosphorylation sites on these molecules. The 
phosphorylation of eNOS in HIRECOxIRKO appears no different to that 
seen in IRKO cells but, again, this may simply reflect the fact that this was 
only assessed at one amino acid residue and at one time point.  
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Clearly, more replicates need to be processed in order to comment sensibly 
on levels of total and phosphorylated Akt and eNOS. These data would allow 
us to determine whether nodes in the PI3K signalling pathway were affected 
at baseline by the expression of the human insulin receptor in endothelial 
cells. Furthermore, insulin-stimulated cells could be used to determine the 
level of insulin sensitivity of each genotype with respect to this signalling 
cascade. These data could validate the insulin sensitisation strategy on a 
molecular level, in conjunction with data on insulin receptor concentrations, 
and also consolidate our understanding of the mechanisms accounting for 
the beneficial vascular phenotypes seen in HIRECOxIRKO mice. From the 
perspective of undesirable off-target effects, it would also allow us to 
appraise the effects of enhancing insulin signalling on Akt, which is important 
given the oncogenic potential of this signalling node. Any translational use of 
this model would need to take such effects into consideration.  
 
In addition to assessing phosphorylation of eNOS, it would be prudent to 
measure the activity of the enzyme. This has previously been performed in 
our laboratory using the L-citrulline assay, which uses the conversion of 
carbon-14-labelled L-arginine by NOS to determine L-citrulline generation. 
Whilst this technique does not allow direct measurement of NO 
concentrations, it provides a surrogate measure, which is important given 
that NO is difficult to quantify due to its volatility. Previous work in IRKO mice 
has shown a loss of augmentation of eNOS activity after stimulating cells 
with insulin [164]; basal levels in unstimulated cells were not directly 
compared. It would be important to perform the L-citrulline assay on PECs 
from all three genotypes in the current project; we hypothesise that 
HIRECOxIRKO cells will show increased eNOS activity. This may be evident 
in unstimulated cells, given that eNOS activity is not restricted to times of 
insulin stimulation. However, the degree of insulin-stimulated eNOS activity 
could also be compared by incubating PECs with insulin prior to performing 
the assay. Alternative methods for assessing eNOS and NO exist: for 
example, the fluorophore diaminofluorescein (DAF) can be used to detect 
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NO via fluorescence measured using a microplate reader. Should the results 
of the L-citrulline assay be equivocal, it would be reasonable to consider 
using a fluorescence-based technique such as this to corroborate any 
findings.  
 
Western blotting for MAP kinases and other elements of the Shc-Ras-Raf 
pathway would also be beneficial. One might envisage augmentation of this 
arm of insulin signalling as a consequence of hIR transgene insertion, and 
this may in part explain the finding of increased endothelial cell proliferation 
in the EdU assay as this pathway is pro-mitotic. It would be somewhat 
surprising if MAPK activity was markedly increased, as one would also 
expect greater endothelin-1 production as a consequence, and this appears 
unlikely given that HIRECOxIRKO mice have lower systolic blood pressure 
than IRKO littermates. It is of course feasible that enhancing insulin 
sensitivity results in asymmetrical augmentation of the parallel signalling 
pathways, favouring the PI3K arm which is selectively inhibited in insulin 
resistance. This could theoretically explain increased proliferation in the 
absence of higher blood pressure. It would be important to ascertain the 
degree of MAPK overactivation given the potentially deleterious effects of 
this on vascular function: as well as producing the vasoconstrictor 
endothelin-1, the MAPK pathway encourages release of growth factors and 
this could encourage a pro-atherosclerotic environment.  
 
There may also be cross-talk between various intracellular signalling 
pathways. One of the more curious findings in our group’s organ bath 
experiments, including those presented in this project, is the relatively 
modest difference between WT and IRKO aortic rings in terms of 
acetylcholine-induced vasodilatation. No difference was observed by 
Wheatcroft et al [60]; in the current study, the relaxation curves appeared 
divergent but there was no significant difference between WT and IRKO with 
respect to the EC50 for vasodilatation. This may be because the 
vasodilatation induced by ACh, whilst eNOS dependent, relies on G-protein 
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coupled receptors and raised cytosolic calcium ion concentration rather than 
insulin-mediated eNOS activation. It is feasible that this is why significant 
differences are not noted in IRKO rings. However, if HIRECOxIRKO 
endothelium is sensitised to insulin and PI3K signalling is indeed enhanced, 
then there may be simultaneous upregulation of G-protein coupled receptor 
pathway activity due to co-regulation of these cascades [207]. Similar cross-
talk has also been demonstrated for MAP kinases [207], which could 
partially explain the increased endothelial cell proliferation. Clearly these 
interactions are complex and detailed interrogation using Western blotting 
for various mediators would help to increase our understanding of the 
intracellular effects of hIR transgene insertion.  
 
 Oxidative stress 6.5.3
 
As discussed in Chapter 1.3.5, oxidative stress is another potential 
mechanism for reduced NO bioavailability in the setting of insulin resistance. 
The superoxide anion reacts with NO to form peroxynitrite, thus reducing the 
concentration of NO in the cell and encouraging further oxidative stress 
through the effects of peroxynitrite. Therefore, even if eNOS activity is 
undisturbed and NO is being produced, the latter can be sequestered by 
ROS and there is evidence of increased ROS in both the IRKO and ESMIRO 
models of insulin resistance in the endothelium [114, 123]. We hypothesised 
that ROS levels may be reduced in HIRECOxIRKO mice and this may 
contribute to the increase in NO bioavailability in this model. However, the 
preliminary results of the DHE assay reveal that HIRECOxIRKO have 
significantly increased superoxide concentrations in PECs compared with 
WT mice. These experiments are incomplete and numbers should be 
augmented, but there is a strong suggestion that IRKO mice have increased 
ROS, in keeping with previous work. This would suggest that, whilst IRKO 
mice are prone to oxidative stress, enhancing endothelial insulin sensitivity 
may not reverse this. Clearly, the interim results of an incomplete experiment 
cannot be used to rule out a role for reduced ROS emphatically, and further 
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work is warranted. As well as completing the DHE assay, it would be 
interesting to appraise NOX2 mRNA as this has been demonstrated to be 
the source of ROS in insulin resistant murine models [114, 123].  
 
 Summary 6.5.4
 
The data above are clearly incomplete and, crucially, the project lacks 
detailed data on intracellular signalling and eNOS activity that would 
consolidate our understanding of the molecular mechanism behind 
increased NO bioavailability in the HIRECOxIRKO. The DHE assay, 
however, provides early data to suggest that there is no gross reduction in 
superoxide concentration in HIRECOxIRKO PECs, suggesting that 
diminished oxidative stress is unlikely to be the primary mechanism. If 
reduced sequestration of NO is not the key difference between IRKO and 
HIRECOxIRKO then it appears that the rescue of vascular function is 
occurring at the level of eNOS. It is tempting to postulate that enhancing 
endothelial insulin sensitivity results in augmented PI3K signalling, resulting 
in either greater eNOS expression or phosphorylation, or both. If this is 
correct, one would expect enhanced eNOS activity and this could explain the 
greater NO bioavailability that appears to be driving improved blood 
pressure, endothelial function and vascular repair in our model.  
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6.6 General limitations 
 
As with all exploratory scientific work, the methods utilised have inherent 
limitations and this must be taken into consideration in our analysis and 
interpretation of data. I have attempted to highlight specific weaknesses in 
relevant subsections throughout my discussion. Additionally, various general 
limitations in this project merit comment.  
 
Firstly, we have used a murine model of insulin resistance, comparing this to 
a “double-cross” with two genetic manipulations. The phenomenon of insulin 
resistance in man is complex and it could be argued that a mouse model 
with a relatively simple receptor knockout strategy cannot fully recapitulate 
the nuances of this phenotype: for example, IRKO mice lack the obesity and 
hyperlipidaemia seen in humans with metabolic syndrome [60]. The multi-
level insulin resistance seen in man is unlikely to be modelled in the IRKO 
mouse, nor can we be sure how sensitive we render the endothelium with 
the HIRECO manipulation. Additionally, the resulting HIRECOxIRKO model 
has no direct corollary in physiology. However, several experiments on IRKO 
mice over a number of years have displayed a convincing and consistent 
vascular phenotype in connection with diverse measures such as blood 
pressure, endothelial function and vascular repair; meanwhile, the 
experiments we have performed here clearly could not have been performed 
in man. Therefore, conceding the general caveat that animal models cannot 
faithfully mimic a complete disease process in man, we feel that the use of 
mice has been a reasonable compromise between purely in vitro work on 
one hand and a wholly physiologically relevant model on the other. Equally, 
larger mammals could theoretically be used but this brings other technical 
challenges and pragmatic considerations such as longer breeding cycles 
and time to maturation. Finally, the aim of this project was to appraise the 
effects of sensitising one tissue (the endothelium) in the setting of systemic 
insulin resistance and, as this specific configuration cannot be recreated in 
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man, nor in cell culture conditions, an animal model is a potential way to 
model the scenario.  
 
The use of an animal model brings another key set of considerations: 
sample sizes and power calculations. Animal research is underpinned by the 
“Three Rs” ethical paradigm: reduce, refine and replace. Thus, whilst it 
would be ideal to ensure several repeats in every experiment, it is important 
to take a pragmatic view on how many replicates are required in order to 
answer an exploratory scientific question. Clinical trials are highly dependent 
on a rationally determined sample size as a clear biologically relevant 
difference (such as a desired drop in mortality rate with a new drug) can 
often be defined with accuracy and this can be fed into power calculations. 
In contrast, the data gathered from this project are expressed as, for 
example, percentage endothelial regeneration or a blood pressure drop in a 
mouse, metrics for which a meaningful biological difference is difficult to 
define. Ideally, results from a small number of mice could be compared as 
pilot data that would inform a power calculation for more rigorous future 
study. However, the observed differences are often small and this would 
likely necessitate the use of prohibitive numbers of mice, both from an 
ethical and a financial perspective. We instead relied on the achievement of 
a mathematically significant result in an appropriate statistical test as a 
preliminary suggestion that a biologically relevant difference had been found. 
Interestingly, almost every prior finding in the IRKO mouse was recreated in 
the current project, suggesting a fairly consistent phenotype in this model 
and, perhaps, reflecting a certain degree of accuracy in our assessment 
despite the small numbers. Given the hypothesis-generating nature of many 
of the experiments presented, some of the results should not be viewed as 
conclusive or definitive, and the findings simply highlight potential 
differences that can form a foundation for future development. One could 
argue that this is as dogmatic as one can be about animal research as a 
whole, and thus whilst it is acknowledged as a criticism of our work, it may 
not diminish the utility of this research.  
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The problem of small sample sizes is compounded by the fact that multiple 
experiments needed to be done on similar organs in this project. Mice are 
clearly small animals and thus generate relatively small quantities of tissue 
even when an entire organ is taken from an adult; therefore, an entire aorta 
per mouse was used for organ bath experiments and more mice needed to 
be sacrificed when the aorta was used for other work, such as qPCR. For 
some experiments, such as vascular injury and the aortic ring work, mice 
needed to be aged in order to reach a size at which surgery or mounting of 
aortae would be technically feasible. No other experiments were performed 
on mice reserved for wire injury and, as a result of perfusion with 
paraformaldehyde at the time of sacrifice, no tissue other than the femoral 
artery could be used. Similarly, mice sacrificed for organ bath experiments 
were generally too old for concomitant removal of lungs for PEC culture as 
the latter set of experiments was optimised in mice aged 4-6 weeks. Thus, 
despite attempting to reduce mouse use and refine experiments by having 
experienced operators perform each technique, large overall numbers of 
mice were required to achieve the relatively small numbers quoted per 
experiment, and this had implications in terms of trying to increase sample 
sizes.  
 
One of the consequences of a relatively small sample size is the need to 
ensure that each data set is as robust and reproducible as it can be. Most of 
the experiments were designed with this in mind; wherever feasible, several 
replicates were performed within each condition. For example, up to 18 
readings were taken for each blood pressure data point; four aortic rings 
were mounted per mouse in the organ bath; multiple wells were seeded for 
each cell culture experiment; and so on. However, the risk of introducing 
bias in these measurements remains and the methodology could be refined 
for future work. For example, my analysis of some data sets was not 
rigorously blinded: mouse IDs were often included in the file name or in the 
image during analysis. Whilst I did not have a working knowledge of the 
genotype for a given mouse ID, and I only retrieved this information 
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retrospectively, a risk of bias was introduced. This could have been reduced 
by genotyping mice after experiments were complete; however, this was 
often difficult as it was important to know genotypes for the practical 
purposes of housing animals and planning broadly equal numbers of each 
genotype in each individual experiment wherever possible. An alternative 
strategy would be to create a code for naming files such that analysis was 
fully blinded and data could later be cross-referenced with mouse IDs and 
only linked to genotypes as the last step. This is less likely to have had a 
significant impact on certain results, such as the organ bath work, in which 
the primary operator was fully blinded and rigorous rules were applied in the 
inclusion or exclusion of data during analysis. However, appraisals such as 
the quality of a blood pressure measurement or counting of cells could be 
more subjectively influenced and blinding, ideally with a second researcher 
and evaluation of inter-observer agreement, would be a more robust method 
for performing these analyses.  
 
A further criticism is our reliance on very specific models of vascular disease 
that do not necessarily recreate the complexity of pathology in man. One of 
the key sets of data in this project was the vascular injury experiment, a 
model involving an acute insult to the endothelium, the effects of which were 
analysed only four days later. These data are interesting in terms of the 
effects of plaque rupture or stent placement on endothelial injury and repair, 
though do not provide significant insights into chronic processes such as 
atherosclerosis, nor do they allow the appraisal of longer term recovery. 
Similarly, the organ bath experiments are ex vivo methods of assessing the 
immediate response of vasculature to short-acting vasoconstrictors and 
vasodilators, with only acute pharmacological NOS inhibition. Most of the in 
vitro data simply served to highlight cellular and molecular mechanisms for 
these basic models. One way to target a more chronic process might be to 
attempt to breed HIRECOxIRKO mice onto an ApoE-/- background to 
appraise the effects of our manipulation on atheroma formation. We also 
tried to circumvent the issue by complementing our vascular injury and 
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organ bath experiments with the study of longer term measures of vascular 
biology such as blood pressure. It is felt that the inclusion of several, varied 
indices of vascular function has therefore provided a data set with broad 
relevance; as such, we have recreated most of the experiments done in 
IRKO mice across multiple earlier studies [60, 123, 164] in the 
HIRECOxIRKO model.   
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6.7 Future directions 
 
In this project, significant new ground has been covered, as we have 
commenced the validation of endothelial insulin sensitisation as a 
therapeutic strategy to address the vascular disease observed in a murine 
model of global insulin resistance. However, this is early work and much 
more investigation would be desirable.  
 
The first observation to make is that this is not yet a complete project even 
within the remit of our initial hypotheses. It will be important to appraise 
insulin receptor expression in endothelial tissues, as well as to complete the 
assays of migration and superoxide production that are reported here as 
interim results. In order to gain mechanistic insights, it will also be crucial to 
perform more Western blots to probe intracellular signalling and identify the 
level at which endothelial insulin sensitisation beneficially affects NO 
production and, thus, vascular function. This may also identify potentially 
harmful off-target effects of our strategy such as Akt overactivation or 
increased flux through the MAPK pathway of insulin signalling, which will 
have implications for translation. Potentially contentious observations such 
as the increased rates of proliferation in HIRECOxIRKO PECs should be 
interrogated in more depth using alternative experimental techniques. It 
would also be prudent to consolidate our understanding of the role of NO in 
the beneficial effects seen in HIRECOxIRKO mice. This could be done in 
vitro by attempting to reverse the favourable HIRECOxIRKO phenotypes 
using L-NMMA. It would also be feasible to infuse L-NMMA chronically and 
repeat key in vivo studies such as blood pressure measurement and wire 
injury after chronic NOS inhibition. Finally, further EPC work such as detailed 
functional studies would help underline our assertion that improvements in 
vascular repair are likely to stem from enhanced endothelial cell function 
rather than rescue of progenitor cell biology.  
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We have demonstrated rescue of endothelial dysfunction and impaired 
vascular repair using the HIRECOxIRKO model. However, other vascular 
aberrances are observed in the context of insulin resistance and the effects 
of our manipulation could be studied in these areas too. As mentioned 
above, the effects of endothelial insulin sensitisation on atherosclerosis 
could be appraised by crossing the HIRECOxIRKO mouse with atheroma-
prone, hyperlipidaemic ApoE-/- mice. Similarly, the effects of this intervention 
on other chronic cardiovascular conditions could theoretically be modelled 
using IRKO and HIRECOxIRKO mice. Murine models of left anterior 
descending coronary artery (LAD) occlusion can enhance our understanding 
of heart failure and there may be merit in examining the interplay between 
this and insulin resistance. IRKO mice have also been demonstrated to 
show impairments in in vitro measures of angiogenesis [164] and this has 
been developed significantly in work from our laboratory group [194]. Given 
the beneficial effects we have observed on the vascular parameters 
evaluated in the current study, one may hypothesise that the HIRECOxIRKO 
mouse will display enhancement of angiogenesis as well, and various in vitro 
and in vivo studies could be performed to assess this.  
 
Ultimately, the aim of this research is to identify novel therapeutic targets in 
the management of insulin resistance-associated vascular disease. Our 
findings represent a decidedly early stage in this process but are an 
important proof of principle, namely that manipulating insulin sensitivity in the 
endothelium can be helpful in reversing vascular derangements despite 
global insulin resistance. With further understanding of this strategy and 
refinement of our knowledge of its beneficial (and perhaps associated 
harmful) effects, it is possible that it will become a target for future therapy. 
Novel methods of drug delivery are being described, and the vascular 
endothelium, as the first point of contact for intravenously delivered agents, 
is an attractive prospect [208]. For example, endothelial cells can take up 
antibodies directed against PECAM-1 and ICAM-1 via endocytosis [209] and 
even transport antibodies across the cell and direct them towards sub-
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endothelial structures [210]. The vascular endothelium could also be 
targeted by placing drug-eluting stents using percutaneous techniques [208]. 
In an era of increasing expertise in biotechnology and more nuanced 
therapeutic approaches, one can envisage the principles underlying this 
model being translated into clinically meaningful results in time, thus allowing 
patients with, or at risk of, diabetes to benefit from our work.  
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6.8 Concluding remarks 
 
Prior to this project being undertaken, it was known that insulin resistance, 
as part of the constellation of risk factors known as the metabolic syndrome,  
is a key independent indicator of adverse vascular outcomes in man. The 
IRKO mouse is one of many murine models of insulin resistance that 
appears to recapitulate the phenomenon: despite preserved glucoregulation, 
these mice are hypertensive and exhibit endothelial dysfunction, impaired 
vascular repair and perturbations in mature endothelial cell and progenitor 
cell biology.  
 
We sought to validate a therapeutic strategy involving the selective 
restoration of endothelial insulin sensitivity in the context of global insulin 
resistance. We hypothesised that this intervention would reverse endothelial 
dysfunction, normalise blood pressure and improve vascular repair in a 
model of arterial wire injury. This project has demonstrated that the 
HIRECOxIRKO is a viable and glucocompetent murine model in which to 
examine these hypotheses. HIRECOxIRKO mice have restoration of blood 
pressure and aortic vasomotor function to the levels of WT littermates. 
Equally, endothelial healing after vascular injury is significantly improved 
compared with IRKO mice, with data to suggest that this recovery is more 
likely to be mediated by endothelial cells than by EPCs.  
 
A key determinant of these beneficial vascular phenotypes appears to be 
increased bioavailability of nitric oxide. Early data from this project appear to 
suggest that HIRECOxIRKO PECs have similar superoxide levels to those 
from IRKO mice, suggesting that the improvement in NO is more likely to 
stem from increased eNOS expression and/or activity than from reduced 
sequestration by ROS. Much work remains to be done in developing these 
assertions further. However, the work in this project adds to existing 
knowledge on the mechanisms behind insulin resistance-associated 
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vascular disease. Furthermore, it identifies a potential therapeutic target that, 
to our knowledge, has not been manipulated in this way before. As such, 
one can envisage the eventual translation of our work to a therapeutic 
strategy in years to come. In this way, the work within this project could form 
the basis of novel methods for managing vascular risk in people with insulin 
resistance and diabetes.  
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